NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic Review

NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic Review | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic Review Shahd Hamran, Zaineh Alnoubani, Aly Mostafa Hassan, Amani A. Al-Rajhi, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-6512957/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Purpose Gene fusions involving Neurotrophic Receptor Tyrosine Kinase ( NTRK ) genes lead to Tropomyosin Receptor Kinase (TRK) overexpression, an oncogenic mechanism rarely prevalent in soft tissue tumors. Detecting NTRK1-3 fusions through advanced molecular techniques has revolutionized cancer care through personalized medicine, such as TRK inhibitors (e.g., larotrectinib, entrectinib). In this systematic review, we examined the prevalence and types of NTRK1-3 gene fusions in soft tissue sarcomas. Design Using terms related to NTRK1-3 and sarcomas, we conducted a comprehensive search of databases (PubMed/MEDLINE, SCOPUS, Web of Science). We screened titles and abstracts, followed by a full-text assessment. We extracted data on study characteristics, molecular characteristics, and clinical outcomes. Data synthesis involved narrative and thematic analysis and study quality assessment using the MASTER scale. Results We included 136 studies (n = 18,077 patients). The most common tumor categories were unclassified soft tissue sarcomas (2,004 patients, 11.09%), gynecological sarcomas (1,019 patients, 5.64%), and liposarcomas (609 patients, 3.37%). Most tumors were gynecological in origin (1,019 patients, 5.64%), followed by the limbs (262 patients, 1.45%). Genomic sequencing was the predominant diagnostic method used in 110 studies. Overall, 551 patients with sarcoma tested positive for NTRK1-3 gene fusions, primarily involving NTRK1 and NTRK3 (~ 93%), with ETV6-NTRK3 fusion being the most frequently reported fusion (174/551). Larotrectinib was used in 142 patients, demonstrating an 83.80% response rate, with low mortality (2.82%) and recurrence (2.11%) rates. Entrectinib had a lower response rate of 63.64% (21/33). Conclusions This systematic review highlights the rarity of NTRK1-3 fusions in sarcomas. TRK inhibitors show high efficacy in sarcomas, emphasizing the necessity of genomic testing in all cases. Biological sciences/Cancer Health sciences/Biomarkers Health sciences/Molecular medicine Health sciences/Oncology Soft tissue tumors Sarcomas NTRK1-3 fusions TRK inhibitors Systematic review Figures Figure 1 Figure 2 Figure 3 Introduction The Tropomyosin Receptor Kinase (TRK) family of receptor tyrosine kinases comprises three types: TRKA, TRKB, and TRKC transmembrane proteins, which are encoded by Neurotrophic Receptor Tyrosine Kinase ( NTRK ) genes 1, 2, and 3, respectively 1 . These TRKs, found in human neuronal tissue, are vital for cell survival and the development and nervous system function, activated by neurotrophins. Neurotrophins, such as nerve growth factor for TRKA, brain-derived growth factor and neurotrophin-4/5 for TRKB, and neurotrophin-3 for TRKC, serve as specific ligands for these receptors. Each of the three TRKs has an extracellular domain for ligand binding, a transmembrane region, and an intracellular domain containing a kinase domain 2 . NTRK1-3 gene fusions with their partner genes are the key oncogenic mechanism, leading to the overexpression of TRK proteins 3 . NTRK1-3 fusions are present in nearly 90% of some rare cancers, such as infantile fibrosarcoma and secretory breast carcinoma, but occur in less than 1% of some common cancers 4 . These fusions are also rare in some other common cancers, such as uterine soft tissue tumors, some variants of malignant melanoma, papillary thyroid carcinoma, and pancreatic adenocarcinoma. However, evidence on NTRK1-3 fusion prevalence in other cancer types remains limited 5 . NTRK1-3 gene fusions or their proteins are often detected using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS) 6 . Agnostic therapy refers to treatment decisions based solely on the tumor's genomic features 7 , enabling personalized and more effective treatment options. This approach has transformed cancer treatment 7 . Precision medicine relies on detecting genomic alterations to guide treatment, using drugs that target tumor-driving mutations rather than tumor anatomic location or type 8 , 9 . One of the most significant advancements in this field is the development of TRK inhibitors, designed to block the oncogenic TRK signaling caused 10 . First-generation TRK inhibitors, larotrectinib and entrectinib, target TRKA, TRKB, and TRKC. Larotrectinib is highly selective for TRKs, whereas entrectinib also inhibits ROS1 and ALK 10 , 11 . These approved first-generation TRK inhibitors have demonstrated significant antitumor activity in clinical trials for treating solid tumors with NTRK1-3 fusions 12 , 13 . Data from a pooled analysis of three clinical trials showed that patients receiving larotrectinib have a response rate between 81% and 100% 14 . In comparison, data from the analysis of three other trials showed that entrectinib has an objective response rate (ORR) of 57% and durable responses, including in patients with brain metastases 15 . Other inhibitors, such as TPX-0005 (repotrectinib), crizotinib, and cabozantinib, are under investigation and show promise in overcoming resistance due to acquired mutations 11 . NTRK1-3 fusion detection is essential for TRK inhibitor eligibility, facilitating personalized and more effective targeted therapies. Molecular testing is integral to precision medicine's diagnostic and therapeutic process, significantly improving patient outcomes, contributing to the broader understanding of cancer biology, and developing novel therapeutic approaches. This study aims to systematize the knowledge regarding the frequency and types of NTRK1-3 gene fusions across a diverse range of soft tissue sarcomas beyond commonly associated sarcomas and infantile fibrosarcoma in pediatrics, underscoring the importance of comprehensive genomic profiling to guide personalized treatment strategies for patients with advanced or metastatic disease. Methods Study Design This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary File S1). The protocol for this systematic review is registered on the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024563594). Data Sources and Search Methods We conducted a comprehensive database search (PubMed/MEDLINE, SCOPUS, Web of Science) using NTRK1-3 and sarcoma-related terms, spanning from their inception to May 2024. Additionally, relevant proceedings from the major oncologic scientific conferences, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association for Cancer Research (AACR) from January 2023 to May 2024 were reviewed. The search was updated on July 14, 2024. Specific search terms related to NTRK1-3 and sarcoma were employed to identify pertinent studies. These terms encompassed various synonyms and related expressions for NTRK receptors and a broad spectrum of sarcoma types. The search terms used for different databases are provided in Supplementary File S2. Procedure for Study Selection The articles retrieved from the database searches were uploaded into EndNote software to remove duplicates. Following deduplication, titles, and abstracts were screened using the Rayyan systematic review management platform ( https://www.rayyan.ai/ ). Full-text articles meeting initial inclusion criteria underwent detailed eligibility assessment by each of the two independent reviewers. Any discrepancies were resolved through consensus or consultation with a third reviewer (SH). Eligibility Eligible studies included case series, case reports, and observational analytical studies investigating NTRK1-3 gene fusions in soft tissue sarcomas. Relevant abstracts without full text were also considered if they reported applicable outcomes. Studies that included a diagnosis of soft tissue sarcoma, reported the frequencies and types of NTRK1-3 fusions and provided detailed descriptions of NTRK1-3 fusion variants were included. Studies exclusively focusing on non-sarcoma malignancies or non-English publications were excluded. Key Definitions Sarcomas are malignant soft tissue (mesenchymal) tumors 16 . Neurotrophic Receptor Tyrosine Kinase ( NTRK ) fusion genes are formed by the fusion of a part of the NTRK1-3 genes with different partner genes, resulting in constitutive activation of the TRK signaling 17 , 18 . Outcomes The primary outcome was to determine the prevalence of NTRK1-3 gene fusions in various types of sarcomas, assessed by the proportion of cases with identified fusions using molecular diagnostic techniques. Secondary outcomes included comparing fusion type distributions, evaluating detection method efficacy, assessing the safety and efficacy of TRK inhibitors, and examining fusion distribution across different sarcoma subtypes. Data Extraction Two independent authors extracted data using Microsoft Excel. The extracted data included study design, patient demographics, tumor type and location, molecular details of NTRK1-3 fusions, detection methods, treatment approaches, and survival outcomes. Data Synthesis The results were synthesized using narrative synthesis methods. Tabular presentations were summarized, including the proportion of fusion, variants' distribution, and clinicopathological correlations. Thematic analysis will explore molecular mechanisms and therapeutic implications. Subgroup analyses were done to assess variations across different sarcoma subtypes. The quality of the studies was assessed using the MethodologicAl STandard for Epidemiological Research (MASTER) scale, which includes 36 safeguards categorized into seven domains 19 . These domains are equal recruitment, equal retention, equal ascertainment, equal implementation, equal prognosis, sufficient analysis, and temporal precedence. We used Stata version 18 (College Station, TX, USA) for the analysis. Ethics This is a systematic review of published literature and thus did not require institutional ethical approval. Results Search results Seven hundred eighty-seven studies were identified from the databases. After removing 186 duplicates, 387 study records were excluded through manual abstract and title screening, and the remaining 214 studies were screened using full text. After full-text screening, 19 studies were excluded because they were reviews, 14 because they did not assess sarcomas, and 10 papers were not available in English. Other reasons for exclusion are illustrated in the PRISMA flowchart (Fig. 1 ). The final review included 136 studies 4 , 14 , 15 , 20 – 152 . Quality assessment of included studies Seven of the 136 articles included were abstracts 77 , 83 , 90 , 111 , 125 , 134 , 141 , and one paper was an integrated analysis of non-published studies 15 , so their quality could not be assessed. The average MASTER scale score for the remaining 128 studies we assessed was 25 out of a maximum score of 36, ranging from 20 in some studies 23 , 36 , 98 , 118 , 119 , 137 up to 29 in others 42 , 47 , 50 , 70 , 71 , 73 , 95 , 97 , 121 , 124 , 146 , indicating a moderate quality with a low-moderate risk of bias. The 128 studies did not have blinding or allocation concealment, which downgraded the studies in the ‘Equal ascertainment’ (domain 3) and the ‘Equal prognosis’ (domain 5) categories of the MASTER scale. Additionally, there were 40 multi-centered studies 4,14,20–24,30,34,40,44,51,53,57,59,61,62,78–80,85,89,94,98,107,108,110,114,115,118,119,129,131–133,136−138,147,148 , so the fourth domain, ‘Equal implementation’, was not fulfilled. Further details of the MASTER scale assessment can be seen in Supplementary File S3. Characteristics of included studies The baseline characteristics in the analyzed studies exhibit considerable heterogeneity in several aspects, including the study design, duration, location, patient demographics, and gender distribution. Out of 136 papers, 50 were case reports 25,28,31,32,38,39,42,47,49,53,55,58,60,65–68,70,71,73,76,81–84,86,88,91–93,95−97,99–101,103,106,109,112,116,120,121,126,128,130,140,145,146,150 , 26 were case series 20 , 27 , 35 , 43 , 45 , 46 , 52 , 56 , 61 , 69 , 72 , 74 , 75 , 80 , 101 , 110 , 113 , 115 , 117 , 118 , 123 , 125 , 132 – 135 , 138 , 152 , 54 were observational retrospective studies 4,14,21–24,26,29,30,33,34,36,37,40,41,44,48,51,54,57,59,62–64,77−79,85,87,89,90,94,98,102,104,108,111,114,122,124,129,131,133,136,137,139,141–144,147−149,151 , one was a prospective cohort 134 , two were retrospective and prospective cohort studies 107 , 119 , two were pooled analyses of three clinical trials 15 , 127 , and one was a study with a partitioned survival model 105 (Supplementary File S3). Notably, 85 studies did not specify the exact length of the study or follow-up period. Of the 51 studies, 19 were from ten to 30 years old. Of these 19 papers, 12 22,30,34,40,54,59,79,89,102,139,144,151 were descriptive studies that utilized archived materials and clinical records to analyze tumor biopsies, while the remaining seven 20 , 45 , 69 , 97 , 117 , 123 , 135 were case series and case reports with long-term patient follow-ups. Additionally, 25 studies 4 , 14 , 37 , 47 , 52 , 55 , 56 , 62 , 77 , 80 , 81 , 86 , 90 , 98 , 107 , 108 , 113 , 114 , 118 , 119 , 129 , 136 , 141 , 143 , 149 had durations ranging from one to five years, including a mixture of case series, case reports, and retrospective studies. Most of the included studies were conducted in the USA (n = 46), followed by China (n = 17), and Japan (n = 14). Eight studies did not specify the geographic location. The remaining studies were distributed across the globe. Figure 2 summarizes the common geographical locations of the included studies. Supplementary File S3 provides detailed information. Forty-four studies did not report gender distribution. The remaining 92 studies 21,22,24,25,28–31,35,36,38,40,42,46,47,49–61,63−76,78,80–84,86−89,91–93,95−97,100–105,109,110,112,114,116–123,126−128,130–132,135,136,138–140,143,145,147,148,150 had a combined sample size of 1,824 patients; 1,139 of them were women (62.45%). Regarding the age of patients, nine studies did not specify the age group, 43 studies 20 – 23 , 25 , 28 – 34 , 38 , 39 , 42 , 44 – 46 , 48 , 49 , 54 , 55 , 59 , 60 , 67 – 70 , 75 , 76 , 82 , 92 , 102 , 106 , 112 , 117 , 120 , 130 , 139 , 142 , 143 , 150 , 152 focused exclusively on pediatric patients (those under 18 years), 38 studies 24,26,36,37,40,43,51,52,62–64,77−80,89,90,98,104,105,107,113,114,119,122–124,129,131–133,136−138,144,147,149,151 included both pediatric and adult populations, and 46 studies 4,15,35,47,50,53,56–58,61,65,66,71–74,81,83,84,86–88,91,93–97,99−101,103,108–110,116,118,121,126–128,140,141,145,146,148 focused solely on adults. The population's age range varied from neonates only a few days old to elderly patients (Supplementary File S3). Sarcoma types This systematic review revealed 18,077 sarcoma patients in 136 studies. Of these, 17 studies 4 , 14 , 62 , 63 , 77 , 90 , 94 , 98 , 110 , 111 , 114 , 133 , 134 , 139 , 141 , 142 , 144 (representing 11,108 patients) did not mention the specific type of soft tissue tumor detected. Among the remaining 6,969 cases, 2,004 were diagnosed as unspecified or unclassified soft tissue tumors. Additionally, 1,019 women presented with gynecologic sarcomas, including 591 with leiomyosarcomas. Other soft tissue tumors included 409 gastrointestinal stromal tumors (GIST), 145 synovial sarcomas, 302 osteosarcomas, 162 angiosarcomas, 37 lipofibromatosis-like neural tumors, 609 liposarcomas, and 151 patients with congenital or infantile fibrosarcomas. Further details on other sarcoma types are detailed in Table 1 . Table 1 Characteristics of the included studies. No. Author, year Country Fusion detection method Total no. of sarcoma patients Number of pts in each type of sarcoma/s Tumor location No. of NTRK fusions 1 Knezevich, 1998 20 Canada, USA cytogenic analysis, karyotype, FISH, RT-PCR, northern & southern blots 4 Four IFS flank (1), lower limb (3) NTRK3 (3) 2 Rubin, 1998 21 USA karyotype, FISH, RT-PCR, DNA sequencing 11 Six CMN, 5 CFS kidney (6), back (2), limbs (2), neck (1) NTRK3 (6) 3 Knezevich, 1998 22 Canada, USA RT-PCR, FISH, Northern Blot 15 Nine cellular CMN, two mixed CMN, four classical CMN NA NTRK3 (10) 4 Argani, 2000 23 USA RT-PCR 11 Eleven CMN NA NTRK3 (10) 5 Bourgeoi, 2000 24 USA RT-PCR 24 Thirteen malignant spindle cell tumors, 11 CFS Limbs (24), head & neck (14), abdomen (7), back (5), buttock (3), chest wall (3), multicentric (2), flank (2), lung (1), prostate (1) NTRK3 (10) 6 Punnett, 2000 25 USA karyotype, FISH, RT-PCR 1 One CFS lower limb/groin/pelvis/pulmonary (1) NTRK3 (1) 7 Sheng, 2001 26 Japan, Sweden RT-PCR, DNA sequencing 40 Ten congenital/IFS, seven adult-type fibrosarcomas, four leiomyosarcomas, four malignant fibrous histiocytomas, four monophasic synovial sarcomas, three MPNST, four DFSP, four fibromatoses limbs (8), jaw angle (1). The rest were not specified. NTRK3 (7) 8 Hisaoka, 2002 27 Japan, China RT-PCR 31 Three desmoid, one hemangiopericytoma, two DFSP, one IFS, one malignant fibrous histiocytoma, three leiomyosarcoma, one embryonal RMS, one alveolar RMS, three synovial sarcoma, four well-differentiated liposarcomas, one differentiated liposarcoma, four myxoid liposarcomas, two extraskeletal Ewing’s sarcomas, one primitive neuroectodermal tumor, one angiosarcoma, one extraskeletal myxoid chondrosarcoma, one clear cell sarcoma NA 27 TrkC ( NTRK3 ) expression & 1 with Tel–TrkC fusion transcript 9 Henno, 2003 28 France Molecular study, IHC, RT-PCR 1 One cellular CMN kidney (1) NTRK3 (1) 10 McCahon, 2003 29 Canada RT-PCR 3 Two IFS, one atypical CMN lower limb (2), kidney (1) NTRK3 (3) 11 Ootsuka, 2007 30 Japan qRT-PCR 2 Two RMS NA NA 12 Mariño-Enríquez, 2008 31 USA karyotype, FISH 1 One CFS Retroperitoneum (1) NTRK3 (1) 13 Himori, 2009 32 Japan RT-PCR 1 One IFS thigh (1) NTRK3 (1) 14 Gadd, 2012 33 USA RT-PCR, FISH, RT–MLP, IHC 14 Twelve CMN, two IFS NA NTRK3 (7) 15 Walther, 2013 34 Sweden Chromosome banding, FISH, RT-PCR, SNP array 6 One embryonal RMS, three IFS, one nodular fibrohistiocytic tumor, one angiomatoid fibrous histiocytoma head & neck, thorax, abdomen, pelvis, extremities, and skin (numbers not reported) NTRK3 (1) 16 Brenca, 2015 35 Italy RT-PCR, FISH 5 Five GIST small intestine (4), rectum (1) NTRK3 (1) 17 Haller, 2016 36 Germany RT-PCR, FISH, RNA sequencing, WGS, western blot 4 Two myopericytoma-like sarcomas, one infantile hemangiopericytoma-like sarcoma, one myofibroblastic sarcoma-like back (1), paravertebral lumbar (1), supraclavicular (1), upper arm (1) NTRK1 (3) 18 Shi, 2016 37 USA CGP 191 191 GIST gastrointestinal tract (191) NTRK3 (2) 19 Nagasubramanian, 2016 38 USA FISH 1 One IFS head & neck (1) NTRK3 (1) 20 Wong, 2016 39 NA RT-PCR, FISH, DNA & RNA sequencing hybrid capture-based assay 1 One SCS buttock (1) NTRK1 (1) 21 Agaram, 2017 40 USA FISH, IHC 14 Fourteen LPFNT limbs (8), flank (1), scalp (1) NTRK1 (6), NTRK1 gene amplification (4) 22 Hechtman, 2017 41 USA NGS, RNA testing, IHC 2 Two sarcomas NA NTRK1 (1), NTRK3 (1) 23 Obayashi, 2017 42 Japan IHC, RT-PCR, gene sequencing 1 One IFS ileocecal region (1) NTRK3 (1) 24 Pavlick, 2017 43 USA FISH, DNA & RNA sequencing, CGP 7 Two IFS, one fibrosarcoma, one fibrosarcoma ex DFSP, one neuroectodermal tumor, one IMT, one dendritic sarcoma NA NTRK1 (4), NTRK3 (3) 25 Chmielecki, 2017 44 USA NGS 311 63 bone sarcomas, 66 RMS, 39 EwS, 37 STS, 19 soft tissue assorted, 18 fibromatoses, five angiosarcomas, six fibrosarcomas, 10 synovial sarcomas, six alveolar soft part sarcomas, seven IMT, 14 DFSP, 11 MPNST, 10 unknown sarcomas. NA NTRK1 (1), NTRK3 (1) 26 Gatalica, 2018 4 USA NGS, IHC 478 One STS, one uterine sarcoma, 476 tumors NA NA NTRK1 (1), NTRK3 (1) 27 Hung, 2018 45 USA NGS, FISH, IHC 160 Five LPFNT, five lipofibromatosis, 10 primitive myxoid mesenchymal tumors of infancy, 10 low-grade myofibroblastic sarcomas, 15 IFS, 15 desmoid fibromatosis, 20 fibrosarcomatous DFSP, 20 spindle-cell RMS, 20 synovial sarcomas, 20 MPNST, 20 low-grade fibromyxoid sarcomas limbs (10), truncal/abdominopelvic/paravertebral region (11) head & neck (5), sacrococcygeal region (1), inguinal region (3), the rest were not specified. NA 28 Kao, 2018 46 USA, Canada, Turkey, Taiwan FISH, RT-PCR, RNA sequencing 10 Nine IFS, one unclassified low- grade SCS Retroperitoneal (3), pelvis (2), spine extradural (1), limbs (3), lumbar (1) NTRK1 (1), NTRK3 (1) 29 Olson, 2018 47 USA RT-PCR, NGS 1 One DFSP back (1) NTRK3 (1) 30 Rudzinski, 2018 48 USA FISH, IHC, RT-PCR, NGS 65 Thirty-one STS NOS, two DFSP, five desmoid, two MPNST, two synovial sarcomas, two spindle cell RMS, six IMT, one BCOR -rearranged sarcoma, one UPS, four high-grade sarcomas, five low-grade spindle cell lesions, one metanephric stromal tumor, one classic mesoblastic nephroma, one cellular mesoblastic nephroma, one clear cell sarcoma of the kidney NA NTRK1 (12), NTRK1 gene amplification (1), NTRK2 (1), NTRK3 (9) 31 Kohsaka, 2018 49 Japan RT-PCR, RNA sequencing 1 One unclassified tumor elbow (1) NTRK1 (1) 32 Takahashi, 2018 50 Japan IHC, FISH 1 One IMT uterus (1) NTRK3 (1) 33 Suurmeijer, 2018 51 NA targeted RNA sequencing, FISH 25 25 spindle cell neoplasms limbs (14), Gastrointestinal tract (2), abdomen (1), Chest wall (4), back (2), Head (2) NTRK1 (14), NTRK2 (1) 34 Lao, 2018 52 China FISH 10 Four LPFNT, three IFS, one MPNST, two SCS limbs (2), buttock (2), right hip (1), left neck (3), right chest wall (1), left flank (1) NTRK1 gene rearrangement (4) 35 Zhou, 2018 53 NA NGS 1 One SCS Lumbosacral region/erector spinae/fifth lumbar vertebra/first sacral vertebra/iliac wing (1) NTRK1 (1) 36 Antunes, 2019 54 Brazil IHC 19 Nineteen osteosarcomas limbs (17), pelvis (1) TrkA expression on IHC (4), TrkB expression on IHC (8) 37 Bender, 2019 55 USA RNA sequencing, DNA-based hybridization capture 1 One IFS forearm (1) NTRK1 (1) 38 Chiang, 2019 56 USA RNA & DNA sequencing, NGS, FISH, IHC 4 Four undifferentiated uterine sarcomas uterine cervix (3), uterine corpus (1) NTRK1 (3), NTRK3 (1) 39 Croce, 2019 57 France, USA, UK RNA & DNA sequencing, RT-PCR, FISH, IHC 13 Thirteen SCS uterine cervix (10), uterine corpus (2), vagina (1) NTRK1 (6), NTRK3 (1) 40 D’Alpino Peixoto, 2019 58 Brazil NGS 1 One GIST rectum (1) NTRK1 (1) 41 Davis, 2019 59 USA NGS, DNA sequencing, FISH, IHC 28 Fifteen IFS, five low-grade SCS, four unclassified tumors, two spindle and round cell sarcoma, one SCS, one myxoid DFSP limbs (17), abdomen (1), pelvis (2), retroperitoneal (2), trunk (2), back (1), dural (1), lung (1), paraspinal (1) NTRK1 (14), NTRK2 (1), NTRK3 (13) 42 Warren, 2019 60 USA NGS 1 One NTRK -rearranged mesenchymal tumor back (1) NTRK1 (1) 43 Yamazaki, 2019 61 Japan RNA sequencing, RT-PCR, Sanger sequencing, FISH 2 Two adult-type fibrosarcoma limbs (2) NTRK3 (2) 44 Solomon, 2019 62 USA DNA based NGS (MSK-IMPACT), RNA sequencing assay (MSKFusion) 1915 NA Various locations, including salivary gland, thyroid, sarcoma, lung, etc. NTRK1 (9), NTRK3 (4) 45 Suurmeijer, 2019 63 NA FISH, targeted RNA sequencing, anchored multiplex RNA sequencing, MSK-IMPACT assay 7 NA limbs (3), abdomino-pelvic (1), retroperitoneal (1), paraspinal (1), mesentery (1). NTRK3 (7) 46 Ameline, 2020 64 Sweden RNA sequencing, RT-PCR, Sanger sequencing validation 113 113 osteosarcomas NA NTRK2 (1), NTRK3 (2) 47 Bertolini, 2020 65 Switzerland NGS 1 One spindle cell neoplasm colon (1) NTRK1 (1) 48 Boyle, 2020 66 UK NGS 1 One uterine sarcoma Uterine cervix (1) NTRK1 (1) 49 Caldwell, 2020 67 USA RT-PCR 1 One IFS arm (1) NTRK3 (1) 50 Goh, 2020 68 Singapore NGS, IHC 1 One UPS abdominal wall (1) NTRK1 (1) 51 Kang, 2020 69 South Korea FISH, NGS 9 One undifferentiated sarcoma, seven IFS, one IMT Dura (1), dermis and subcutaneous tissue (1), tongue (1), buttock (1), shoulder (1), foot (1), abdominal cavity (1), sacrococcygeal area (1), lung (1) NTRK1 (2), NTRK3 (7) 52 Olsen, 2020 70 USA IHC, FISH 1 One undifferentiated SCS pelvis-abdomen (1) NTRK3 gene rearrangement (1) 53 Panse, 2020 71 USA FISH, Targeted RNA sequencing 1 One LPFNT scalp (1) NTRK1 (1) 54 Rabban, 2020 72 USA IHC, NGS 22 Three cervical sarcomas, 19 uterine adenosarcomas cervix (3), uterus (19) NTRK1 (2), NTRK3 (1) 55 So, 2020 73 China IHC, FISH, NGS 1 One myxoid SCS calf (1) NTRK1 (1) 56 Vargas, 2020 74 Australia Array comparative genomic hybridization, NGS, FISH, pan-TRK IHC 6 Two inflammatory myofibroblastic-like tumors, one EwS, one fibrosarcoma-like tumor, one lung spindle and epithelioid cell sarcoma, and one uterine MPNST-like sarcoma liver (1), subcutaneous (1), thyroid (1), lung (1), uterine cervix (1), toe (1) NTRK1 (1), NTRK2 (1), NTRK3 (2), NTRK3 gene rearrangement (2) 57 Khuong-Quang, 2020 75 Australia WGS, RNA sequencing 1 One congenital/IFS Chest (1) NTRK3 (1) 58 Rekhi, 2020 76 India NGS-based targeted panel, FISH 1 One SCS neck (1) NTRK1 (1) 59 Wang, 2020 77 China NGS 312 NA NA NTRK1 (4), NTRK3 (7) 60 Atiq, 2021 78 USA DNA & RNA sequencing, FISH, IHC 6 Four unclassified mesenchymal tumors, two IFS small bowel (3), stomach (1), rectum (1), mesentery (1) NTRK1 (4), NTRK3 (2) 61 Brčić, 2021 79 Austria NGS, IHC 491 116 myxofibrosarcomas, 82 soft tissue and uterine leiomyosarcomas, 55 UPS, 45 synovial sarcomas, 37 myxoid liposarcomas, 34 atypical lipomatous tumors/well-differentiated liposarcomas, 34 dedifferentiated liposarcomas, 19 DFSP, 12 low-grade fibromyxoid sarcomas, 10 angiosarcomas, eight SFT, eight SCSs, five myxoinflammatory fibroblastic sarcomas, four pleomorphic liposarcomas, four alveolar soft part sarcomas, three spindle cell/pleomorphic sarcoma, three clear cell sarcomas, two extraskeletal myxoid chondrosarcomas, two embryonal RMS, two sclerosing epithelioid fibrosarcomas, one epithelioid sarcoma, one mesenchymal chondrosarcoma, one MPNST, one pleomorphic RMS, one IFS, one LPFNT limbs (3), lung (1), neck (1), others not specified NTRK1 (2), NTRK3 (2) 62 Chen, 2021 80 USA RNA-based NGS 6 Two EwS, one osteosarcoma, one unspecified high-grade malignant neoplasm, one lipofibromatosis-like features, one malignant SFT chest wall (1), limbs (4), paraspinal neck (1) NTRK1 (1), NTRK2 (1) 63 Chen, 2021 81 China NGS 1 One unclassified mesenchymal sarcoma scalp (1) NTRK1 (1) 64 Goulding, 2021 82 New Zealand NGS, FISH, IHC 1 One high-risk RMS vagina (1) NTRK1 (1) 65 Hodgson, 2021 83 Canada NGS 1 One cervical sarcoma uterine cervix (1) NTRK3 (1) 66 Punjabi, 2021 84 Singapore IHC, RT-PCR, Sanger sequencing 1 One NTRK3-SQSTM1 fusion SCS ankle (1) NTRK3 (1) 67 Lam, 2021 85 Netherlands Pan-trk IHC 381 137 conventional chondrosarcomas, 36 dedifferentiated chondrosarcomas, 20 clear cell chondrosarcomas, 19 mesenchymal chondrosarcomas, 123 osteosarcomas, 26 angiosarcomas, 20 EwS NA 17 pan-TRK IHC positive 68 Lanman, 2021 86 USA NGS 1 One uterine sarcoma uterus (1) NTRK3 (1) 69 Liu, 2021 87 USA Targeted RNA sequencing, RT-PCR, Sanger sequencing 8 Five chondroid tenosynovial giant cell tumor, one chondroid neoplasm of synovium, one atypical chondroid neoplasm, one giant cell-rich lesion chondroid stroma TMJ/temporal bone (4), limbs (4) NTRK1 (1) 70 Percy, 2021 88 Belgium NGS 1 One SCS Distal left leg/Kager space/posterior cortical of the tibia/left Achilles tendon (1) NTRK1 (1) 71 Xu, 2021 89 China NGS 195 23 GIST, 22 osteosarcomas, 14 liposarcomas, 13 leiomyosarcomas, 12 myxofibrosarcomas, nine synovial sarcomas, seven EwS, five chondrosarcomas, five RMS, five aggressive fibromatosis, four angiosarcomas, four DFSP, four UPS, two epithelioid hemangioendotheliomas, two myofibroblastic sarcomas, two myxoid sarcomas, one SFT, one embryonic undifferentiated sarcoma, one alveolar soft part sarcoma, one clear cell sarcoma, one malignant granular cell tumor, 50 unclassified STS, four unclassified osteogenic sarcomas, two IFS, one NTRK -rearrangement spindle cell mesenchymal tumor. NA NTRK1 (2), NTRK1 rearrangement (4), NTRK3 (4), NTRK3 rearrangement (1) 72 Peng, 2021 90 China Targeted NGS, FISH, IHC 547 NA NA NA 73 Bai, 2022 91 China NGS, FISH, IHC 1 One high-grade UPS chest wall (1) NTRK3 (1) 74 Bridgewater, 2022 14 UK WGS 1174 NA NA NTRK1 (1), NTRK2 (2), NTRK3 (4) 75 Czaja, 2022 92 USA NGS, IHC 1 One LPFNT back (1) NTRK1 (1) 76 Dang, 2022 93 China NGS, IHC 1 One NTRK fusion cervical sarcoma uterine cervix (1) NTRK3 (1) 77 Demetri, 2022 15 USA & South Korea NGS, IHC, FISH, PCR, Sanger sequencing, or NanoString 26 Ten sarcoma NOS, 5 SCS, 2 GIST, 2 leiomyosarcoma, 1 angiosarcoma, 1 cervical adenosarcoma, 1 chondrosarcoma, 1 endometrial sarcoma, 1 endometrial stromal sarcoma, 1 Follicular dendritic cell sarcoma, 1 MPNST NA NA 78 Hibar, 2022 94 USA NGS 287 NA NA NA 79 Jiang, 2022 95 China RT-PCR, FISH, DNA Sequencing 1 One primary renal fibrosarcoma kidney (1) NTRK3 (1) 80 Overfield, 2022 96 USA NA 1 One NTRK ‑rearranged spindle cell tumor knee (1) NTRK1 (1) 81 Recine, 2022 97 Italy IHC, NGS 1 One NTRK ‑rearranged spindle cell tumor abdominal cutaneous lesion (1) NTRK1 (1) 82 Silvertown, 2022 98 Canada IHC, NGS 165 One SCS, two MPNST, 162 tumors NA chest (2), arm (1), not specified (162) NTRK1 (1), NTRK3 (2) 83 Kobayashi, 2022 99 Japan RNA & DNA panel testing, IHC, FISH 1 One MPNST buttock (1) NTRK3 (1) 84 Kyriazogloua, 2022 100 Greece NGS, RT-PCR 1 One unclassified myxoid SCS left gluteal area (1) NTRK3 (1) 85 Nilforoushan, 2022 101 USA DNA & RNA sequencing 2 Two SCS cervix (2) NTRK1 (1), NTRK3 (1) 86 Nozzoli, 2022 102 Italy IHC, NGS, RT-PCR 105 96 EwS, three EWSR1 -non-ETS round cell sarcomas, one sarcoma with BCOR genetic alteration, five undifferentiated STS soft tissue (23), bone (82) NTRK3 (2) 87 Rahim, 2022 103 Kuwait DNA-based NGS, RNA-based gene fusion assay, pan-TRK IHC 1 One SCS ileum (1) NTRK1 (1) 88 Siozopoulou, 2022 104 Belgium NGS 70 Ten chondrosarcomas, three EwS, five osteosarcomas, seven angiosarcomas, eight Kaposi sarcomas, five leiomyosarcomas, nine liposarcomas, five myxofibrosarcomas, three RMS, three synovial sarcomas, 12 sarcoma NOS Bone (19), extremities (17), trunk and back (5), head & neck (4), skin and subcutaneous fat tissue (12), abdomen (6), mediastinum (5), retroperitoneum (2) NTRK3 (2) 89 Suh, 2022 105 USA NA 250 32 liposarcomas, 59 leiomyosarcoma, 27 synovial sarcomas, 132 STS NOS NA NA 90 Thorwarth, 2022 106 Germany Single-nucleotide variant analysis, WES 1 One IFS intrathoracic (1) NTRK3 (1) 91 Tsai, 2022 107 Taiwan RNA sequencing, FISH, RT-PCR, IHC 7 Seven spindle cell neoplasms lung (1), heart (1), right pleura (1), prostate (1), uterine cervix (2), NA (1) NTRK1 (5), NTRK3 (1), NTRK3 gene rearrangement (1) 92 Van Bockstal, 2022 108 Belgium Pan-TRK IHC and subsequent molecular NTRK testing, FISH, RNA sequencing 6 Three IFS, two SCS, one LPFNT NA NTRK1 (1), NTRK3 (4) 93 Wang, 2022 109 China FISH, RNA-sequencing, NGS 1 One SCS femur (1) NTRK3 (1) 94 Young, 2022 110 NA Pan-TRK IHC, FISH 2 NA Peri-adrenal (1), retroperitoneal (1) NTRK1 gene rearrangement (2) 95 Moyers, 2022 111 NA Genomic sequencing 4256 3,424 STS, 832 bone sarcomas NA NA 96 Gong, 2023 112 China NGS, FISH, IHC 1 One spindle cell neoplasm brain (1) NTRK1 (1) 97 Agostara, 2023 113 Italy NGS 4 Four primary cardiac sarcomas heart (4) NTRK3 (1) 98 Bornstein-Quevedo, 2023 114 Mexico NGS, IHC 99 Two STS, one IFS, 96 tumors NA NA NTRK1 (2), NTRK3 (1) 99 Cammareri, 2023 115 France RNA sequencing, NGS, FISH 330 31 adipocytic tumors, 45 fibroblastic and myofibroblastic tumors, 44 vascular tumors and malformations, 15 smooth muscle tumors, 16 skeletal muscle tumors, 36 MPNST, 23 undifferentiated small round cell sarcomas of bone and soft tissue, 12 mesenchymal tumors of the digestive system, 74 tumors of uncertain differentiation, 19 cutaneous soft tissue tumors, five thoracic SMARCA4-deficient undifferentiated tumors, seven chordomas, three biphenotypic sinonasal sarcomas NA NTRK1 (3), NTRK2 (1) 100 Challa, 2023 116 USA NGS 1 One mesenchymal neoplasm esophagus (1) NTRK3 (1) 101 Corral Sánchez, 2023 117 Spain RT-PCR, FISH 8 Eight IFS trunk (4), limbs (3), neck (1) NTRK3 (4) 102 Creus-Bachiller, 2023 118 Spain RNA sequencing, WGS 5 Three MPNST, one NTRK -associated SCS, one unclassifiable tumor back (3), limbs (2) NTRK1 (1) 103 Dufresne, 2023 119 France whole-exome RNA-sequencing 16 Two LPFNT, one peripheral nerve sheath tumor, one cutaneous spindle cell mesenchymal tumor, three IMT, one GIST, two dedifferentiated liposarcomas, two UPS, one leiomyosarcoma, one intimal sarcoma, one high-grade uterine sarcoma, one neurofibromatosis type 1-associated MPNST Back (4), limbs (4), abdomen (2), pulmonary artery (1), mediastinal (1), spermatic cord (1), uterine (1) NTRK1 (8), NTRK3 (8) 104 Furtado, 2023 120 USA RT-PCR, FISH, WGS, WES, RNA sequencing 1 One IFS buttock (1) NTRK3 (1) 105 Palmerini, 2023 121 Italy NGS 1 One undifferentiated SCS foot (1) NTRK3 (1) 106 Yin, 2023 122 China IHC, NGS, Sanger sequencing, PCR, FISH 13 Four LPFNT, eight MPNST-like, one myxofibrosarcoma-like. Back (1), abdominal wall (1), limb (6), buttock (2), small intestine (1), Rectum (2) NTRK1 (12) 107 Kobayashi, 2023 123 Japan NGS 6 One NTRK -rearranged spindle cell neoplasm, one sarcoma intermediate malignancy, three SFT, one dedifferentiated liposarcoma limb (4), buttock (1), perineal (1) NTRK1 (4), NTRK3 (2) 108 Kojima, 2023 124 Japan NGS, FISH, IHC 203 38 mesenchymal tumors, 15 IMT, 20 UPS, 20 myxofibrosarcomas, 20 MPNST, 20 DFSP, 10 dedifferentiated liposarcomas, 10 SFT, 10 synovial sarcomas, 10 leiomyosarcomas, 10 BCOR -associated sarcomas, 10 GIST, five spindle cell/sclerosing RMS, five atypical spindle cell lipomatous tumors Head & neck (6), limbs (19), Intradural (1), pelvic iliac bone (1), chest (3), breast (1), kidney (1), jejunum (1), retroperitoneum (3), NA (167) NTRK1 (13), NTRK2 (2), NTRK3 (7) 109 Krsková, 2023 125 Czech Republic PCR, Genome-wide DNA methylation profiling 11 One SCS, one high-grade sarcoma, one pediatric sarcoma NA NTRK1 (3) 110 Kubota, 2023 126 Japan NGS 1 One EwS mediastinum (1) NTRK1 (1) 111 Kummar, 2023 127 USA DNA & RNA based NGS, FISH 36 One chondrosarcoma, one bone sarcoma NOS, four GIST, eight soft tissue tumors NOS, six MPNST, four SCS, three epithelioid spindle sarcomas, two IMT, two myopericytomas, two stromal tumors, one dedifferentiated liposarcoma, one fibrosarcoma, one synovial sarcoma NA NTRK1 (19), NTRK2 (1), NTRK3 (16) 112 Lin, 2023 128 USA RNA-based NGS, gene fusion panel analysis 1 One malignant SFT gluteal area (1) NTRK2 (1) 113 Romanko, 2023 129 NA 50/30-end unbalanced expression test, variant-specific PCR, NGS 226 44 IMT, one CMN, 56 sarcoma NOS, 18 EwS, 19 leiomyosarcomas, 14 liposarcomas, one spindle cell RMS, eight chondroblastic osteosarcomas, two clear cell sarcomas, 11 MPNST, seven alveolar RMS, three IFS, seven RMS NOS, three fibrosarcomas, five osteosarcomas, eight synovial sarcomas, five endometrial stromal sarcomas, three UPS, four embryonal RMS, two myxofibrosarcomas, one Ewing-like sarcoma, one SCS, two DFSP, one angiosarcoma NA NTRK1 (4), NTRK3 (5) 114 Sahni, 2023 130 Bangladesh, India FISH, NGS 1 One IFS leg (1) NTRK3 (1) 115 Suurmeijer, 2023 131 Netherlands, USA FISH, targeted RNA sequencing, Pan-TRK IHC 4 One MPNST-like, one adult fibrosarcoma-like, one MPNST, one IFS-like tumor head & neck (1), tibia (1), pelvis (1), chest wall (1) NTRK1 (1), NTRK3 (1) 116 Xu, 2023 132 USA FISH, targeted RNA sequencing 13 Four IFS, two lipofibromatosis-like neural tumor, three MPNST-like, two adult-type fibrosarcoma-like, one IMT-like, one myxoma-like tumor head & neck region (13) NTRK1 (4), NTRK3 (5) 117 Xu, 2023 133 China DNA sequencing, RNA sequencing, IHC 571 49 fibrosarcoma, six IFS, one RMS, two STS, four SCS, one prostatic stromal tumor, two mucinous liposarcomas, one leiomyosarcoma, 505 NA thigh, lung, mediastinal lymph nodes, double lung metastasis, retroperitoneal area, and abdomen (numbers NA) NTRK1 (8), NTRK3 (9) 118 Dong, 2023 134 NA RNA & DNA-based NGS 99 NA NA NTRK3 (1) 119 Moura, 2023 135 France IHC, RNA sequencing, FISH 351 Two COL1A1-PDGFB rearranged sarcoma, 50 adenosarcomas, 122 low-grade endometrial stromal sarcomas, four low-grade endometrial stromal sarcomas with high-grade transformation, 46 high-grade endometrial stromal sarcomas, 13 uterine smooth muscle tumors of uncertain malignant potential, 19 leiomyosarcomas, 73 undifferentiated uterine sarcomas, four IMT, two SFT, one embryonal RMS, one hybrid peripheral nerve sheath tumor, one low-grade fibromyxoid sarcoma, one fibroblastic/myofibroblastic tumor of uncertain malignant potential, 12 NTRK -rearranged sarcomas Uterine corpus (324), cervix (9), vulva (2), metastasis (16) NTRK1 (8), NTRK3 (4) 120 Hasegawa, 2024 136 Germany RT-PCR, NGS, IHC 82 Ten leiomyosarcomas, six myxofibrosarcomas, six myxoid liposarcomas, five pleomorphic leiomyosarcomas, four high-grade myxofibrosarcomas, four MPNST, four alveolar soft part sarcomas, four high-grade sarcoma NOS, three dedifferentiated liposarcomas, three osteosarcomas, three DFSP, three synovial sarcomas, three UPS, two extraskeletal osteosarcomas, two epithelioid hemangioendotheliomas, two epithelioid sarcomas, one low-grade myxofibrosarcoma, one well-differentiated liposarcoma, one periosteal osteosarcoma, one myxoid sarcoma, one high-grade myxoid sarcoma, one low-grade myxoid sarcoma, one IMT, one EwS, one RMS, one angiosarcoma, one extraskeletal myxoid chondrosarcoma, one chondrosarcoma, one intimal sarcoma, one malignant triton tumor, one superficial CD34-positive fibroblastic tumor, one high-grade SCS, one small-round cell sarcoma NOS, one low-grade sarcoma NOS. NA NTRK1 (1), NTRK3 (1) 121 Hernandez, 2024 137 Spain NGS, IHC 36 28 gynecological sarcomas, six GIST, one IFS, one MPNST NA NTRK3 (2) 122 Klubíčková, 2024 138 Czech Republic RNA & DNA sequencing 22 Eleven IFS, five pattern SPH, two LPFNT, one MPNST, one myopericytoma-like tumor, one LPFNT/SPH, one epithelioid/rhabdoid tumor limbs (6), retroperitoneum (3), uterus (1), cervix (1), face (3), Hip (1), duodenum (1), scalp (1), coccygeal region (1), 2nuchal region (1), orbit (1), back (1) NTRK1 (5), NTRK3 (7) 123 Orbach, 2024 139 France NGS, FISH, RT-PCR 93 NA limbs (57), non-parameningeal head & neck (10), thoracic (9), abdomen/pelvis (8), orbit (4), kidney (3), paraspinal (2) NA 124 Szalai, 2024 140 Hungary NGS 1 One SCS of uterine cervix cervix (1) NTRK1 (1) 125 Nakada, 2024 141 Japan NGS 1387 357 leiomyosarcomas, 178 dedifferentiated liposarcomas, 82 UPS, 770 NA NA NA 126 Huang, 2024 142 China NGS 28 NA NA NA 127 Vince, 2024 143 Brazil NGS 11 Eight IFS, one MPNST, one low-grade STS, one mesenchymal SCS/MPNST various NTRK1 (7), NTRK3 (4) 128 Zhang, 2024 144 Finland pan-TRK IHC, NGS 381 One fibrosarcoma, one EwS, 379 tumors NA NA NTRK1 (1), NTRK2 (1) 129 Cao, 2024 145 China IHC, FISH, NGS 1 One spindle cell neoplasm pelvis (1) NTRK1 (1) 130 de Castro, 2024 146 Brazil IHC, RNA-sequencing 1 One uterine sarcoma uterus (1) NTRK3 (1) 131 Gao, 2024 147 China IHC, NGS, FISH 8 Eight spindle cell neoplasms colon (3), small intestine (2), rectum (2), stomach (1) NTRK1 (7), NTRK2 (1) 132 Grant, 2024 148 UK IHC, NGS 3 Three uterine sarcomas uterus (3) NTRK1 (2), NTRK3 (1) 133 Nakata, 2024 149 Japan NGS 2077 One angiomatoid fibrous histiocytoma, 106 angiosarcomas, 187 dedifferentiated liposarcomas, 30 well-differentiated liposarcomas, 24 EwS, 166 GIST, 81 NOS sarcoma, 1482 unclassified sarcomas NA NTRK1 (12), NTRK3 (7) 134 Chen, 2024 150 Switzerland IHC, NGS 1 One STS thigh (1) NTRK1 (1) 135 Willis, 2024 151 USA NGS, RT-PCR, FISH 5 One liposarcoma, one MPNST, one IFS, one Mullerian adenosarcoma, one uterine leiomyosarcoma NA NA 136 Motta, 2024 152 Italy IHC, RNA sequencing 8 Eight IFS-like mesenchymal tumors NA NTRK1 (2) Comprehensive genomic profiling (CGP); Congenital Fibrosarcoma (CFS); Congenital Mesoblastic Nephroma (CMN), Dermatofibrosarcoma Protuberans (DFSP); Ewing sarcoma (EWS), Fibrosarcoma (FS); Fluorescence in-situ hybridization (FISH); Gastrointestinal Stromal Tumors (GIST); Infantile Fibrosarcoma (IFS); Inflammatory myofibroblastic Tumor (IMT); Lipofibromatosis-like Neural Tumor (LPFNT), Memorial Sloan Kettering - Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT); Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type 1 (NF1); Not Mentioned (NM); Not Otherwise Specified (NOS); Number (No.); Polymerase Chain Reaction (PCR), Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR); Real-Time Polymerase Chain Reaction (RT-PCR); Real-Time Multiple Ligation-dependent Probe (RT-MLP); Rhabdomyosarcoma (RMS); Single-nucleotide polymorphism (SNP); Soft Tissue Sarcoma (STS); Solitary Fibrous Tumor (SFT); Spindle Cell Sarcoma (SCS); Stromal & Perivascular Hyalinization (SPH); Temporomandibular Joint (TMJ); Undifferentiated Polymorphic Sarcoma (UPS); Whole-Exome Sequencing (WES); Whole Genome Sequencing (WGS). Twenty-two studies 39 , 51 , 53 , 57 , 65 , 70 , 73 , 76 , 84 , 88 , 96 , 97 , 100 , 101 , 103 , 107 , 109 , 112 , 121 , 140 , 145 , 147 reported only spindle cell sarcomas (n = 72 patients), while 13 studies 20 , 25 , 31 , 32 , 38 , 42 , 55 , 67 , 75 , 106 , 117 , 120 , 130 reported only congenital or infantile fibrosarcomas (n = 23 patients), and three studies 35 , 37 , 58 focused on patients with GIST (n = 197 patients). Further details on studies reporting specific sarcomas are described in Supplementary Table 1. Tumor location Regarding tumor location, 39 out of 136 papers did not specify tumor location. A total of 1,019 sarcomas were gynecologic tumors located in the uterus, cervix, or vagina, 262 tumors were in the limbs, and 80 tumors were within the head and neck region. Other anatomic locations of sarcomas are described in Table 1 . Supplementary Table 2 summarizes the number of studies and patients for each sarcoma location. Mutation detection methods Two studies 96 , 105 , with a total sample size of 251 patients, did not mention the method used to detect NTRK1-3 alterations. Thirty-eight studies 14 , 15 , 37 , 44 , 53 , 55 , 58 , 60 , 62 , 65 , 66 , 75 , 77 , 80 , 81 , 83 , 86 , 88 , 89 , 94 , 101 , 104 , 106 , 111 , 113 , 116 , 118 , 119 , 121 , 123 , 126 , 128 , 134 , 138 , 140 – 143 , 149 , encompassing a total of 12,404 patients out of 18,077 (68.62%), used only genomic sequencing techniques for NTRK1-3 fusion detection. These methods included RNA-based sequencing, DNA-based sequencing, whole-genome sequencing (WGS), whole-exome sequencing (WES), Sanger sequencing, comprehensive genomic profiling (CGP), NGS, or combinations of these approaches. FISH alone was used only in two studies 38 , 52 , adding up to 11 patients (0.06%), and IHC alone was also used in two studies 54 , 85 , involving a total of 400 patients (2.21%). Seven studies 23 , 24 , 27 , 29 , 30 , 32 , 67 , with 73 patients (0.40%), used RT-PCR alone. Combined diagnostic methods were also commonly used; for instance, genomic sequencing with IHC was used in 18 studies 4 , 41 , 68 , 72 , 79 , 92 , 93 , 97 , 98 , 103 , 114 , 133 , 137 , 144 , 146 , 148 , 150 , 152 with a total of 2,263 patients (12.52%). Genomic sequencing with RT-PCR was used in eight studies 26 , 47 , 49 , 64 , 87 , 100 , 125 , 129 (401 patients, 2.22%); genomic sequencing with FISH in 11 studies 43 , 51 , 63 , 69 , 71 , 76 , 109 , 115 , 127 , 130 , 132 (431 patients, 2.38%), FISH and IHC in four studies 40 , 50 , 70 , 110 (18 patients, 0.10%), and FISH with RT-PCR in two studies 35 , 117 (13 patients, 0.07%). Some studies used multi-modal diagnostic tests; for example, genomic sequencing combined with FISH and IHC was utilized in 17 studies 45 , 56 , 59 , 73 , 74 , 78 , 82 , 90 , 91 , 99 , 108 , 112 , 124 , 131 , 135 , 145 , 147 (1,329 patients, 7.35%); genomic sequencing combined with FISH and RT-PCR in seven studies 39 , 46 , 61 , 95 , 120 , 139 , 151 (113 patients, 0.63%); genomic sequencing combined with IHC and RT-PCR in four studies 42 , 84 , 102 , 136 (189 patients, 1.05%). Moreover, five studies 15 , 48 , 57 , 107 , 122 utilized all four detection methods, genomic sequencing, IHC, RT-PCR, and FISH; giving a total of 124 patients (0.69%). "Other methods," including varied diagnostic techniques such as cytogenetic analysis, karyotyping, Northern blotting, Western blotting, and Southern blotting, were employed in nine studies 20 – 22 , 25 , 28 , 31 , 33 , 34 , 36 involving 57 patients (0.32%). These methods illustrate the diverse diagnostic approaches used across studies, with genomic sequencing as an essential tool for detecting NTRK1-3 genomic alterations, utilized in 110 out of 136 studies with 17,269 patients, either alone or in combination with other techniques (Fig. 3 ). Prevalence of NTRK mutations in sarcoma Out of 18,077 patients with sarcoma, 821 patients had a genomic alteration in one of the NTRK1-3 genes (4.54%). NTRK1-3 fusions were the most common (551/821 patients; 67.11%), followed by a positive TRK protein on IHC staining (57/821 patients; 6.94%), NTRK gene rearrangement (10/821 patients; 1.22%), NTRK gene amplification (6/821 patients; 0.73%), or NTRK gene mutation (5/821 patients; 0.61%). Moreover, seven studies 90 , 94 , 111 , 139 , 141 , 142 , 151 with 165/821 patients (20.10%) did not specify the NTRK1-3 genomic alterations. Further details on NTRK1-3 alterations can be found in Table 1 . NTRK fusion partners Overall, the NTRK1-3 gene fusions mainly were either in the NTRK1 gene (251/551 patients; 45.56%) or the NTRK3 gene (259/551 patients; 47.01%), with only 15 out of 551 fusions affecting the NTRK2 gene (2.72%). The NTRK1 gene was mostly found to be fused with either the TPM3 (91/251 NTRK1 gene fusions; 36.25%) or the LMNA genes (89/251 NTRK1 gene fusions; 35.46%). The NTRK3 gene, on the other hand, was mostly found to be fused with the ETV6 gene (174/259 NTRK3 gene fusions; 67.18%). Further details on NTRK1-3 gene fusion partners can be found in Supplementary File S3. Twenty-nine studies 20 – 26 , 28 , 29 , 31 – 35 , 37 , 38 , 42 , 50 , 67 , 95 , 100 , 102 , 106 , 116 , 117 , 120 , 130 , 134 , 137 , involving 83 patients (0.46% of patients with sarcoma), reported ETV6-NTRK3 gene fusion only. Twelve studies 39 , 49 , 53 , 55 , 58 , 60 , 71 , 73 , 92 , 103 , 118 , 150 , with 12 patients, reported LMNA-NTRK1 gene fusion only (0.07% of patients with sarcoma). Moreover, two studies 48 , 59 , with 51 patients, reported TPM3-NTRK1, LMNA-NTRK1, MIR548F1-NTRK1, SQSTM1-NTRK1, TPR-NTRK1, STRN-NTRK2, ETV6-NTRK3 , and EML4-NTRK3 gene fusions (0.28% of patients with sarcoma). Further details are shown in Table 2 . Table 2 NTRK1-3 fusions with the number of studies and patients. NTRK fusions* Number of studies* Number of patients* ETV6-NTRK3 29 83 TPM3-NTRK1, LMNA-NTRK1, MIR548F1-NTRK1, SQSTM1-NTRK1, TPR-NTRK1, STRN-NTRK2, ETV6-NTRK3, EML4-NTRK3 2 51 LMNA-NTRK1, ETV6-NTRK3 2 20 LMNA-NTRK1, TPM3- NTRK1, KIRREL1- NTRK1, MEF2D-NTRK1, PEAB1- NTRK1, PHF20-NTRK1, ETV6-NTRK3 1 19 TPM3-NTRK1, LMNA-NTRK1, IRF2BP2-NTRK1, ETV6-NTRK3, RBPMS-NTRK3, MORF4L1-NTRK3, PPFIA2-NTRK3, MEF2A-NTRK3 1 17 TPM3-NTRK1, TPR-NTRK1, ETV6-NTRK3 2 17 TPM3-NTRK1, TPR-NTRK1, TSNAX-NTRK1, LMNA-NTRK1, CCDC171-NTRK1, VAMP4-NTRK1, GON4L-NTRK1, RAB14-NTRK3, FANCI-NTRK3, MCTP2-NTRK3, RBPMS-NTRK3, ETV6-NTRK3, TFG-NTRK3 1 16 LMNA-NTRK1, TPM3-NTRK1, KANK1-NTRK2, ETV6-NTRK3, EIF2S2-NTRK3, STRN3-NTRK3, STRN-NTRK3, RPS17-NTRK3 1 15 LMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, PEAR-NTRK1, ETV6-NTRK3, TPM4-NTRK3, EEF1A1-NTRK3 1 13 LMNA-NTRK1, TPM3-NTRK1, TPR–NTRK1, SPECC1L–NTRK2 1 13 LMNA-NTRK1 12 12 LMNA-NTRK1, CPSF6-NTRK1, TPM3-NTRK1, GAS2L1-NTRK1, IGR-NTRK1, SQSTM1-NTRK1 1 12 LMNA-NTRK1, TPM3- NTRK1, SPECCL1-NTRK3, EML4-NTRK3 1 12 LMNA-NTRK1, TPM3-NTRK1, EML4-NTRK3, ETV6-NTRK3, STRN-NTRK3, RBPMS-NTRK3 1 12 LMNA-NTRK1, TPM3-NTRK1, ETV6-NTRK3 1 11 TPR-NTRK1, LMNA-NTRK1, ETV6–NTRK3 1 9 TPR-NTRK1, TPM3-NTRK1, MEF2D-NTRK1, ETV6-NTRK3 1 9 TPM3-NTRK1, EML4-NTRK3 2 9 SQSTM1-NTRK1, LMNA-NTRK1, TPR-NTRK1, TFG-NTRK3, ETV6–NTRK3 1 7 TPR-NTRK1, TPM3-NTRK1, SPECC1L–NTRK3 2 6 TPM3–NTRK1, LMNA–NTRK1, TPR–NTRK1, ETV6–NTRK3, SPECC1L–NTRK3 1 6 LMNA-NTRK1, TPM3-NTRK1, TRN-NTRK2 1 6 LMNA-NTRK1, IRF2BP2-NTRK1, MEF2A-NTRK3, ITFG1-NTRK3, ETV6-NTRK3 1 6 TPM3-NTRK1, LMNA-NTRK1, SQSTM1-NTRK3 1 6 LMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, YWHAE‑NTRK3, PPFIBP‑NTRK3 1 6 LMNA-NTRK1, TPR-NTRK1, TPM3-NTRK1 1 6 TPM3-NTRK1, ETV6-NTRK3, TFG-NTRK3, SPECC1L-NTRK3 1 5 TPM3-NTRK1 5 5 LMNA-NTRK1, TPM3-NTRK1, ETV6-NTRK3, RBPMS - NTRK3 1 4 TPM3-NTRK1, MTMR2–NTRK2, ETV6–NTRK3 1 4 LMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, RBPMS-NTRK3 1 4 TPM4-NTRK3, ETV6-NTRK3, TFG-NTRK3, EML4-NTRK3 1 4 TPM3-NTRK1, SPECC1L–NTRK3 2 4 EML4-NTRK3 4 4 TMP3-NTRK1, STRN3-NTRK2 1 4 LMNA-NTRK1, TPM3-NTRK1 1 3 SPECC1L–NTRK3 3 3 TPM3-NTRK1, SQSTM1-NTRK3, SPECC1L–NTRK3 1 3 UFD1-NTRK2, VPS18-NTRK3, RALGPS2-NTRK3 1 3 LMNA-NTRK1, STRN3-NTRK3 1 2 LMNA-NTRK1, TPM4-NTRK3 1 2 TPM3-NTRK1, UPF2-NTRK3 1 2 TPR-NTRK1, KANK1-NTRK2 1 2 ETV6-NTRK3, TFG-NTRK3 1 2 SQSTM1-NTRK1, TFG-NTRK3 1 2 STRN-NTRK3, STRN3-NTRK3 1 2 TPM3-NTRK1, LPPR1-NTRK2 1 2 KHDRBS1-NTRK1 1 1 PHF20-NTRK1 1 1 DCTN1–NTRK1 1 1 TPM4-NTRK1 1 1 SNRNP70-NTRK3 1 1 FN1-NTRK1 1 1 SPECC1L-NTRK1 1 1 NUMA1-NTRK1 1 1 HMBOX1-NTRK3 1 1 TMTC2-NTRK3 1 1 STRN-NTRK2 1 1 SQSTM1-NTRK3 1 1 * NTRK fusions, number of studies, and number of patients are mutually exclusive, they are not repeated twice. Treatment outcomes with TRK inhibitors Most studies investigated the efficacy and safety of larotrectinib alone; 24 studies explored larotrectinib monotherapy with a cumulative follow-up of 622 months 37 , 38 , 59 , 67 , 70 , 72 , 75 , 78 , 80 , 88 , 97 , 101 , 117 , 121 , 127 , 128 , 130 , 133 , 136 , 139 , 142 , 143 , 147 , 151 . A total of 1,106 patients with sarcoma were included in those studies, of which 142 had NTRK1-3 gene fusions and received larotrectinib therapy. In patients treated with larotrectinib, the response rate to therapy was 83.80% (119/142), with 2.82% (4/142) deaths, 8.45% (12/142) metastases, and 2.11% (3/142) recurrences. Entrectinib was explored in six studies 15 , 79 , 82 , 99 , 140 , 150 where 33 patients were treated with a total follow-up period of 114 months. Entrectinib showed a response rate of 63.64% (21/33). Moreover, five studies 74 , 86 , 104 , 119 , 126 explored the effects of combined larotrectinib and entrectinib therapies, reporting a response rate of 41.67% (10/24), metastasis rate of 41.67% (10/24), recurrence rate of 25% (6/24), and a death rate of 20.83% (5/24). One study 138 included 22 patients taking triple therapy of larotrectinib, entrectinib, and selitrectinib, which were followed up on for an average of 70 months. The response rate was 31.82% (7/22), with 9.09% recurrence (2/22) and a mere 4.55% (1/22) reported metastasis and death 138 . Limited data are available for combining larotrectinib with selitrectinib or repotrectinib, with three studies 68 , 106 , 148 and one study 120 on these combinations, respectively. In these smaller cohorts, outcomes suggest moderate responses with some recurrences and metastases. Further details are depicted in Table 3 . Table 3 The therapeutic outcomes from studies investigating the efficacy of various TRK inhibitors, including larotrectinib, entrectinib, and combinations with other inhibitors, such as selitrectinib and repotrectinib, in the context of NTRK -positive sarcomas. TRK inhibitor No. of studies No. of patients Follow-up (months) Outcome Total On TRK inhibitors Response to therapy Death Metastasis Recurrence Larotrectinib 24 1106 142 622 119/142 4/142 12/142 3/142 83.80% 2.82% 8.45% 2.11% Entrectinib 6 521 33 114 21/33 0/7* 0/7* 1/7* 63.64% 0.0% 0.0% 14.29% Larotrectinib, Entrectinib 4 94 24 159 10/24 5/24 10/24 6/24 41.67% 20.83% 41.67% 25.0% Larotrectinib, Entrectinib, Selitrectinib 1 22 22 70 7/22 1/22 1/22 2/22 31.82% 4.55% 4.55% 9.09% Larotrectinib, Repotrectinib 1 1 1 NA 0/1 0/1 1/1 1/1 0.0% 0.0% 100.0% 100.0% Larotrectinib, Selitrectinib 3 5 5 25 3/5 1/5 3/5 3/5 60.0% 20.0% 60.0% 60.0% * Although 33 patients received Entrectinib, detailed data on death, metastasis, and recurrence were available for only 7 patients in our review. NA: not available Discussion In this systematic review, we synthesized and analyzed available evidence on NTRK1-3 fusions in soft tissue tumors/sarcomas. Our findings indicate that NTRK1-3 fusions are present in a small subset of sarcomas, with most fusions being NTRK1 or NTRK3 . Tumors harboring NTRK1-3 fusions often exhibit distinct clinical and pathological characteristics, such as younger age, and distinctive morphologic features, such as densely packed spindle cells and myxoid stroma 153 . These tumors commonly affect specific anatomical sites, like the extremities in infantile fibrosarcoma and the lungs or abdomen in inflammatory myofibroblastic tumors 153 . NTRK1-3 fusions involve gene rearrangements leading to constitutive activation of the TRK signaling pathway, promoting tumorigenesis 104 , 153 . The clinical behavior of these cancers may substantially vary, with some showing favorable responses to TRK inhibitors, highlighting the importance of routine comprehensive genomic testing for personalized treatment 10 . Our systematic review provides an updated and comprehensive synthesis of the literature on NTRK1-3 fusions in sarcomas, addressing gaps left by previous reviews. It builds upon prior work by incorporating studies published in recent years, which reflect advancements in diagnostic techniques and the identification of additional NTRK fusion-positive cases. Unlike the review by Assi et al. 154 that was current to 2020, our review includes studies up to mid-2024. Moreover, several prior reviews focused on specific sarcoma subtypes or did not cover the entire spectrum of sarcomas, thereby limiting the generalizability of their conclusions 155 , 156 . Other reviews focused on one population demographic, like reporting NTRK1-3 fusions in the pediatric population only 102 . Our systematic review attempted to cover the entire spectrum of soft tissue sarcomas and incorporate the newest publications, providing a more complete and contemporary understanding of the prevalence and clinical implications of NTRK1-3 fusions. This systematic review confirms that the NTRK1-3 fusions are rare in soft tissue sarcomas. Our descriptive analysis shows that ETV6-NTRK3 fusion is the most prevalent, with documentation in 174 patients. Following this, a cohort of NTRK1 -related fusions, such as TMP3-NTRK1 and LMNA-NTRK1 , indicates a notable presence in NTRK -positive sarcomas. Our review identified 1,019 female patients with gynecological sarcomas. The molecular characterization study by Gatalica et al. supports these findings, highlighting ETV6-NTRK3 and TMP3-NTRK1 as the most prevalent fusions 4 . Furthermore, a systematic review and meta-analysis by Forsythe et al. revealed the prevalence of NTRK1-3 fusions to be 90.56% in 91 patients with infantile fibrosarcomas and 0.34% in 93 patients with uterine sarcomas 155 . However, due to the rarity of these tumors, no large studies have been able to rigorously explore or confirm the association between NTRK1-3 fusions and specific sarcoma subtypes beyond the few known rare entities. Various diagnostic techniques are employed to detect NTRK1-3 fusions, each with advantages and limitations. FISH and RT-PCR are traditional methods that have been widely used for their sensitivity and specificity 5 . However, genomic sequencing (DNA or RNA-based) has emerged as the gold standard and is the most commonly used diagnostic modality, offering comprehensive genomic profiling and the ability to detect a wide range of genomic alterations, including novel and rare fusions 11 . Despite its higher cost and technical complexity, genomic sequencing is increasingly preferred in clinical settings due to its robust diagnostic capabilities and was recommended by the ESMO guideline for routine testing in patients with advanced cancers, including sarcomas 157 . The identification and targeting of NTRK1-3 fusions have several critical clinical implications. For oncologists, incorporating routine genetic testing for NTRK1-3 fusions into diagnostic workflows can significantly enhance the precision of treatment plans. Patients diagnosed with NTRK1-3 fusion-positive sarcomas can be directed toward TRK inhibitors, which offer a more effective and less toxic alternative compared to traditional chemotherapy as shown in clinical trials 158 , 159 . Second, it provides important prognostic information, as NTRK fusion-positive sarcomas have distinct clinical behaviors and outcomes as previously mentioned. Lastly, the detection of NTRK1-3 fusions can guide the development of personalized treatment plans, improving overall patient management and outcomes. TRK inhibitors, such as larotrectinib and entrectinib, have revolutionized the treatment landscape for patients with NTRK1-3 fusion-positive tumors. Clinical trials have demonstrated significant responses, with high overall response rates and durable responses in many patients 160 . Although with limited evidence due to the infrequency of NTRK gene fusion mutation and the new emergence of TRK inhibitor drugs, we observed that larotrectinib was the most utilized TRK inhibitor, employed as monotherapy in 24 studies 37 , 38 , 59 , 67 , 70 , 72 , 75 , 78 , 80 , 88 , 97 , 101 , 117 , 121 , 127 , 128 , 130 , 133 , 136 , 139 , 142 , 143 , 147 , 151 , and demonstrated a response rate of 83.80% (119/142 patients). This high response rate reinforces the clinical value of identifying NTRK fusions and initiating targeted therapy. Among the 142 cases, only four (2.82%) patients died, 12 (8.45%) developed metastasis and three (2.11%) exhibited local recurrence. Similarly, entrectinib was also predominantly used as monotherapy in six studies 15 , 79 , 82 , 99 , 140 , 150 with 33 patients, yielding a response rate of 63.64%. While our findings suggest that larotrectinib may offer a marginal advantage over entrectinib, these results should be interpreted with caution given the differences in sample sizes between the two treatment groups. Nevertheless, the overall findings of our review are consistent with those reported by Suh et al. 161 . Thus, with the evidence presented here, we recommend screening for NTRK1-3 fusion genes in patients with soft tissue sarcomas unresponsive to common modalities of management, including surgery, chemotherapy, and radiotherapy 162 . Based on literature review, patients with a high suspicion of NTRK1-3 fusion, genomic DNA- or RNA-based sequencing is recommended. RNA-based genomic sequencing provides the highest sensitivity and specificity in detecting NTRK1-3 fusions, with specificity reaching up to 100% 163 . In cases with a lower suspicion of NTRK1-3 fusion, such as in sarcomas other than congenital fibrosarcoma, the initial step should be to perform pan-TRK IHC. If the IHC results are positive, then RNA-based NGS should be used to confirm the presence of an NTRK fusion 164 . Moreover, TRK inhibitors are highly effective in treating soft tissue sarcomas in adult and pediatric populations, with low rates of non-adherence, severe adverse effects, and mortality. This systematic review provides evidence-based recommendations for using TRK inhibitors in clinical settings, aiding clinicians in decision-making and providing precision medicine options for refractory cases. Some limitations of our studies include the variations in study design, patient populations, detection methods, and reporting standards, making it difficult to combine and compare results and draw firm conclusions. Additionally, there is limited availability of data regarding specific types of sarcomas and the presence of various NTRK1-3 fusion partners and types for each sarcoma subtype, which can complicate the synthesis and interpretation of prevalence data and constrain the review's comprehensiveness. Conclusions This systematic review confirms the rarity of NTRK1-3 fusions in soft tissue sarcomas. Given the notable clinical efficacy of TRK inhibitors in sarcomas, genomic testing remains essential in all sarcoma cases to identify these potentially targetable alterations and should be incorporated into diagnostic workflows in the era of precision oncology. Declarations The authors have no conflicts of interest to declare. CRediT Authors contributions SH – Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing, Funding acquisition, Supervision, Project administration ZAN– Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing, Supervision, Project administration AMH– Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing AAR– Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing HER– Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing MAA- Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing GRB– Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing, Funding acquisition, Supervision ZG- Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Review & Editing SV– Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review & Editing, Funding acquisition, Supervision, Project administration, Guarantor of Review Data availability This study is a systematic review of published studies, and the data used in this work are from the included studies. The availability of the underlying individual patient data is subject to the primary publications’ journal policies. References Lange AM, Lo HW: Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers (Basel) 10, 2018 Nakagawara A: Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169:107–14, 2001 Amatu A, Sartore-Bianchi A, Siena S: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:e000023, 2016 Gatalica Z, Xiu J, Swensen J, et al: Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 32:147–153, 2019 Marchetti A, Ferro B, Pasciuto MP, et al: NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. Pathologica 114:199–216, 2022 Zito Marino F, Pagliuca F, Ronchi A, et al: NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine. Int J Mol Sci 21, 2020 Schwartzberg L, Kim ES, Liu D, et al: Precision Oncology: Who, How, What, When, and When Not? Am Soc Clin Oncol Educ Book 37:160–169, 2017 Vranic S, Basu GD, Hall DW, et al: Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Med Acad 51:217–231, 2022 Vranic S, Gatalica Z: Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Biomol Biomed 24:673–675, 2024 Cocco E, Scaltriti M, Drilon A: NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731–747, 2018 Marchiò C, Scaltriti M, Ladanyi M, et al: ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30:1417–1427, 2019 Administration USFaD: FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor, 2018 Administration USFaD: FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor 2019 Bridgewater J, Jiao X, Parimi M, et al: Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project. Cancer Treat Res Commun 33:100623, 2022 Demetri GD, De Braud F, Drilon A, et al: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 28:1302–1312, 2022 Brownstein JM, DeLaney TF: Malignant Soft-Tissue Sarcomas. Hematol Oncol Clin North Am 34:161–175, 2020 Hechtman JF: NTRK insights: best practices for pathologists. Mod Pathol 35:298–305, 2022 Nguyen MA, Colebatch AJ, Van Beek D, et al: NTRK fusions in solid tumours: what every pathologist needs to know. Pathology 55:596–609, 2023 Ahmed AI, Kaleem MZ, Elshoeibi AM, et al: MASTER scale for methodological quality assessment: Reliability assessment and update. Knezevich SR, McFadden DE, Tao W, et al: A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184–7, 1998 Rubin BP, Chen CJ, Morgan TW, et al: Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153:1451–8, 1998 Knezevich SR, Garnett MJ, Pysher TJ, et al: ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58:5046–8, 1998 Argani P, Fritsch M, Kadkol SS, et al: Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol 13:29–36, 2000 Bourgeois JM, Knezevich SR, Mathers JA, et al: Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 24:937–46, 2000 Punnett HH, Tomczak EZ, Pawel BR, et al: ETV6-NTRK3 gene fusion in metastasizing congenital fibrosarcoma. Med Pediatr Oncol 35:137–9, 2000 Sheng WQ, Hisaoka M, Okamoto S, et al: Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol 115:348–55, 2001 Hisaoka M, Sheng WQ, Tanaka A, et al: Gene expression of TrkC (NTRK3) in human soft tissue tumours. J Pathol 197:661–7, 2002 Henno S, Loeuillet L, Henry C, et al: Cellular mesoblastic nephroma: morphologic, cytogenetic and molecular links with congenital fibrosarcoma. Pathology-Research and Practice 199:35–40, 2003 McCahon E, Sorensen PH, Davis JH, et al: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol 40:288–92, 2003 Ootsuka S, Asami S, Sasaki T, et al: Analyses of novel prognostic factors in neuroblastoma patients. Biol Pharm Bull 30:2294–9, 2007 Mariño-Enríquez A, Li P, Samuelson J, et al: Congenital fibrosarcoma with a novel complex 3-way translocation t(12;15;19) and unusual histologic features. Hum Pathol 39:1844–8, 2008 Himori K, Hatori M, Watanabe M, et al: Infantile fibrosarcoma of thigh–a case report. Ups J Med Sci 110:85–93, 2005 Gadd S, Beezhold P, Jennings L, et al: Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol 228:119–30, 2012 Walther C, Nilsson J, von Steyern FV, et al: Cytogenetic and single nucleotide polymorphism array findings in soft tissue tumors in infants. Cancer Genet 206:299–303, 2013 Brenca M, Rossi S, Polano M, et al: Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 238:543–9, 2016 Haller F, Knopf J, Ackermann A, et al: Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 238:700–10, 2016 Shi E, Chmielecki J, Tang CM, et al: FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med 14:339, 2016 Nagasubramanian R, Wei J, Gordon P, et al: Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer 63:1468–70, 2016 Wong V, Pavlick D, Brennan T, et al: Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. J Natl Cancer Inst 108, 2016 Agaram NP, Zhang L, Sung YS, et al: Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors. Am J Surg Pathol 40:1407–16, 2016 Hechtman JF, Benayed R, Hyman DM, et al: Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol 41:1547–1551, 2017 Obayashi J, Koizumi H, Hoshikawa M, et al: A Case of Congenital Infantile Fibrosarcoma of the Bowel Presenting as a Neonatal Intussusception. Pathol Int 67:644–648, 2017 Pavlick D, Schrock AB, Malicki D, et al: Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer 64, 2017 Chmielecki J, Bailey M, He J, et al: Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res 77:509–519, 2017 Hung YP, Fletcher CDM, Hornick JL: Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 73:634–644, 2018 Kao YC, Fletcher CDM, Alaggio R, et al: Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol 42:28–38, 2018 Olson N, Rouhi O, Zhang L, et al: A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4-NTRK3 fusion. J Cutan Pathol 45:933–939, 2018 Rudzinski ER, Lockwood CM, Stohr BA, et al: Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol 42:927–935, 2018 Kohsaka S, Saito T, Akaike K, et al: Pediatric soft tissue tumor of the upper arm with LMNA-NTRK1 fusion. Hum Pathol 72:167–173, 2018 Takahashi A, Kurosawa M, Uemura M, et al: Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report. J Int Med Res 46:3498–3503, 2018 Suurmeijer AJH, Dickson BC, Swanson D, et al: A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57:611–621, 2018 Lao IW, Sun M, Zhao M, et al: Lipofibromatosis-like neural tumour: a clinicopathological study of ten additional cases of an emerging novel entity. Pathology 50:519–523, 2018 Zhou N, Schäfer R, Li T, et al: A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. BMC Cancer 18:842, 2018 Antunes BP, Becker RG, Brunetto AT, et al: Expression of neurotrophins and their receptors in primary osteosarcoma. Rev Col Bras Cir 46:e2094, 2019 Bender J, Anderson B, Bloom DA, et al: Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib. Cold Spring Harb Mol Case Stud 5, 2019 Chiang S, Cotzia P, Hyman DM, et al: NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Am J Surg Pathol 42:791–798, 2018 Croce S, Hostein I, Longacre TA, et al: Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Modern Pathology 32:1008–1022, 2019 D’Alpino Peixoto R, Medeiros BA, Cronemberger EH: Resected high-risk rectal GIST harboring NTRK1 fusion: a case report and review of the literature. Journal of Gastrointestinal Cancer 52:316–319, 2021 Davis JL, Lockwood CM, Stohr B, et al: Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. The American journal of surgical pathology 43:435–445, 2019 Warren M, Anselmo D, Takeda M, et al: NTRK-rearranged mesenchymal tumour in a 3‐year‐old female: a diagnostic quandary. Histopathology 75, 2019 Yamazaki F, Nakatani F, Asano N, et al: Novel NTRK3 Fusions in Fibrosarcomas of Adults. Am J Surg Pathol 43:523–530, 2019 Solomon JP, Linkov I, Rosado A, et al: NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38–46, 2020 Suurmeijer AJ, Dickson BC, Swanson D, et al: The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes, Chromosomes and Cancer 58:739–746, 2019 Ameline B, Saba KH, Kovac M, et al: NTRK fusions in osteosarcoma are rare and non-functional events. The Journal of Pathology: Clinical Research 6:107–112, 2020 Bertolini R, Bode PK, Sawatzki M: Unusual colonic polyp in a young woman. Gastroenterology 160:e12-e13, 2021 Boyle W, Williams A, Sundar S, et al: TMP3-NTRK1 rearranged uterine sarcoma: a case report. Case Reports in Women's Health 28:e00246, 2020 Caldwell KJ, De La Cuesta E, Morin C, et al: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib. Pediatric Blood & Cancer 67:e28330, 2020 Goh XN, Seng MS-F, Loh AHP, et al: Larotrectinib followed by selitrectinib in a novel DCTN1–NTRK1 fusion undifferentiated pleomorphic sarcoma. Journal of Oncology Pharmacy Practice 27:485–489, 2021 Kang J, Park JW, Won J-K, et al: Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Diagnostic pathology 15:1–11, 2020 Olsen MR, Denu RA, Lyon JB, et al: Undifferentiated and unresectable sarcoma with NTRK3-fusion in a pediatric patient treated with larotrectinib and proton beam radiotherapy. Journal of pediatric hematology/oncology 44:e770-e774, 2022 Panse G, Reisenbichler E, Snuderl M, et al: LMNA-NTRK1 rearranged mesenchymal tumor (lipofibromatosis‐like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. Journal of cutaneous pathology 48:290–294, 2021 Rabban JT, Devine WP, Sangoi AR, et al: NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 77:100–111, 2020 So YK, Chow C, To KF, et al: Myxoid spindle cell sarcoma with LMNA-NTRK fusion: expanding the morphologic spectrum of NTRK-rearranged tumors. International journal of surgical pathology 28:574–578, 2020 Vargas AC, Ardakani NM, Wong DD, et al: Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation. Histopathology 78:932–942, 2021 Khuong-Quang D-A, Brown LM, Wong M, et al: Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors. Molecular Case Studies 6:a005710, 2020 Rekhi B, Shetty O, Bapat P, et al: A Case of Inv (1)(q23q31) TPR-NTRK1 Fusion-Positive Spindle Cell Neoplasm in an Infant—Uncovered by Next-Generation Sequencing: Diagnostic Challenge, Review, and Therapeutic Implications. International Journal of Surgical Pathology 29:102–108, 2021 Wang W-x, Xu C-w, Lei L, et al: Large-scale study of NTRK fusions in Chinese solid tumors and using next generation sequencing: A multicenter study. Cancer Research 80:38–38, 2020 Atiq MA, Davis JL, Hornick JL, et al: Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Modern Pathology 34:95–103, 2021 Brčić I, Godschachner TM, Bergovec M, et al: Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Modern Pathology 34:396–407, 2021 Chen T, Wang Y, Goetz L, et al: Novel fusion sarcomas including targetable NTRK and ALK. Annals of Diagnostic Pathology 54:151800, 2021 Chen W, Wang H, Jiang D, et al: Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. World Journal of Surgical Oncology 19:1–6, 2021 Goulding E, Morreau P, De Silva M, et al: Case report: NTRK1-rearranged cervical sarcoma with fibrosarcoma like morphology presenting in a 13-year-old managed with a neo-adjuvant TRK-inhibitor and surgical excision. Gynecologic Oncology Reports 37:100845, 2021 Hodgson A, Pun C, Djordjevic B, et al: NTRK-rearranged cervical sarcoma: expanding the clinicopathologic spectrum. International Journal of Gynecological Pathology 40:73–77, 2021 Punjabi LS, Sittampalam K: Expanding the spectrum of adult NTRK3-rearranged spindle cell neoplasms: a recurrent NTRK3-SQSTM1 fusion spindle cell tumor with deceptively bland morphology. American Journal of Clinical Pathology 157:485–493, 2022 Lam SW, Briaire-de Bruijn IH, van Wezel T, et al: NTRK fusions are extremely rare in bone tumours. Histopathology 79:880–885, 2021 Lanman T, Hayden Gephart M, Bui N, et al: Isolated leptomeningeal progression in a patient with NTRK fusion + uterine sarcoma: a case report. Case Reports in Oncology 14:1841–1846, 2022 Liu YJ, Wang W, Yeh J, et al: Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis. Modern Pathology 34:1373–1383, 2021 Percy C, Schubert T, Galant C, et al: Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report. Clinical Case Reports 9:1694, 2021 Xu L, Xie X, Shi X, et al: Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. Oncology Letters 21:1–12, 2021 Peng Y, Chen H, Zhao X, et al: The capability of NTRK fusion detection by next-generation sequencing/FISH/IHC in 25976 solid tumor patients. Cancer Research 81:2285–2285, 2021 Bai C, Zhang L, Wang Y, et al: A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma. J Cancer Res Clin Oncol 148:2933–2937, 2022 Czaja R, Layng KV, Barrett A, et al: An NTRK-1-associated soft tissue tumor showing distinctive nodules with peripheral accentuation of cellularity. J Cutan Pathol 50:343–348, 2023 Dang X, Xiang T, Zhao C, et al: EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review. Front Med (Lausanne) 9:832376, 2022 Hibar DP, Demetri GD, Peters S, et al: Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. PLoS One 17:e0270571, 2022 Jiang H: A novel ETV6-NTRK3 gene fusion in primary renal fibrosarcoma. Eur Rev Med Pharmacol Sci 26:4705–4708, 2022 Overfield CJ, Edgar MA, Wessell DE, et al: NTRK-rearranged spindle cell neoplasm of the lower extremity: radiologic-pathologic correlation. Skeletal Radiol 51:1707–1713, 2022 Recine F, De Vita A, Fausti V, et al: Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy. Front Oncol 11:740676, 2021 Silvertown JD, Lisle C, Semenuk L, et al: Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Mol Diagn Ther 27:87–103, 2023 Kobayashi H, Makise N, Shinozaki-Ushiku A, et al: Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene. Genes Chromosomes Cancer 62:47–51, 2023 Kyriazoglou A, Dimitriadis E, Mahaira L, et al: Myxoid spindle cell sarcoma with ETV6-NTRK3 fusion. Cancer Genet 268–269:93–96, 2022 Nilforoushan N, Wethington SL, Nonogaki H, et al: NTRK-Fusion Sarcoma of the Uterine Cervix: Report of 2 Cases With Comparative Clinicopathologic Features. Int J Gynecol Pathol 41:642–648, 2022 Nozzoli F, Lazar AJ, Castiglione F, et al: NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities. Pathol Oncol Res 28:1610237, 2022 Rahim S, Alkhaldi SS, Alasousi K, et al: Intestinal LMNA::NTRK1-fused spindle cell neoplasm with S100 and CD34 coexpression: a new case. BMJ Case Rep 15, 2022 Siozopoulou V, Marcq E, De Winne K, et al: NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects. Pathol Oncol Res 28:1610423, 2022 Suh K, Carlson JJ, Xia F, et al: The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spec Pharm 28:622–630, 2022 Thorwarth A, Haase K, Röefzaad C, et al: Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion. JCO Precis Oncol 6:e2100283, 2022 Tsai JW, Lee JC, Hsieh TH, et al: Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements. Mod Pathol 35:911–921, 2022 Van Bockstal MR, Beniuga G, Craciun L, et al: The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology 89:393–406, 2022 Wang Z, Wang J: Primary NTRK-rearranged spindle cell neoplasm of bone harboring an HMBOX1::NTRK3 gene fusion. Genes Chromosomes Cancer 62:477–482, 2023 Young V, Wong D, Yan M, et al: NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern. Human Pathology Reports 28:300618, 2022 Moyers JT, Brazel D, Kumar P, et al: Abstract 2184: Landscape of genomic alterations of ultra-rare sarcomas (URS) from 1,079 patients in the AACR GENIE real world database: Clinical implications. Cancer Research 82:2184–2184, 2022 Gong H, Gao K, Mao P, et al: A rare case of spindle cell neoplasm with NTRK-fusion in central nervous system. Pathol Int 73:52–54, 2023 Agostara AG, Patelli G, Bencardino K, et al: 72P Molecular characterization of advanced primary cardiac sarcomas. ESMO Open 8, 2023 Bornstein-Quevedo L, Bautista-Wong C, Mojica-González Z, et al: Identification of NTRK fusion genes. Experience in Mexico. Gaceta Mexicana de Oncologia 22, 2023 Cammareri C, Beltzung F, Michal M, et al: PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications. Virchows Arch 483:145–156, 2023 Challa B, Jones D, Kim AC, et al: NTRK-rearranged mesenchymal tumour in oesophagus with DOG1 immunohistochemical expression: is it a gastrointestinal stromal tumour? Pathology 56:602–604, 2024 Corral Sánchez MD, Jiménez Carrascoso R, Rubio Aparicio P, et al: Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series. Clin Transl Oncol 25:3307–3311, 2023 Creus-Bachiller E, Fernández-Rodríguez J, Magallón-Lorenz M, et al: Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities. Mol Oncol 18:895–917, 2024 Dufresne A, Pissaloux D, Ngo C, et al: Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. ESMO Open 8:101202, 2023 Furtado LV, Kacar M, Mostafavi R, et al: Progressive metastatic infantile fibrosarcoma with multiple acquired mutations. Cold Spring Harb Mol Case Stud 9, 2023 Palmerini E, Frega G, Gambarotti M, et al: NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report. Front Oncol 13:1252359, 2023 Yin L, Shi C, He X, et al: NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China. Pathology 55:362–374, 2023 Kobayashi H, Teramura Y, Yamashita K, et al: Imaging findings of NTRK–rearranged spindle cell neoplasms: A case series. Mol Clin Oncol 18:14, 2023 Kojima N, Mori T, Motoi T, et al: Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions. Mod Pathol 36:100083, 2023 Krsková L, Balko J, Strnadová M, et al: 60P Spindle cell sarcomas with tyrosine kinase rearrangement. ESMO Open 8, 2023 Kubota Y, Kawano M, Iwasaki T, et al: Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. Medicine (Baltimore) 102:e36232, 2023 Kummar S, Shen L, Hong DS, et al: Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 129:3772–3782, 2023 Lin R, Mallick AB, Wang ZX, et al: Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy. Diagn Pathol 18:116, 2023 Romanko AA, Mulkidjan RS, Tiurin VI, et al: Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples. Int J Mol Sci 24, 2023 Sahni S, Rastogi S, Yadav R, et al: Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib. Ecancermedicalscience 17:1575, 2023 Suurmeijer AJH, Xu B, Torrence D, et al: Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature. Genes Chromosomes Cancer 63:e23205, 2024 Xu B, Suurmeijer AJH, Agaram NP, et al: Head and Neck Mesenchymal Tumors with Kinase Fusions: A Report of 15 Cases With Emphasis on Wide Anatomic Distribution and Diverse Histologic Appearance. Am J Surg Pathol 47:248–258, 2023 Xu Y, Shi X, Wang W, et al: Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. NPJ Precis Oncol 7:75, 2023 Dong R, Li L, Gong L, et al: Abstract 2152: Targetable oncogenic fusions and other alterations in bone and soft-tissue tumors assessed by RNA and DNA-based next-generation sequencing in real-world experience. Cancer Research 83:2152–2152, 2023 Moura MS, Costa J, Velasco V, et al: Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls. Histopathology 84:451–462, 2024 Hasegawa N, Hayashi T, Niizuma H, et al: Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Clin Orthop Relat Res 482:549–563, 2024 Hernandez S, Conde E, Molero A, et al: Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. Arch Pathol Lab Med 148:318–326, 2024 Klubíčková N, Dermawan JK, Mosaieby E, et al: Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations. J Pathol 263:61–73, 2024 Orbach D, Carton M, Khadir SK, et al: Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study). ESMO Open 9:103006, 2024 Szalai L, Vereczkey I, Szemes M, et al: NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion. Virchows Arch 484:527–531, 2024 Nakada E, Fujiwara T, Kunisada T, et al: Abstract 6456: The utility of clinical sequencing in the diagnosis and treatment of soft tissue sarcomas; Real world data based on nation-wide database. Cancer Research 84:6456–6456, 2024 Huang J, Song M, Lu S, et al: Clinical and molecular characteristics and targeted therapy of pediatric non-infantile fibrosarcoma NTRK rearrangement–related tumors, American Society of Clinical Oncology, 2024 Vince CSC, Brassesco MS, Mançano BM, et al: Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology. JCO Precision Oncology 8:e2300713, 2024 Zhang W, Schmitz AA, Kallionpää RE, et al: Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Acta Oncologica (Stockholm, Sweden) 63:542–551, 2024 Cao Q, Huang Z, Liang H, et al: Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic. Front Oncol 14:1308916, 2024 de Castro JVA, Dos Santos PJS, Mantoan H, et al: Uterine Sarcoma With EML4::NTRK3 Fusion: A Spectrum of Mesenchymal Neoplasms Harboring Actionable Gene Fusions. Int J Gynecol Pathol 43:56–60, 2024 Gao X, Xu S, Zhu P, et al: Primary NTRK -rearranged Spindle Cell Neoplasm of the Gastrointestinal Tract: A Clinicopathological and Molecular Analysis of 8 Cases. Am J Surg Pathol 48:623–631, 2024 Grant L, Boyle W, Williams S, et al: Uterine Neurotrophic Tyrosine Receptor Kinase Rearranged Spindle Cell Neoplasms: Three Cases of an Emerging Entity. Int J Gynecol Pathol 43:326–334, 2024 Nakata E, Osone T, Ogawa T, et al: Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Cancer Med 13:e7351, 2024 Chen Y, Steiner S, Hagedorn C, et al: Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA:: NTRK1-rearranged soft‐tissue sarcoma cell model. The Journal of Pathology 263:257–269, 2024 Willis C, Au T, Hejazi A, et al: Clinical characteristics and treatment patterns of patients with NTRK fusion–positive solid tumors: A multisite cohort study at US academic cancer centers. Journal of managed care & specialty pharmacy 30:672–683, 2024 Motta M, Barresi S, Pizzi S, et al: RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors. The Journal of Pathology 263:166–177, 2024 Siozopoulou V, Smits E, De Winne K, et al: NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel) 11, 2021 Assi T, Rassy E, Nassereddine H, et al: TRK inhibition in soft tissue sarcomas: A comprehensive review. Semin Oncol 47:73–84, 2020 Forsythe A, Zhang W, Phillip Strauss U, et al: A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther Adv Med Oncol 12:1758835920975613, 2020 Davis JL, Al-Ibraheemi A, Rudzinski ER, et al: Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathology 80:4–18, 2022 Mosele MF, Westphalen CB, Stenzinger A, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Annals of Oncology 35:588–606, 2024 Simmons C, Deyell RJ, MacNeill AJ, et al: Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma. Int J Cancer 149:1691–1704, 2021 Demetri GD, Antonescu CR, Bjerkehagen B, et al: Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 31:1506–1517, 2020 Lassen U, Bokemeyer C, Garcia-Foncillas J, et al: Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis. JCO Precis Oncol 7:e2200651, 2023 Suh K, Carlson JJ, Xia F, et al: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers. J Comp Eff Res 11:1011–1019, 2022 Bagaria SP, Ashman JB, Daugherty LC, et al: Compliance with National Comprehensive Cancer Network guidelines in the use of radiation therapy for extremity and superficial trunk soft tissue sarcoma in the United States. J Surg Oncol 109:633–8, 2014 Beadling C, Wald AI, Warrick A, et al: A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. J Mol Diagn 18:165–75, 2016 Penault-Llorca F, Rudzinski ER, Sepulveda AR: Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460–467, 2019 Additional Declarations No competing interests reported. Supplementary Files SupplementaryFileS1.docx SupplementaryFileS2.docx SupplementaryfileS3.xlsx SupplementaryTablesNTRK.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-6512957","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":459477670,"identity":"43e340f2-2c83-4fa9-847a-03b4342daa72","order_by":0,"name":"Shahd Hamran","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Shahd","middleName":"","lastName":"Hamran","suffix":""},{"id":459477671,"identity":"818c0f9b-f7b0-4ee9-b374-9b2f33752d97","order_by":1,"name":"Zaineh Alnoubani","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Zaineh","middleName":"","lastName":"Alnoubani","suffix":""},{"id":459477672,"identity":"5b6788d1-74b7-44b4-809f-a3f387d8bc6f","order_by":2,"name":"Aly Mostafa Hassan","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Aly","middleName":"Mostafa","lastName":"Hassan","suffix":""},{"id":459477673,"identity":"ff0675f6-8873-4429-8ae2-7f4e984543d0","order_by":3,"name":"Amani A. Al-Rajhi","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Amani","middleName":"A.","lastName":"Al-Rajhi","suffix":""},{"id":459477674,"identity":"f87ff019-7564-454c-80a3-714c3f4fdd49","order_by":4,"name":"Humam Emad Rajha","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Humam","middleName":"Emad","lastName":"Rajha","suffix":""},{"id":459477675,"identity":"906c72cb-5a8f-4def-aa63-26f6b7f84e38","order_by":5,"name":"Munirah Altaissan","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Munirah","middleName":"","lastName":"Altaissan","suffix":""},{"id":459477676,"identity":"60cc565a-5069-4b22-993f-f32f5294f10e","order_by":6,"name":"Giridhara Rathnaiah Babu","email":"","orcid":"","institution":"Qatar University","correspondingAuthor":false,"prefix":"","firstName":"Giridhara","middleName":"Rathnaiah","lastName":"Babu","suffix":""},{"id":459477677,"identity":"160e24bf-8b75-4173-a31a-9d3d4030cc40","order_by":7,"name":"Zoran Gatalica","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Zoran","middleName":"","lastName":"Gatalica","suffix":""},{"id":459477678,"identity":"133ee139-c98a-49df-a60f-ee476a8c88de","order_by":8,"name":"Semir Vranic","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA5klEQVRIiWNgGAWjYJCCAxCKsYHhA5BiYydFC+MMkBZmUqxj5gGTBFTJt3cnHq5gOJzPP7u58bPNr23yfMwMjB8+5uDWYnDm7IaDZxgOW864c7BZOrfvtmEbMwOz5MxteLRI5G442MCQZsBwI7GNObfnNiNQCxszLx4t8vPfQrTIg7RY9ty2J6iF4QYvSIuNgQFIC8OP24kEtRicATnMwMbA8EZis2Rvw+3kNmbGZrx+kW8/u/ljQ4WEgdyN9Icffvy5bTu/vfngh4/4HAaxC0oztoHJBkLqkcEfUhSPglEwCkbBSAEA38hRvPjDEUcAAAAASUVORK5CYII=","orcid":"","institution":"Qatar University","correspondingAuthor":true,"prefix":"","firstName":"Semir","middleName":"","lastName":"Vranic","suffix":""}],"badges":[],"createdAt":"2025-04-23 13:08:56","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-6512957/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-6512957/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":83355255,"identity":"015678e0-cdae-4f8a-ba46-bce1f7460242","added_by":"auto","created_at":"2025-05-23 15:03:42","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":166790,"visible":true,"origin":"","legend":"\u003cp\u003ePreferred reporting items for systematic reviews and meta-analyses (PRISMA) flowchart for the search results.\u003c/p\u003e","description":"","filename":"Figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/1cb1a2684cc393070ca82a7c.png"},{"id":83356339,"identity":"477b5c0d-fff1-4b29-9bb6-7e063afbedf9","added_by":"auto","created_at":"2025-05-23 15:11:42","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":100927,"visible":true,"origin":"","legend":"\u003cp\u003eGeographical location of included studies.\u003c/p\u003e","description":"","filename":"Figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/dfc7aa5a9edb36f6b33a6b91.png"},{"id":83355254,"identity":"b3c71583-79dc-4aa0-90d5-443671b3e9bf","added_by":"auto","created_at":"2025-05-23 15:03:42","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":122851,"visible":true,"origin":"","legend":"\u003cp\u003eThe type of diagnostic methods used for diagnosing \u003cem\u003eNTRK1-3\u003c/em\u003efusions in sarcomas.\u003c/p\u003e\n\u003cp\u003eFluorescence In Situ Hybridization (FISH), Immunohistochemistry (IHC), Not Available (NA), Genomic Sequencing (GS), Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)\u003c/p\u003e","description":"","filename":"Figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/dc182ae5246c7a51e5e3eb48.png"},{"id":83357506,"identity":"937192ef-6c87-45f0-9968-b9b4c1df6168","added_by":"auto","created_at":"2025-05-23 15:27:44","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3086258,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/c5292df2-4eb4-4bdd-b5c1-98f7f2190da3.pdf"},{"id":83356841,"identity":"0aa7e878-8f57-4a80-975f-b696feb2f19f","added_by":"auto","created_at":"2025-05-23 15:19:42","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":29801,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryFileS1.docx","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/4918c481eb3b6d77eb72d356.docx"},{"id":83355253,"identity":"b397247f-7a5d-491c-92a2-3e8b2fdf7b21","added_by":"auto","created_at":"2025-05-23 15:03:42","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":18944,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryFileS2.docx","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/4f0e53eae73c8a9fcba83446.docx"},{"id":83355258,"identity":"ac9e03ea-b696-427a-b66d-c957993964ec","added_by":"auto","created_at":"2025-05-23 15:03:42","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":232652,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryfileS3.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/7c242fbe18ea618c427d084b.xlsx"},{"id":83355259,"identity":"24136bc1-f2b3-43b6-87ee-2ccdb0daa7c4","added_by":"auto","created_at":"2025-05-23 15:03:42","extension":"docx","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":77681,"visible":true,"origin":"","legend":"","description":"","filename":"SupplementaryTablesNTRK.docx","url":"https://assets-eu.researchsquare.com/files/rs-6512957/v1/202c02f2574279bfe9a23559.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic Review","fulltext":[{"header":"Introduction","content":"\u003cp\u003eThe Tropomyosin Receptor Kinase (TRK) family of receptor tyrosine kinases comprises three types: TRKA, TRKB, and TRKC transmembrane proteins, which are encoded by Neurotrophic Receptor Tyrosine Kinase (\u003cem\u003eNTRK\u003c/em\u003e) genes 1, 2, and 3, respectively \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. These TRKs, found in human neuronal tissue, are vital for cell survival and the development and nervous system function, activated by neurotrophins. Neurotrophins, such as nerve growth factor for TRKA, brain-derived growth factor and neurotrophin-4/5 for TRKB, and neurotrophin-3 for TRKC, serve as specific ligands for these receptors. Each of the three TRKs has an extracellular domain for ligand binding, a transmembrane region, and an intracellular domain containing a kinase domain \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions with their partner genes are the key oncogenic mechanism, leading to the overexpression of TRK proteins \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003cem\u003eNTRK1-3\u003c/em\u003e fusions are present in nearly 90% of some rare cancers, such as infantile fibrosarcoma and secretory breast carcinoma, but occur in less than 1% of some common cancers \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. These fusions are also rare in some other common cancers, such as uterine soft tissue tumors, some variants of malignant melanoma, papillary thyroid carcinoma, and pancreatic adenocarcinoma. However, evidence on \u003cem\u003eNTRK1-3\u003c/em\u003e fusion prevalence in other cancer types remains limited \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions or their proteins are often detected using immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), reverse transcription-polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS) \u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Agnostic therapy refers to treatment decisions based solely on the tumor's genomic features \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e, enabling personalized and more effective treatment options. This approach has transformed cancer treatment \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Precision medicine relies on detecting genomic alterations to guide treatment, using drugs that target tumor-driving mutations rather than tumor anatomic location or type \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOne of the most significant advancements in this field is the development of TRK inhibitors, designed to block the oncogenic TRK signaling caused \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. First-generation TRK inhibitors, larotrectinib and entrectinib, target TRKA, TRKB, and TRKC. Larotrectinib is highly selective for TRKs, whereas entrectinib also inhibits ROS1 and ALK \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e,\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. These approved first-generation TRK inhibitors have demonstrated significant antitumor activity in clinical trials for treating solid tumors with \u003cem\u003eNTRK1-3\u003c/em\u003e fusions \u003csup\u003e\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e,\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Data from a pooled analysis of three clinical trials showed that patients receiving larotrectinib have a response rate between 81% and 100% \u003csup\u003e14\u003c/sup\u003e. In comparison, data from the analysis of three other trials showed that entrectinib has an objective response rate (ORR) of 57% and durable responses, including in patients with brain metastases \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Other inhibitors, such as TPX-0005 (repotrectinib), crizotinib, and cabozantinib, are under investigation and show promise in overcoming resistance due to acquired mutations \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. \u003cem\u003eNTRK1-3\u003c/em\u003e fusion detection is essential for TRK inhibitor eligibility, facilitating personalized and more effective targeted therapies. Molecular testing is integral to precision medicine's diagnostic and therapeutic process, significantly improving patient outcomes, contributing to the broader understanding of cancer biology, and developing novel therapeutic approaches.\u003c/p\u003e \u003cp\u003eThis study aims to systematize the knowledge regarding the frequency and types of \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions across a diverse range of soft tissue sarcomas beyond commonly associated sarcomas and infantile fibrosarcoma in pediatrics, underscoring the importance of comprehensive genomic profiling to guide personalized treatment strategies for patients with advanced or metastatic disease.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy Design\u003c/h2\u003e \u003cp\u003e This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supplementary File S1). The protocol for this systematic review is registered on the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024563594).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eData Sources and Search Methods\u003c/h3\u003e\n\u003cp\u003eWe conducted a comprehensive database search (PubMed/MEDLINE, SCOPUS, Web of Science) using \u003cem\u003eNTRK1-3\u003c/em\u003e and sarcoma-related terms, spanning from their inception to May 2024. Additionally, relevant proceedings from the major oncologic scientific conferences, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association for Cancer Research (AACR) from January 2023 to May 2024 were reviewed. The search was updated on July 14, 2024. Specific search terms related to \u003cem\u003eNTRK1-3\u003c/em\u003e and sarcoma were employed to identify pertinent studies. These terms encompassed various synonyms and related expressions for \u003cem\u003eNTRK\u003c/em\u003e receptors and a broad spectrum of sarcoma types. The search terms used for different databases are provided in Supplementary File S2.\u003c/p\u003e\n\u003ch3\u003eProcedure for Study Selection\u003c/h3\u003e\n\u003cp\u003eThe articles retrieved from the database searches were uploaded into EndNote software to remove duplicates. Following deduplication, titles, and abstracts were screened using the Rayyan systematic review management platform (\u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://www.rayyan.ai/\u003c/span\u003e\u003cspan address=\"https://www.rayyan.ai/\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e). Full-text articles meeting initial inclusion criteria underwent detailed eligibility assessment by each of the two independent reviewers. Any discrepancies were resolved through consensus or consultation with a third reviewer (SH).\u003c/p\u003e\n\u003ch3\u003eEligibility\u003c/h3\u003e\n\u003cp\u003eEligible studies included case series, case reports, and observational analytical studies investigating \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions in soft tissue sarcomas. Relevant abstracts without full text were also considered if they reported applicable outcomes. Studies that included a diagnosis of soft tissue sarcoma, reported the frequencies and types of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions and provided detailed descriptions of \u003cem\u003eNTRK1-3\u003c/em\u003e fusion variants were included. Studies exclusively focusing on non-sarcoma malignancies or non-English publications were excluded.\u003c/p\u003e\n\u003ch3\u003eKey Definitions\u003c/h3\u003e\n\u003cp\u003eSarcomas are malignant soft tissue (mesenchymal) tumors \u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. Neurotrophic Receptor Tyrosine Kinase (\u003cem\u003eNTRK\u003c/em\u003e) fusion genes are formed by the fusion of a part of the \u003cem\u003eNTRK1-3\u003c/em\u003e genes with different partner genes, resulting in constitutive activation of the TRK signaling \u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e,\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eOutcomes\u003c/h2\u003e \u003cp\u003eThe primary outcome was to determine the prevalence of \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions in various types of sarcomas, assessed by the proportion of cases with identified fusions using molecular diagnostic techniques. Secondary outcomes included comparing fusion type distributions, evaluating detection method efficacy, assessing the safety and efficacy of TRK inhibitors, and examining fusion distribution across different sarcoma subtypes.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eData Extraction\u003c/h3\u003e\n\u003cp\u003eTwo independent authors extracted data using Microsoft Excel. The extracted data included study design, patient demographics, tumor type and location, molecular details of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions, detection methods, treatment approaches, and survival outcomes.\u003c/p\u003e\n\u003ch3\u003eData Synthesis\u003c/h3\u003e\n\u003cp\u003eThe results were synthesized using narrative synthesis methods. Tabular presentations were summarized, including the proportion of fusion, variants' distribution, and clinicopathological correlations. Thematic analysis will explore molecular mechanisms and therapeutic implications. Subgroup analyses were done to assess variations across different sarcoma subtypes. The quality of the studies was assessed using the MethodologicAl STandard for Epidemiological Research (MASTER) scale, which includes 36 safeguards categorized into seven domains \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. These domains are equal recruitment, equal retention, equal ascertainment, equal implementation, equal prognosis, sufficient analysis, and temporal precedence. We used Stata version 18 (College Station, TX, USA) for the analysis.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eEthics\u003c/h2\u003e \u003cp\u003eThis is a systematic review of published literature and thus did not require institutional ethical approval.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eSearch results\u003c/h2\u003e \u003cp\u003eSeven hundred eighty-seven studies were identified from the databases. After removing 186 duplicates, 387 study records were excluded through manual abstract and title screening, and the remaining 214 studies were screened using full text. After full-text screening, 19 studies were excluded because they were reviews, 14 because they did not assess sarcomas, and 10 papers were not available in English. Other reasons for exclusion are illustrated in the PRISMA flowchart (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). The final review included 136 studies \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan additionalcitationids=\"CR21 CR22 CR23 CR24 CR25 CR26 CR27 CR28 CR29 CR30 CR31 CR32 CR33 CR34 CR35 CR36 CR37 CR38 CR39 CR40 CR41 CR42 CR43 CR44 CR45 CR46 CR47 CR48 CR49 CR50 CR51 CR52 CR53 CR54 CR55 CR56 CR57 CR58 CR59 CR60 CR61 CR62 CR63 CR64 CR65 CR66 CR67 CR68 CR69 CR70 CR71 CR72 CR73 CR74 CR75 CR76 CR77 CR78 CR79 CR80 CR81 CR82 CR83 CR84 CR85 CR86 CR87 CR88 CR89 CR90 CR91 CR92 CR93 CR94 CR95 CR96 CR97 CR98 CR99 CR100 CR101 CR102 CR103 CR104 CR105 CR106 CR107 CR108 CR109 CR110 CR111 CR112 CR113 CR114 CR115 CR116 CR117 CR118 CR119 CR120 CR121 CR122 CR123 CR124 CR125 CR126 CR127 CR128 CR129 CR130 CR131 CR132 CR133 CR134 CR135 CR136 CR137 CR138 CR139 CR140 CR141 CR142 CR143 CR144 CR145 CR146 CR147 CR148 CR149 CR150 CR151\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR152\" class=\"CitationRef\"\u003e152\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eQuality assessment of included studies\u003c/h2\u003e \u003cp\u003eSeven of the 136 articles included were abstracts \u003csup\u003e\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e,\u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e,\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e,\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e,\u003cspan citationid=\"CR125\" class=\"CitationRef\"\u003e125\u003c/span\u003e,\u003cspan citationid=\"CR134\" class=\"CitationRef\"\u003e134\u003c/span\u003e,\u003cspan citationid=\"CR141\" class=\"CitationRef\"\u003e141\u003c/span\u003e\u003c/sup\u003e, and one paper was an integrated analysis of non-published studies \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, so their quality could not be assessed. The average MASTER scale score for the remaining 128 studies we assessed was 25 out of a maximum score of 36, ranging from 20 in some studies \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e,\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e,\u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e,\u003cspan citationid=\"CR137\" class=\"CitationRef\"\u003e137\u003c/span\u003e\u003c/sup\u003e up to 29 in others \u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e,\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e,\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e,\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e,\u003cspan citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e,\u003cspan citationid=\"CR124\" class=\"CitationRef\"\u003e124\u003c/span\u003e,\u003cspan citationid=\"CR146\" class=\"CitationRef\"\u003e146\u003c/span\u003e\u003c/sup\u003e, indicating a moderate quality with a low-moderate risk of bias. The 128 studies did not have blinding or allocation concealment, which downgraded the studies in the \u0026lsquo;Equal ascertainment\u0026rsquo; (domain 3) and the \u0026lsquo;Equal prognosis\u0026rsquo; (domain 5) categories of the MASTER scale. Additionally, there were 40 multi-centered studies \u003csup\u003e4,14,20\u0026ndash;24,30,34,40,44,51,53,57,59,61,62,78\u0026ndash;80,85,89,94,98,107,108,110,114,115,118,119,129,131\u0026ndash;133,136\u0026minus;138,147,148\u003c/sup\u003e, so the fourth domain, \u0026lsquo;Equal implementation\u0026rsquo;, was not fulfilled. Further details of the MASTER scale assessment can be seen in Supplementary File S3.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eCharacteristics of included studies\u003c/h2\u003e \u003cp\u003eThe baseline characteristics in the analyzed studies exhibit considerable heterogeneity in several aspects, including the study design, duration, location, patient demographics, and gender distribution. Out of 136 papers, 50 were case reports \u003csup\u003e25,28,31,32,38,39,42,47,49,53,55,58,60,65\u0026ndash;68,70,71,73,76,81\u0026ndash;84,86,88,91\u0026ndash;93,95\u0026minus;97,99\u0026ndash;101,103,106,109,112,116,120,121,126,128,130,140,145,146,150\u003c/sup\u003e, 26 were case series \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e,\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e,\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e,\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e,\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e,\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e,\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e,\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e,\u003cspan citationid=\"CR110\" class=\"CitationRef\"\u003e110\u003c/span\u003e,\u003cspan citationid=\"CR113\" class=\"CitationRef\"\u003e113\u003c/span\u003e,\u003cspan citationid=\"CR115\" class=\"CitationRef\"\u003e115\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e,\u003cspan citationid=\"CR123\" class=\"CitationRef\"\u003e123\u003c/span\u003e,\u003cspan citationid=\"CR125\" class=\"CitationRef\"\u003e125\u003c/span\u003e,\u003cspan additionalcitationids=\"CR133 CR134\" citationid=\"CR132\" class=\"CitationRef\"\u003e132\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR135\" class=\"CitationRef\"\u003e135\u003c/span\u003e,\u003cspan citationid=\"CR138\" class=\"CitationRef\"\u003e138\u003c/span\u003e,\u003cspan citationid=\"CR152\" class=\"CitationRef\"\u003e152\u003c/span\u003e\u003c/sup\u003e, 54 were observational retrospective studies \u003csup\u003e4,14,21\u0026ndash;24,26,29,30,33,34,36,37,40,41,44,48,51,54,57,59,62\u0026ndash;64,77\u0026minus;79,85,87,89,90,94,98,102,104,108,111,114,122,124,129,131,133,136,137,139,141\u0026ndash;144,147\u0026minus;149,151\u003c/sup\u003e, one was a prospective cohort \u003csup\u003e\u003cspan citationid=\"CR134\" class=\"CitationRef\"\u003e134\u003c/span\u003e\u003c/sup\u003e, two were retrospective and prospective cohort studies \u003csup\u003e\u003cspan citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e,\u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e\u003c/sup\u003e, two were pooled analyses of three clinical trials \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR127\" class=\"CitationRef\"\u003e127\u003c/span\u003e\u003c/sup\u003e, and one was a study with a partitioned survival model \u003csup\u003e\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e\u003c/sup\u003e (Supplementary File S3). Notably, 85 studies did not specify the exact length of the study or follow-up period. Of the 51 studies, 19 were from ten to 30 years old. Of these 19 papers, 12 \u003csup\u003e22,30,34,40,54,59,79,89,102,139,144,151\u003c/sup\u003e were descriptive studies that utilized archived materials and clinical records to analyze tumor biopsies, while the remaining seven \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR123\" class=\"CitationRef\"\u003e123\u003c/span\u003e,\u003cspan citationid=\"CR135\" class=\"CitationRef\"\u003e135\u003c/span\u003e\u003c/sup\u003e were case series and case reports with long-term patient follow-ups. Additionally, 25 studies \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e,\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e,\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e,\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e,\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e,\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e,\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e,\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e,\u003cspan citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e,\u003cspan citationid=\"CR108\" class=\"CitationRef\"\u003e108\u003c/span\u003e,\u003cspan citationid=\"CR113\" class=\"CitationRef\"\u003e113\u003c/span\u003e,\u003cspan citationid=\"CR114\" class=\"CitationRef\"\u003e114\u003c/span\u003e,\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e,\u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e,\u003cspan citationid=\"CR129\" class=\"CitationRef\"\u003e129\u003c/span\u003e,\u003cspan citationid=\"CR136\" class=\"CitationRef\"\u003e136\u003c/span\u003e,\u003cspan citationid=\"CR141\" class=\"CitationRef\"\u003e141\u003c/span\u003e,\u003cspan citationid=\"CR143\" class=\"CitationRef\"\u003e143\u003c/span\u003e,\u003cspan citationid=\"CR149\" class=\"CitationRef\"\u003e149\u003c/span\u003e\u003c/sup\u003e had durations ranging from one to five years, including a mixture of case series, case reports, and retrospective studies. Most of the included studies were conducted in the USA (n\u0026thinsp;=\u0026thinsp;46), followed by China (n\u0026thinsp;=\u0026thinsp;17), and Japan (n\u0026thinsp;=\u0026thinsp;14). Eight studies did not specify the geographic location. The remaining studies were distributed across the globe. Figure\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e summarizes the common geographical locations of the included studies. Supplementary File S3 provides detailed information.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eForty-four studies did not report gender distribution. The remaining 92 studies \u003csup\u003e21,22,24,25,28\u0026ndash;31,35,36,38,40,42,46,47,49\u0026ndash;61,63\u0026minus;76,78,80\u0026ndash;84,86\u0026minus;89,91\u0026ndash;93,95\u0026minus;97,100\u0026ndash;105,109,110,112,114,116\u0026ndash;123,126\u0026minus;128,130\u0026ndash;132,135,136,138\u0026ndash;140,143,145,147,148,150\u003c/sup\u003e had a combined sample size of 1,824 patients; 1,139 of them were women (62.45%). Regarding the age of patients, nine studies did not specify the age group, 43 studies \u003csup\u003e\u003cspan additionalcitationids=\"CR21 CR22\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan additionalcitationids=\"CR29 CR30 CR31 CR32 CR33\" citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan additionalcitationids=\"CR45\" citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e,\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e,\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e,\u003cspan additionalcitationids=\"CR68 CR69\" citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e,\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e,\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e,\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e,\u003cspan citationid=\"CR112\" class=\"CitationRef\"\u003e112\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR142\" class=\"CitationRef\"\u003e142\u003c/span\u003e,\u003cspan citationid=\"CR143\" class=\"CitationRef\"\u003e143\u003c/span\u003e,\u003cspan citationid=\"CR150\" class=\"CitationRef\"\u003e150\u003c/span\u003e,\u003cspan citationid=\"CR152\" class=\"CitationRef\"\u003e152\u003c/span\u003e\u003c/sup\u003e focused exclusively on pediatric patients (those under 18 years), 38 studies \u003csup\u003e24,26,36,37,40,43,51,52,62\u0026ndash;64,77\u0026minus;80,89,90,98,104,105,107,113,114,119,122\u0026ndash;124,129,131\u0026ndash;133,136\u0026minus;138,144,147,149,151\u003c/sup\u003e included both pediatric and adult populations, and 46 studies \u003csup\u003e4,15,35,47,50,53,56\u0026ndash;58,61,65,66,71\u0026ndash;74,81,83,84,86\u0026ndash;88,91,93\u0026ndash;97,99\u0026minus;101,103,108\u0026ndash;110,116,118,121,126\u0026ndash;128,140,141,145,146,148\u003c/sup\u003e focused solely on adults. The population's age range varied from neonates only a few days old to elderly patients (Supplementary File S3).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eSarcoma types\u003c/h2\u003e \u003cp\u003eThis systematic review revealed 18,077 sarcoma patients in 136 studies. Of these, 17 studies \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e,\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e,\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e,\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e,\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e,\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e,\u003cspan citationid=\"CR110\" class=\"CitationRef\"\u003e110\u003c/span\u003e,\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e,\u003cspan citationid=\"CR114\" class=\"CitationRef\"\u003e114\u003c/span\u003e,\u003cspan citationid=\"CR133\" class=\"CitationRef\"\u003e133\u003c/span\u003e,\u003cspan citationid=\"CR134\" class=\"CitationRef\"\u003e134\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR141\" class=\"CitationRef\"\u003e141\u003c/span\u003e,\u003cspan citationid=\"CR142\" class=\"CitationRef\"\u003e142\u003c/span\u003e,\u003cspan citationid=\"CR144\" class=\"CitationRef\"\u003e144\u003c/span\u003e\u003c/sup\u003e (representing 11,108 patients) did not mention the specific type of soft tissue tumor detected. Among the remaining 6,969 cases, 2,004 were diagnosed as unspecified or unclassified soft tissue tumors. Additionally, 1,019 women presented with gynecologic sarcomas, including 591 with leiomyosarcomas. Other soft tissue tumors included 409 gastrointestinal stromal tumors (GIST), 145 synovial sarcomas, 302 osteosarcomas, 162 angiosarcomas, 37 lipofibromatosis-like neural tumors, 609 liposarcomas, and 151 patients with congenital or infantile fibrosarcomas. Further details on other sarcoma types are detailed in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eCharacteristics of the included studies.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eNo.\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAuthor, year\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCountry\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFusion detection method\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eTotal no. of sarcoma patients\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNumber of pts in each type of sarcoma/s\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eTumor location\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNo. of NTRK fusions\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKnezevich, 1998 \u003csup\u003e20\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCanada, USA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ecytogenic analysis, karyotype, FISH, RT-PCR, northern \u0026amp; southern blots\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eflank (1), lower limb (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRubin, 1998 \u003csup\u003e21\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ekaryotype, FISH, RT-PCR, DNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSix CMN, 5 CFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ekidney (6), back (2), limbs (2), neck (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (6)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKnezevich, 1998 \u003csup\u003e22\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCanada, USA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, Northern Blot\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNine cellular CMN, two mixed CMN, four classical CMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eArgani, 2000 \u003csup\u003e23\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEleven CMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBourgeoi, 2000 \u003csup\u003e24\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThirteen malignant spindle cell tumors, 11 CFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eLimbs (24), head \u0026amp; neck (14), abdomen (7), back (5), buttock (3), chest wall (3), multicentric (2), flank (2), lung (1), prostate (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (10)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePunnett, 2000 \u003csup\u003e25\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ekaryotype, FISH, RT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne CFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elower limb/groin/pelvis/pulmonary (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSheng, 2001 \u003csup\u003e26\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan, Sweden\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, DNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTen congenital/IFS, seven adult-type fibrosarcomas, four leiomyosarcomas, four malignant fibrous histiocytomas, four monophasic synovial sarcomas, three MPNST, four DFSP, four fibromatoses\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (8), jaw angle (1). The rest were not specified.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHisaoka, 2002 \u003csup\u003e27\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan, China\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThree desmoid, one hemangiopericytoma, two DFSP, one IFS, one malignant fibrous histiocytoma, three leiomyosarcoma, one embryonal RMS, one alveolar RMS, three synovial sarcoma, four well-differentiated liposarcomas, one differentiated liposarcoma, four myxoid liposarcomas, two extraskeletal Ewing\u0026rsquo;s sarcomas, one primitive neuroectodermal tumor, one angiosarcoma, one extraskeletal myxoid chondrosarcoma, one clear cell sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e27 TrkC (\u003cem\u003eNTRK3\u003c/em\u003e) expression \u0026amp; 1 with Tel\u0026ndash;TrkC fusion transcript\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHenno, 2003 \u003csup\u003e28\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMolecular study, IHC, RT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne cellular CMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ekidney (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMcCahon, 2003 \u003csup\u003e29\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCanada\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo IFS, one atypical CMN\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elower limb (2), kidney (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOotsuka, 2007 \u003csup\u003e30\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eqRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo RMS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMari\u0026ntilde;o-Enr\u0026iacute;quez, 2008 \u003csup\u003e31\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ekaryotype, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne CFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eRetroperitoneum (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHimori, 2009 \u003csup\u003e32\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ethigh (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGadd, 2012 \u003csup\u003e33\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, RT\u0026ndash;MLP, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwelve CMN, two IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWalther, 2013 \u003csup\u003e34\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSweden\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eChromosome banding, FISH, RT-PCR, SNP array\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne embryonal RMS, three IFS, one nodular fibrohistiocytic tumor, one angiomatoid fibrous histiocytoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ehead \u0026amp; neck, thorax, abdomen, pelvis, extremities, and skin (numbers not reported)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBrenca, 2015 \u003csup\u003e35\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFive GIST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003esmall intestine (4), rectum (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHaller, 2016 \u003csup\u003e36\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGermany\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, RNA sequencing, WGS, western blot\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo myopericytoma-like sarcomas, one infantile hemangiopericytoma-like sarcoma, one myofibroblastic sarcoma-like\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eback (1), paravertebral lumbar (1), supraclavicular (1), upper arm (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e18\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eShi, 2016 \u003csup\u003e37\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eCGP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e191\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e191 GIST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003egastrointestinal tract (191)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNagasubramanian, 2016 \u003csup\u003e38\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ehead \u0026amp; neck (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWong, 2016 \u003csup\u003e39\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, DNA \u0026amp; RNA sequencing hybrid capture-based assay\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ebuttock (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e21\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAgaram, 2017 \u003csup\u003e40\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e14\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFourteen LPFNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (8), flank (1), scalp (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (6),\u003c/p\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e gene amplification (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHechtman, 2017 \u003csup\u003e41\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, RNA testing, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e23\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eObayashi, 2017 \u003csup\u003e42\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, RT-PCR, gene sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eileocecal region (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePavlick, 2017 \u003csup\u003e43\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, DNA \u0026amp; RNA sequencing, CGP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo IFS, one fibrosarcoma, one fibrosarcoma ex DFSP, one neuroectodermal tumor, one IMT, one dendritic sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChmielecki, 2017 \u003csup\u003e44\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e311\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e63 bone sarcomas, 66 RMS, 39 EwS, 37 STS, 19 soft tissue assorted, 18 fibromatoses, five angiosarcomas, six fibrosarcomas, 10 synovial sarcomas, six alveolar soft part sarcomas, seven IMT, 14 DFSP, 11 MPNST, 10 unknown sarcomas.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGatalica, 2018 \u003csup\u003e4\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e478\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne STS, one uterine sarcoma, 476 tumors NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e27\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHung, 2018 \u003csup\u003e45\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e160\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFive LPFNT, five lipofibromatosis, 10 primitive myxoid mesenchymal tumors of infancy, 10 low-grade myofibroblastic sarcomas, 15 IFS, 15 desmoid fibromatosis, 20 fibrosarcomatous DFSP, 20 spindle-cell RMS, 20 synovial sarcomas, 20 MPNST, 20 low-grade fibromyxoid sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (10), truncal/abdominopelvic/paravertebral region (11) head \u0026amp; neck (5), sacrococcygeal region (1), inguinal region (3), the rest were not specified.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKao, 2018 \u003csup\u003e46\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA, Canada, Turkey, Taiwan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, RT-PCR, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNine IFS, one unclassified low- grade SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eRetroperitoneal (3), pelvis (2), spine extradural (1), limbs (3), lumbar (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOlson, 2018 \u003csup\u003e47\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne DFSP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eback (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e30\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRudzinski, 2018 \u003csup\u003e48\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, IHC, RT-PCR, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThirty-one STS NOS, two DFSP, five desmoid, two MPNST, two synovial sarcomas, two spindle cell RMS, six IMT, one \u003cem\u003eBCOR\u003c/em\u003e-rearranged sarcoma, one UPS, four high-grade sarcomas, five low-grade spindle cell lesions, one metanephric stromal tumor, one classic mesoblastic nephroma, one cellular mesoblastic nephroma, one clear cell sarcoma of the kidney\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (12), \u003cem\u003eNTRK1\u003c/em\u003e gene amplification (1), \u003cem\u003eNTRK2\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e31\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKohsaka, 2018 \u003csup\u003e49\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne unclassified tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eelbow (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTakahashi, 2018 \u003csup\u003e50\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterus (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSuurmeijer, 2018 \u003csup\u003e51\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003etargeted RNA sequencing, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e25 spindle cell neoplasms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (14), Gastrointestinal tract (2), abdomen (1), Chest wall (4), back (2), Head (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (14), \u003cem\u003eNTRK2\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e34\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLao, 2018 \u003csup\u003e52\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour LPFNT, three IFS, one MPNST, two SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (2), buttock (2), right hip (1), left neck (3), right chest wall (1), left flank (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e gene rearrangement (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e35\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhou, 2018 \u003csup\u003e53\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eLumbosacral region/erector spinae/fifth lumbar vertebra/first sacral vertebra/iliac wing (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAntunes, 2019 \u003csup\u003e54\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBrazil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNineteen osteosarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (17), pelvis (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eTrkA expression on IHC (4), TrkB expression on IHC (8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e37\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBender, 2019 \u003csup\u003e55\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, DNA-based hybridization capture\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eforearm (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e38\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChiang, 2019 \u003csup\u003e56\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA \u0026amp; DNA sequencing, NGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour undifferentiated uterine sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterine cervix (3), uterine corpus (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (3), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e39\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCroce, 2019 \u003csup\u003e57\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance, USA, UK\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA \u0026amp; DNA sequencing, RT-PCR, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThirteen SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterine cervix (10), uterine corpus (2), vagina (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (6), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e40\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eD\u0026rsquo;Alpino Peixoto, 2019 \u003csup\u003e58\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBrazil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne GIST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003erectum (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e41\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDavis, 2019 \u003csup\u003e59\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, DNA sequencing, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFifteen IFS, five low-grade SCS, four unclassified tumors, two spindle and round cell sarcoma, one SCS, one myxoid DFSP\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (17), abdomen (1), pelvis (2), retroperitoneal (2), trunk (2), back (1), dural (1), lung (1), paraspinal (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (14), NTRK2 (1), NTRK3 (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e42\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWarren, 2019 \u003csup\u003e60\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK\u003c/em\u003e-rearranged mesenchymal tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eback (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e43\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYamazaki, 2019 \u003csup\u003e61\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, RT-PCR, Sanger sequencing, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo adult-type fibrosarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e44\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSolomon, 2019 \u003csup\u003e62\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA based NGS (MSK-IMPACT), RNA sequencing assay (MSKFusion)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1915\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eVarious locations, including salivary gland, thyroid, sarcoma, lung, etc.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (9), \u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e45\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSuurmeijer, 2019 \u003csup\u003e63\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, targeted RNA sequencing, anchored multiplex RNA sequencing, MSK-IMPACT assay\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (3), abdomino-pelvic (1), retroperitoneal (1), paraspinal (1), mesentery (1).\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e46\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAmeline, 2020 \u003csup\u003e64\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSweden\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, RT-PCR, Sanger sequencing validation\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e113\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e113 osteosarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK2\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e47\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBertolini, 2020 \u003csup\u003e65\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSwitzerland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne spindle cell neoplasm\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecolon (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e48\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBoyle, 2020 \u003csup\u003e66\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUK\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne uterine sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eUterine cervix (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e49\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCaldwell, 2020 \u003csup\u003e67\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003earm (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e50\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGoh, 2020 \u003csup\u003e68\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSingapore\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne UPS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eabdominal wall (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e51\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKang, 2020 \u003csup\u003e69\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSouth Korea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne undifferentiated sarcoma, seven IFS, one IMT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eDura (1), dermis and subcutaneous tissue (1), tongue (1), buttock (1), shoulder (1), foot (1), abdominal cavity (1), sacrococcygeal area (1), lung (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e52\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOlsen, 2020 \u003csup\u003e70\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne undifferentiated SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003epelvis-abdomen (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e gene rearrangement (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePanse, 2020 \u003csup\u003e71\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, Targeted RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne LPFNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003escalp (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e54\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRabban, 2020 \u003csup\u003e72\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThree cervical sarcomas, 19 uterine adenosarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecervix (3), uterus (19)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e55\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSo, 2020 \u003csup\u003e73\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, FISH, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne myxoid SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecalf (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e56\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVargas, 2020 \u003csup\u003e74\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAustralia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eArray comparative genomic hybridization, NGS, FISH, pan-TRK IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo inflammatory myofibroblastic-like tumors, one EwS, one fibrosarcoma-like tumor, one lung spindle and epithelioid cell sarcoma, and one uterine MPNST-like sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eliver (1), subcutaneous (1), thyroid (1), lung (1), uterine cervix (1), toe (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK2\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (2),\u003c/p\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e gene rearrangement (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e57\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKhuong-Quang, 2020 \u003csup\u003e75\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAustralia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eWGS, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne congenital/IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eChest (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e58\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRekhi, 2020 \u003csup\u003e76\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eIndia\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS-based targeted panel, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eneck (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e59\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWang, 2020 \u003csup\u003e77\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e312\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e60\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAtiq, 2021 \u003csup\u003e78\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA \u0026amp; RNA sequencing, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour unclassified mesenchymal tumors, two IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003esmall bowel (3), stomach (1), rectum (1), mesentery (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e61\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBrčić, 2021 \u003csup\u003e79\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eAustria\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e491\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e116 myxofibrosarcomas, 82 soft tissue and uterine leiomyosarcomas, 55 UPS, 45 synovial sarcomas, 37 myxoid liposarcomas, 34 atypical lipomatous tumors/well-differentiated liposarcomas, 34 dedifferentiated liposarcomas, 19 DFSP, 12 low-grade fibromyxoid sarcomas, 10 angiosarcomas, eight SFT, eight SCSs, five myxoinflammatory fibroblastic sarcomas, four pleomorphic liposarcomas, four alveolar soft part sarcomas, three spindle cell/pleomorphic sarcoma, three clear cell sarcomas, two extraskeletal myxoid chondrosarcomas, two embryonal RMS, two sclerosing epithelioid fibrosarcomas, one epithelioid sarcoma, one mesenchymal chondrosarcoma, one MPNST, one pleomorphic RMS, one IFS, one LPFNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (3), lung (1), neck (1), others not specified\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e62\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChen, 2021 \u003csup\u003e80\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA-based NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo EwS, one osteosarcoma, one unspecified high-grade malignant neoplasm, one lipofibromatosis-like features, one malignant SFT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003echest wall (1), limbs (4), paraspinal neck (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK2\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e63\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChen, 2021 \u003csup\u003e81\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne unclassified mesenchymal sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003escalp (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGoulding, 2021 \u003csup\u003e82\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNew Zealand\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne high-risk RMS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003evagina (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e65\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHodgson, 2021 \u003csup\u003e83\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCanada\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne cervical sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterine cervix (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e66\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePunjabi, 2021 \u003csup\u003e84\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSingapore\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, RT-PCR, Sanger sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK3-SQSTM1\u003c/em\u003e fusion SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eankle (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e67\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLam, 2021 \u003csup\u003e85\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNetherlands\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePan-trk IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e381\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e137 conventional chondrosarcomas, 36 dedifferentiated chondrosarcomas, 20 clear cell chondrosarcomas, 19 mesenchymal chondrosarcomas, 123 osteosarcomas, 26 angiosarcomas, 20 EwS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e17 pan-TRK IHC positive\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e68\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLanman, 2021 \u003csup\u003e86\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne uterine sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterus (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e69\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLiu, 2021 \u003csup\u003e87\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTargeted RNA sequencing, RT-PCR, Sanger sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFive chondroid tenosynovial giant cell tumor, one chondroid neoplasm of synovium, one atypical chondroid neoplasm, one giant cell-rich lesion chondroid stroma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eTMJ/temporal bone (4), limbs (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePercy, 2021 \u003csup\u003e88\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBelgium\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eDistal left leg/Kager space/posterior cortical of the tibia/left Achilles tendon (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e71\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eXu, 2021 \u003csup\u003e89\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e195\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e23 GIST, 22 osteosarcomas, 14 liposarcomas, 13 leiomyosarcomas, 12 myxofibrosarcomas, nine synovial sarcomas, seven EwS, five chondrosarcomas, five RMS, five aggressive fibromatosis, four angiosarcomas, four DFSP, four UPS, two epithelioid hemangioendotheliomas, two myofibroblastic sarcomas, two myxoid sarcomas, one SFT, one embryonic undifferentiated sarcoma, one alveolar soft part sarcoma, one clear cell sarcoma, one malignant granular cell tumor, 50 unclassified STS, four unclassified osteogenic sarcomas, two IFS, one \u003cem\u003eNTRK\u003c/em\u003e-rearrangement spindle cell mesenchymal tumor.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2),\u003c/p\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e rearrangement (4), \u003cem\u003eNTRK3\u003c/em\u003e (4),\u003c/p\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e rearrangement (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e72\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePeng, 2021 \u003csup\u003e90\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eTargeted NGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e547\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e73\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBai, 2022 \u003csup\u003e91\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne high-grade UPS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003echest wall (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e74\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBridgewater, 2022 \u003csup\u003e14\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUK\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eWGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1174\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK2\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e75\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCzaja, 2022 \u003csup\u003e92\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne LPFNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eback (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e76\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDang, 2022 \u003csup\u003e93\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK\u003c/em\u003e fusion cervical sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterine cervix (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e77\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDemetri, 2022 \u003csup\u003e15\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA \u0026amp; South Korea\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC, FISH, PCR, Sanger sequencing, or NanoString\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e26\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTen sarcoma NOS, 5 SCS, 2 GIST, 2 leiomyosarcoma, 1 angiosarcoma, 1 cervical adenosarcoma, 1 chondrosarcoma, 1 endometrial sarcoma, 1 endometrial stromal sarcoma, 1 Follicular dendritic cell sarcoma, 1 MPNST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e78\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHibar, 2022 \u003csup\u003e94\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e287\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e79\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eJiang, 2022 \u003csup\u003e95\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, DNA Sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne primary renal fibrosarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ekidney (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e80\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOverfield, 2022 \u003csup\u003e96\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK\u003c/em\u003e‑rearranged spindle cell tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eknee (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e81\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRecine, 2022 \u003csup\u003e97\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK\u003c/em\u003e‑rearranged spindle cell tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eabdominal cutaneous lesion (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSilvertown, 2022 \u003csup\u003e98\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCanada\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e165\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS, two MPNST, 162 tumors NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003echest (2), arm (1), not specified (162)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e83\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKobayashi, 2022 \u003csup\u003e99\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA \u0026amp; DNA panel testing, IHC, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne MPNST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ebuttock (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e84\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKyriazogloua, 2022 \u003csup\u003e100\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGreece\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, RT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne unclassified myxoid SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eleft gluteal area (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e85\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNilforoushan, 2022 \u003csup\u003e101\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA \u0026amp; RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecervix (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e86\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNozzoli, 2022 \u003csup\u003e102\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS, RT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e105\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e96 EwS, three \u003cem\u003eEWSR1\u003c/em\u003e-non-ETS round cell sarcomas, one sarcoma with \u003cem\u003eBCOR\u003c/em\u003e genetic alteration, five undifferentiated STS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003esoft tissue (23), bone (82)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e87\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRahim, 2022 \u003csup\u003e103\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eKuwait\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA-based NGS, RNA-based gene fusion assay, pan-TRK IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eileum (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e88\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSiozopoulou, 2022 \u003csup\u003e104\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBelgium\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTen chondrosarcomas, three EwS, five osteosarcomas, seven angiosarcomas, eight Kaposi sarcomas, five leiomyosarcomas, nine liposarcomas, five myxofibrosarcomas, three RMS, three synovial sarcomas, 12 sarcoma NOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eBone (19), extremities (17), trunk and back (5), head \u0026amp; neck (4), skin and subcutaneous fat tissue (12), abdomen (6), mediastinum (5), retroperitoneum (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e89\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSuh, 2022 \u003csup\u003e105\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e250\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e32 liposarcomas, 59 leiomyosarcoma, 27 synovial sarcomas, 132 STS NOS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e90\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eThorwarth, 2022 \u003csup\u003e106\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGermany\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eSingle-nucleotide variant analysis, WES\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eintrathoracic (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e91\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eTsai, 2022 \u003csup\u003e107\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTaiwan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, FISH, RT-PCR, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eSeven spindle cell neoplasms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elung (1), heart (1), right pleura (1), prostate (1), uterine cervix (2), NA (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (5), \u003cem\u003eNTRK3\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e gene rearrangement (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e92\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVan Bockstal, 2022 \u003csup\u003e108\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBelgium\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePan-TRK IHC and subsequent molecular NTRK testing, FISH, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThree IFS, two SCS, one LPFNT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e93\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWang, 2022 \u003csup\u003e109\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, RNA-sequencing, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003efemur (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYoung, 2022 \u003csup\u003e110\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePan-TRK IHC, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ePeri-adrenal (1), retroperitoneal (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e gene rearrangement (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e95\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMoyers, 2022 \u003csup\u003e111\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eGenomic sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4256\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3,424 STS, 832 bone sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e96\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGong, 2023 \u003csup\u003e112\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne spindle cell neoplasm\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ebrain (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e97\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAgostara, 2023 \u003csup\u003e113\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour primary cardiac sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eheart (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e98\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eBornstein-Quevedo, 2023 \u003csup\u003e114\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMexico\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo STS, one IFS, 96 tumors NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCammareri, 2023 \u003csup\u003e115\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, NGS, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e330\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e31 adipocytic tumors, 45 fibroblastic and myofibroblastic tumors, 44 vascular tumors and malformations, 15 smooth muscle tumors, 16 skeletal muscle tumors, 36 MPNST, 23 undifferentiated small round cell sarcomas of bone and soft tissue, 12 mesenchymal tumors of the digestive system, 74 tumors of uncertain differentiation, 19 cutaneous soft tissue tumors, five thoracic SMARCA4-deficient undifferentiated tumors, seven chordomas, three biphenotypic sinonasal sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (3), \u003cem\u003eNTRK2\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e100\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChalla, 2023 \u003csup\u003e116\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne mesenchymal neoplasm\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eesophagus (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e101\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCorral S\u0026aacute;nchez, 2023 \u003csup\u003e117\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSpain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEight IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003etrunk (4), limbs (3), neck (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e102\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCreus-Bachiller, 2023 \u003csup\u003e118\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSpain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA sequencing, WGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThree MPNST, one \u003cem\u003eNTRK\u003c/em\u003e-associated SCS, one unclassifiable tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eback (3), limbs (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e103\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDufresne, 2023 \u003csup\u003e119\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ewhole-exome RNA-sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo LPFNT, one peripheral nerve sheath tumor, one cutaneous spindle cell mesenchymal tumor, three IMT, one GIST, two dedifferentiated liposarcomas, two UPS, one leiomyosarcoma, one intimal sarcoma, one high-grade uterine sarcoma, one neurofibromatosis type 1-associated MPNST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eBack (4), limbs (4), abdomen (2), pulmonary artery (1), mediastinal (1), spermatic cord (1), uterine (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (8), \u003cem\u003eNTRK3\u003c/em\u003e (8)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e104\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eFurtado, 2023 \u003csup\u003e120\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, FISH, WGS, WES, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ebuttock (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e105\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ePalmerini, 2023 \u003csup\u003e121\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne undifferentiated SCS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003efoot (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e106\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eYin, 2023 \u003csup\u003e122\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS, Sanger sequencing, PCR, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour LPFNT, eight MPNST-like, one myxofibrosarcoma-like.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eBack (1), abdominal wall (1), limb (6), buttock (2), small intestine (1), Rectum (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (12)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e107\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKobayashi, 2023 \u003csup\u003e123\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne \u003cem\u003eNTRK\u003c/em\u003e-rearranged spindle cell neoplasm, one sarcoma intermediate malignancy, three SFT, one dedifferentiated liposarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimb (4), buttock (1), perineal (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e108\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKojima, 2023 \u003csup\u003e124\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e203\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e38 mesenchymal tumors, 15 IMT, 20 UPS, 20 myxofibrosarcomas, 20 MPNST, 20 DFSP, 10 dedifferentiated liposarcomas, 10 SFT, 10 synovial sarcomas, 10 leiomyosarcomas, 10 \u003cem\u003eBCOR\u003c/em\u003e-associated sarcomas, 10 GIST, five spindle cell/sclerosing RMS, five atypical spindle cell lipomatous tumors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eHead \u0026amp; neck (6), limbs (19), Intradural (1), pelvic iliac bone (1), chest (3), breast (1), kidney (1), jejunum (1), retroperitoneum (3), NA (167)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (13), \u003cem\u003eNTRK2\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e109\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKrskov\u0026aacute;, 2023 \u003csup\u003e125\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCzech Republic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003ePCR, Genome-wide DNA methylation profiling\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS, one high-grade sarcoma, one pediatric sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e110\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKubota, 2023 \u003csup\u003e126\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne EwS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003emediastinum (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e111\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKummar, 2023 \u003csup\u003e127\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA \u0026amp; RNA based NGS, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne chondrosarcoma, one bone sarcoma NOS, four GIST, eight soft tissue tumors NOS, six MPNST, four SCS, three epithelioid spindle sarcomas, two IMT, two myopericytomas, two stromal tumors, one dedifferentiated liposarcoma, one fibrosarcoma, one synovial sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (19), \u003cem\u003eNTRK2\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e112\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eLin, 2023 \u003csup\u003e128\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA-based NGS, gene fusion panel analysis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne malignant SFT\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003egluteal area (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK2\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e113\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eRomanko, 2023 \u003csup\u003e129\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e50/30-end unbalanced expression test, variant-specific PCR, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e226\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e44 IMT, one CMN, 56 sarcoma NOS, 18 EwS, 19 leiomyosarcomas, 14 liposarcomas, one spindle cell RMS, eight chondroblastic osteosarcomas, two clear cell sarcomas, 11 MPNST, seven alveolar RMS, three IFS, seven RMS NOS, three fibrosarcomas, five osteosarcomas, eight synovial sarcomas, five endometrial stromal sarcomas, three UPS, four embryonal RMS, two myxofibrosarcomas, one Ewing-like sarcoma, one SCS, two DFSP, one angiosarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e114\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSahni, 2023 \u003csup\u003e130\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBangladesh, India\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne IFS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eleg (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e115\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSuurmeijer, 2023 \u003csup\u003e131\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNetherlands, USA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, targeted RNA sequencing, Pan-TRK IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne MPNST-like, one adult fibrosarcoma-like, one MPNST, one IFS-like tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ehead \u0026amp; neck (1), tibia (1), pelvis (1), chest wall (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e116\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eXu, 2023 \u003csup\u003e132\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFISH, targeted RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eFour IFS, two lipofibromatosis-like neural tumor, three MPNST-like, two adult-type fibrosarcoma-like, one IMT-like, one myxoma-like tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ehead \u0026amp; neck region (13)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (4), \u003cem\u003eNTRK3\u003c/em\u003e (5)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e117\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eXu, 2023 \u003csup\u003e133\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eDNA sequencing, RNA sequencing, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e571\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e49 fibrosarcoma, six IFS, one RMS, two STS, four SCS, one prostatic stromal tumor, two mucinous liposarcomas, one leiomyosarcoma, 505 NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ethigh, lung, mediastinal lymph nodes, double lung metastasis, retroperitoneal area, and abdomen (numbers NA)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (8), \u003cem\u003eNTRK3\u003c/em\u003e (9)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e118\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eDong, 2023 \u003csup\u003e134\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA \u0026amp; DNA-based NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e99\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e119\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMoura, 2023 \u003csup\u003e135\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, RNA sequencing, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e351\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTwo COL1A1-PDGFB rearranged sarcoma, 50 adenosarcomas, 122 low-grade endometrial stromal sarcomas, four low-grade endometrial stromal sarcomas with high-grade transformation, 46 high-grade endometrial stromal sarcomas, 13 uterine smooth muscle tumors of uncertain malignant potential, 19 leiomyosarcomas, 73 undifferentiated uterine sarcomas, four IMT, two SFT, one embryonal RMS, one hybrid peripheral nerve sheath tumor, one low-grade fibromyxoid sarcoma, one fibroblastic/myofibroblastic tumor of uncertain malignant potential, 12 \u003cem\u003eNTRK\u003c/em\u003e-rearranged sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eUterine corpus (324), cervix (9), vulva (2), metastasis (16)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (8), \u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e120\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHasegawa, 2024 \u003csup\u003e136\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eGermany\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRT-PCR, NGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e82\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eTen leiomyosarcomas, six myxofibrosarcomas, six myxoid liposarcomas, five pleomorphic leiomyosarcomas, four high-grade myxofibrosarcomas, four MPNST, four alveolar soft part sarcomas, four high-grade sarcoma NOS, three dedifferentiated liposarcomas, three osteosarcomas, three DFSP, three synovial sarcomas, three UPS, two extraskeletal osteosarcomas, two epithelioid hemangioendotheliomas, two epithelioid sarcomas, one low-grade myxofibrosarcoma, one well-differentiated liposarcoma, one periosteal osteosarcoma, one myxoid sarcoma, one high-grade myxoid sarcoma, one low-grade myxoid sarcoma, one IMT, one EwS, one RMS, one angiosarcoma, one extraskeletal myxoid chondrosarcoma, one chondrosarcoma, one intimal sarcoma, one malignant triton tumor, one superficial CD34-positive fibroblastic tumor, one high-grade SCS, one small-round cell sarcoma NOS, one low-grade sarcoma NOS.\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e121\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHernandez, 2024 \u003csup\u003e137\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSpain\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, IHC\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e36\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e28 gynecological sarcomas, six GIST, one IFS, one MPNST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e122\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eKlub\u0026iacute;čkov\u0026aacute;, 2024 \u003csup\u003e138\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eCzech Republic\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eRNA \u0026amp; DNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEleven IFS, five pattern SPH, two LPFNT, one MPNST, one myopericytoma-like tumor, one LPFNT/SPH, one epithelioid/rhabdoid tumor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (6), retroperitoneum (3), uterus (1), cervix (1), face (3), Hip (1), duodenum (1), scalp (1), coccygeal region (1), 2nuchal region (1), orbit (1), back (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (5), \u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e123\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eOrbach, 2024 \u003csup\u003e139\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFrance\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, FISH, RT-PCR\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e93\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003elimbs (57), non-parameningeal head \u0026amp; neck (10), thoracic (9), abdomen/pelvis (8), orbit (4), kidney (3), paraspinal (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e124\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eSzalai, 2024 \u003csup\u003e140\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eHungary\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne SCS of uterine cervix\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecervix (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e125\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNakada, 2024 \u003csup\u003e141\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1387\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e357 leiomyosarcomas, 178 dedifferentiated liposarcomas, 82 UPS, 770 NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e126\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eHuang, 2024 \u003csup\u003e142\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e127\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eVince, 2024 \u003csup\u003e143\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBrazil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEight IFS, one MPNST, one low-grade STS, one mesenchymal SCS/MPNST\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003evarious\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (7), \u003cem\u003eNTRK3\u003c/em\u003e (4)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e128\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eZhang, 2024 \u003csup\u003e144\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eFinland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003epan-TRK IHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e381\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne fibrosarcoma, one EwS, 379 tumors NA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1), \u003cem\u003eNTRK2\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e129\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eCao, 2024 \u003csup\u003e145\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, FISH, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne spindle cell neoplasm\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003epelvis (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e130\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003ede Castro, 2024 \u003csup\u003e146\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eBrazil\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, RNA-sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne uterine sarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterus (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e131\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGao, 2024 \u003csup\u003e147\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eChina\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEight spindle cell neoplasms\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ecolon (3), small intestine (2), rectum (2), stomach (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (7), \u003cem\u003eNTRK2 (1)\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e132\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eGrant, 2024 \u003csup\u003e148\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUK\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eThree uterine sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003euterus (3)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2), \u003cem\u003eNTRK3\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e133\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNakata, 2024 \u003csup\u003e149\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eJapan\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e2077\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne angiomatoid fibrous histiocytoma, 106 angiosarcomas, 187 dedifferentiated liposarcomas, 30 well-differentiated liposarcomas, 24 EwS, 166 GIST, 81 NOS sarcoma, 1482 unclassified sarcomas\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (12), \u003cem\u003eNTRK3\u003c/em\u003e (7)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e134\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eChen, 2024 \u003csup\u003e150\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eSwitzerland\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, NGS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne STS\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003ethigh (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (1)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e135\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eWillis, 2024 \u003csup\u003e151\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eUSA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eNGS, RT-PCR, FISH\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eOne liposarcoma, one MPNST, one IFS, one Mullerian adenosarcoma, one uterine leiomyosarcoma\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e136\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMotta, 2024 \u003csup\u003e152\u003c/sup\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eItaly\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eIHC, RNA sequencing\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c5\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eEight IFS-like mesenchymal tumors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u003cem\u003eNTRK1\u003c/em\u003e (2)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"1\" nameend=\"c9\" namest=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003eComprehensive genomic profiling (CGP); Congenital Fibrosarcoma (CFS); Congenital Mesoblastic Nephroma (CMN), Dermatofibrosarcoma Protuberans (DFSP); Ewing sarcoma (EWS), Fibrosarcoma (FS); Fluorescence in-situ hybridization (FISH); Gastrointestinal Stromal Tumors (GIST); Infantile Fibrosarcoma (IFS); Inflammatory myofibroblastic Tumor (IMT); Lipofibromatosis-like Neural Tumor (LPFNT), Memorial Sloan Kettering - Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT); Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type 1 (NF1); Not Mentioned (NM); Not Otherwise Specified (NOS); Number (No.); Polymerase Chain Reaction (PCR), Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR); Real-Time Polymerase Chain Reaction (RT-PCR); Real-Time Multiple Ligation-dependent Probe (RT-MLP); Rhabdomyosarcoma (RMS); Single-nucleotide polymorphism (SNP); Soft Tissue Sarcoma (STS); Solitary Fibrous Tumor (SFT); Spindle Cell Sarcoma (SCS); Stromal \u0026amp; Perivascular Hyalinization (SPH); Temporomandibular Joint (TMJ); Undifferentiated Polymorphic Sarcoma (UPS); Whole-Exome Sequencing (WES); Whole Genome Sequencing (WGS).\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003eTwenty-two studies \u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e,\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e,\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e,\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e,\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e,\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e,\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e,\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e,\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e,\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e,\u003cspan citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e,\u003cspan citationid=\"CR109\" class=\"CitationRef\"\u003e109\u003c/span\u003e,\u003cspan citationid=\"CR112\" class=\"CitationRef\"\u003e112\u003c/span\u003e,\u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e,\u003cspan citationid=\"CR140\" class=\"CitationRef\"\u003e140\u003c/span\u003e,\u003cspan citationid=\"CR145\" class=\"CitationRef\"\u003e145\u003c/span\u003e,\u003cspan citationid=\"CR147\" class=\"CitationRef\"\u003e147\u003c/span\u003e\u003c/sup\u003e reported only spindle cell sarcomas (n\u0026thinsp;=\u0026thinsp;72 patients), while 13 studies \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e,\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e\u003c/sup\u003e reported only congenital or infantile fibrosarcomas (n\u0026thinsp;=\u0026thinsp;23 patients), and three studies \u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e\u003c/sup\u003e focused on patients with GIST (n\u0026thinsp;=\u0026thinsp;197 patients). Further details on studies reporting specific sarcomas are described in Supplementary Table\u0026nbsp;1.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eTumor location\u003c/h2\u003e \u003cp\u003eRegarding tumor location, 39 out of 136 papers did not specify tumor location. A total of 1,019 sarcomas were gynecologic tumors located in the uterus, cervix, or vagina, 262 tumors were in the limbs, and 80 tumors were within the head and neck region. Other anatomic locations of sarcomas are described in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. Supplementary Table\u0026nbsp;2 summarizes the number of studies and patients for each sarcoma location.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eMutation detection methods\u003c/h2\u003e \u003cp\u003eTwo studies \u003csup\u003e\u003cspan citationid=\"CR96\" class=\"CitationRef\"\u003e96\u003c/span\u003e,\u003cspan citationid=\"CR105\" class=\"CitationRef\"\u003e105\u003c/span\u003e\u003c/sup\u003e, with a total sample size of 251 patients, did not mention the method used to detect \u003cem\u003eNTRK1-3\u003c/em\u003e alterations. Thirty-eight studies \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e,\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e,\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e,\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e,\u003cspan citationid=\"CR62\" class=\"CitationRef\"\u003e62\u003c/span\u003e,\u003cspan citationid=\"CR65\" class=\"CitationRef\"\u003e65\u003c/span\u003e,\u003cspan citationid=\"CR66\" class=\"CitationRef\"\u003e66\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR77\" class=\"CitationRef\"\u003e77\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e,\u003cspan citationid=\"CR81\" class=\"CitationRef\"\u003e81\u003c/span\u003e,\u003cspan citationid=\"CR83\" class=\"CitationRef\"\u003e83\u003c/span\u003e,\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e,\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR89\" class=\"CitationRef\"\u003e89\u003c/span\u003e,\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e,\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e,\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e,\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e,\u003cspan citationid=\"CR113\" class=\"CitationRef\"\u003e113\u003c/span\u003e,\u003cspan citationid=\"CR116\" class=\"CitationRef\"\u003e116\u003c/span\u003e,\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e,\u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e,\u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e,\u003cspan citationid=\"CR123\" class=\"CitationRef\"\u003e123\u003c/span\u003e,\u003cspan citationid=\"CR126\" class=\"CitationRef\"\u003e126\u003c/span\u003e,\u003cspan citationid=\"CR128\" class=\"CitationRef\"\u003e128\u003c/span\u003e,\u003cspan citationid=\"CR134\" class=\"CitationRef\"\u003e134\u003c/span\u003e,\u003cspan citationid=\"CR138\" class=\"CitationRef\"\u003e138\u003c/span\u003e,\u003cspan additionalcitationids=\"CR141 CR142\" citationid=\"CR140\" class=\"CitationRef\"\u003e140\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR143\" class=\"CitationRef\"\u003e143\u003c/span\u003e,\u003cspan citationid=\"CR149\" class=\"CitationRef\"\u003e149\u003c/span\u003e\u003c/sup\u003e, encompassing a total of 12,404 patients out of 18,077 (68.62%), used only genomic sequencing techniques for \u003cem\u003eNTRK1-3\u003c/em\u003e fusion detection. These methods included RNA-based sequencing, DNA-based sequencing, whole-genome sequencing (WGS), whole-exome sequencing (WES), Sanger sequencing, comprehensive genomic profiling (CGP), NGS, or combinations of these approaches. FISH alone was used only in two studies \u003csup\u003e\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e, adding up to 11 patients (0.06%), and IHC alone was also used in two studies \u003csup\u003e\u003cspan citationid=\"CR54\" class=\"CitationRef\"\u003e54\u003c/span\u003e,\u003cspan citationid=\"CR85\" class=\"CitationRef\"\u003e85\u003c/span\u003e\u003c/sup\u003e, involving a total of 400 patients (2.21%). Seven studies \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e,\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e,\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e,\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e\u003c/sup\u003e, with 73 patients (0.40%), used RT-PCR alone.\u003c/p\u003e \u003cp\u003eCombined diagnostic methods were also commonly used; for instance, genomic sequencing with IHC was used in 18 studies \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e,\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e,\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e,\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e,\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e,\u003cspan citationid=\"CR93\" class=\"CitationRef\"\u003e93\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR98\" class=\"CitationRef\"\u003e98\u003c/span\u003e,\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e,\u003cspan citationid=\"CR114\" class=\"CitationRef\"\u003e114\u003c/span\u003e,\u003cspan citationid=\"CR133\" class=\"CitationRef\"\u003e133\u003c/span\u003e,\u003cspan citationid=\"CR137\" class=\"CitationRef\"\u003e137\u003c/span\u003e,\u003cspan citationid=\"CR144\" class=\"CitationRef\"\u003e144\u003c/span\u003e,\u003cspan citationid=\"CR146\" class=\"CitationRef\"\u003e146\u003c/span\u003e,\u003cspan citationid=\"CR148\" class=\"CitationRef\"\u003e148\u003c/span\u003e,\u003cspan citationid=\"CR150\" class=\"CitationRef\"\u003e150\u003c/span\u003e,\u003cspan citationid=\"CR152\" class=\"CitationRef\"\u003e152\u003c/span\u003e\u003c/sup\u003e with a total of 2,263 patients (12.52%). Genomic sequencing with RT-PCR was used in eight studies \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e,\u003cspan citationid=\"CR64\" class=\"CitationRef\"\u003e64\u003c/span\u003e,\u003cspan citationid=\"CR87\" class=\"CitationRef\"\u003e87\u003c/span\u003e,\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e,\u003cspan citationid=\"CR125\" class=\"CitationRef\"\u003e125\u003c/span\u003e,\u003cspan citationid=\"CR129\" class=\"CitationRef\"\u003e129\u003c/span\u003e\u003c/sup\u003e (401 patients, 2.22%); genomic sequencing with FISH in 11 studies \u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e,\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e,\u003cspan citationid=\"CR63\" class=\"CitationRef\"\u003e63\u003c/span\u003e,\u003cspan citationid=\"CR69\" class=\"CitationRef\"\u003e69\u003c/span\u003e,\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e,\u003cspan citationid=\"CR76\" class=\"CitationRef\"\u003e76\u003c/span\u003e,\u003cspan citationid=\"CR109\" class=\"CitationRef\"\u003e109\u003c/span\u003e,\u003cspan citationid=\"CR115\" class=\"CitationRef\"\u003e115\u003c/span\u003e,\u003cspan citationid=\"CR127\" class=\"CitationRef\"\u003e127\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e,\u003cspan citationid=\"CR132\" class=\"CitationRef\"\u003e132\u003c/span\u003e\u003c/sup\u003e (431 patients, 2.38%), FISH and IHC in four studies \u003csup\u003e\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e,\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e,\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR110\" class=\"CitationRef\"\u003e110\u003c/span\u003e\u003c/sup\u003e (18 patients, 0.10%), and FISH with RT-PCR in two studies \u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e\u003c/sup\u003e (13 patients, 0.07%).\u003c/p\u003e \u003cp\u003eSome studies used multi-modal diagnostic tests; for example, genomic sequencing combined with FISH and IHC was utilized in 17 studies \u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR56\" class=\"CitationRef\"\u003e56\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e,\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e,\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e,\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e,\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e,\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e,\u003cspan citationid=\"CR91\" class=\"CitationRef\"\u003e91\u003c/span\u003e,\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e,\u003cspan citationid=\"CR108\" class=\"CitationRef\"\u003e108\u003c/span\u003e,\u003cspan citationid=\"CR112\" class=\"CitationRef\"\u003e112\u003c/span\u003e,\u003cspan citationid=\"CR124\" class=\"CitationRef\"\u003e124\u003c/span\u003e,\u003cspan citationid=\"CR131\" class=\"CitationRef\"\u003e131\u003c/span\u003e,\u003cspan citationid=\"CR135\" class=\"CitationRef\"\u003e135\u003c/span\u003e,\u003cspan citationid=\"CR145\" class=\"CitationRef\"\u003e145\u003c/span\u003e,\u003cspan citationid=\"CR147\" class=\"CitationRef\"\u003e147\u003c/span\u003e\u003c/sup\u003e (1,329 patients, 7.35%); genomic sequencing combined with FISH and RT-PCR in seven studies \u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e,\u003cspan citationid=\"CR61\" class=\"CitationRef\"\u003e61\u003c/span\u003e,\u003cspan citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e,\u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR151\" class=\"CitationRef\"\u003e151\u003c/span\u003e\u003c/sup\u003e (113 patients, 0.63%); genomic sequencing combined with IHC and RT-PCR in four studies \u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR84\" class=\"CitationRef\"\u003e84\u003c/span\u003e,\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e,\u003cspan citationid=\"CR136\" class=\"CitationRef\"\u003e136\u003c/span\u003e\u003c/sup\u003e (189 patients, 1.05%). Moreover, five studies \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR57\" class=\"CitationRef\"\u003e57\u003c/span\u003e,\u003cspan citationid=\"CR107\" class=\"CitationRef\"\u003e107\u003c/span\u003e,\u003cspan citationid=\"CR122\" class=\"CitationRef\"\u003e122\u003c/span\u003e\u003c/sup\u003e utilized all four detection methods, genomic sequencing, IHC, RT-PCR, and FISH; giving a total of 124 patients (0.69%). \"Other methods,\" including varied diagnostic techniques such as cytogenetic analysis, karyotyping, Northern blotting, Western blotting, and Southern blotting, were employed in nine studies \u003csup\u003e\u003cspan additionalcitationids=\"CR21\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e,\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e,\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e,\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e,\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e involving 57 patients (0.32%). These methods illustrate the diverse diagnostic approaches used across studies, with genomic sequencing as an essential tool for detecting \u003cem\u003eNTRK1-3\u003c/em\u003e genomic alterations, utilized in 110 out of 136 studies with 17,269 patients, either alone or in combination with other techniques (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003cb\u003ePrevalence of\u003c/b\u003e \u003cb\u003eNTRK\u003c/b\u003e \u003cb\u003emutations in sarcoma\u003c/b\u003e\u003c/p\u003e \u003cp\u003eOut of 18,077 patients with sarcoma, 821 patients had a genomic alteration in one of the \u003cem\u003eNTRK1-3\u003c/em\u003e genes (4.54%). \u003cem\u003eNTRK1-3\u003c/em\u003e fusions were the most common (551/821 patients; 67.11%), followed by a positive TRK protein on IHC staining (57/821 patients; 6.94%), \u003cem\u003eNTRK\u003c/em\u003e gene rearrangement (10/821 patients; 1.22%), \u003cem\u003eNTRK\u003c/em\u003e gene amplification (6/821 patients; 0.73%), or \u003cem\u003eNTRK\u003c/em\u003e gene mutation (5/821 patients; 0.61%). Moreover, seven studies \u003csup\u003e\u003cspan citationid=\"CR90\" class=\"CitationRef\"\u003e90\u003c/span\u003e,\u003cspan citationid=\"CR94\" class=\"CitationRef\"\u003e94\u003c/span\u003e,\u003cspan citationid=\"CR111\" class=\"CitationRef\"\u003e111\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR141\" class=\"CitationRef\"\u003e141\u003c/span\u003e,\u003cspan citationid=\"CR142\" class=\"CitationRef\"\u003e142\u003c/span\u003e,\u003cspan citationid=\"CR151\" class=\"CitationRef\"\u003e151\u003c/span\u003e\u003c/sup\u003e with 165/821 patients (20.10%) did not specify the \u003cem\u003eNTRK1-3\u003c/em\u003e genomic alterations. Further details on \u003cem\u003eNTRK1-3\u003c/em\u003e alterations can be found in Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eNTRK fusion partners\u003c/h2\u003e \u003cp\u003eOverall, the \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions mainly were either in the \u003cem\u003eNTRK1\u003c/em\u003e gene (251/551 patients; 45.56%) or the \u003cem\u003eNTRK3\u003c/em\u003e gene (259/551 patients; 47.01%), with only 15 out of 551 fusions affecting the \u003cem\u003eNTRK2\u003c/em\u003e gene (2.72%). The \u003cem\u003eNTRK1\u003c/em\u003e gene was mostly found to be fused with either the \u003cem\u003eTPM3\u003c/em\u003e (91/251 \u003cem\u003eNTRK1\u003c/em\u003e gene fusions; 36.25%) or the \u003cem\u003eLMNA\u003c/em\u003e genes (89/251 \u003cem\u003eNTRK1\u003c/em\u003e gene fusions; 35.46%). The \u003cem\u003eNTRK3\u003c/em\u003e gene, on the other hand, was mostly found to be fused with the \u003cem\u003eETV6\u003c/em\u003e gene (174/259 \u003cem\u003eNTRK3\u003c/em\u003e gene fusions; 67.18%). Further details on \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusion partners can be found in Supplementary File S3.\u003c/p\u003e \u003cp\u003eTwenty-nine studies \u003csup\u003e\u003cspan additionalcitationids=\"CR21 CR22 CR23 CR24 CR25\" citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e,\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e,\u003cspan additionalcitationids=\"CR32 CR33 CR34\" citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e,\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e,\u003cspan citationid=\"CR95\" class=\"CitationRef\"\u003e95\u003c/span\u003e,\u003cspan citationid=\"CR100\" class=\"CitationRef\"\u003e100\u003c/span\u003e,\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e,\u003cspan citationid=\"CR116\" class=\"CitationRef\"\u003e116\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e,\u003cspan citationid=\"CR134\" class=\"CitationRef\"\u003e134\u003c/span\u003e,\u003cspan citationid=\"CR137\" class=\"CitationRef\"\u003e137\u003c/span\u003e\u003c/sup\u003e, involving 83 patients (0.46% of patients with sarcoma), reported \u003cem\u003eETV6-NTRK3\u003c/em\u003e gene fusion only. Twelve studies \u003csup\u003e\u003cspan citationid=\"CR39\" class=\"CitationRef\"\u003e39\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e,\u003cspan citationid=\"CR53\" class=\"CitationRef\"\u003e53\u003c/span\u003e,\u003cspan citationid=\"CR55\" class=\"CitationRef\"\u003e55\u003c/span\u003e,\u003cspan citationid=\"CR58\" class=\"CitationRef\"\u003e58\u003c/span\u003e,\u003cspan citationid=\"CR60\" class=\"CitationRef\"\u003e60\u003c/span\u003e,\u003cspan citationid=\"CR71\" class=\"CitationRef\"\u003e71\u003c/span\u003e,\u003cspan citationid=\"CR73\" class=\"CitationRef\"\u003e73\u003c/span\u003e,\u003cspan citationid=\"CR92\" class=\"CitationRef\"\u003e92\u003c/span\u003e,\u003cspan citationid=\"CR103\" class=\"CitationRef\"\u003e103\u003c/span\u003e,\u003cspan citationid=\"CR118\" class=\"CitationRef\"\u003e118\u003c/span\u003e,\u003cspan citationid=\"CR150\" class=\"CitationRef\"\u003e150\u003c/span\u003e\u003c/sup\u003e, with 12 patients, reported \u003cem\u003eLMNA-NTRK1\u003c/em\u003e gene fusion only (0.07% of patients with sarcoma). Moreover, two studies \u003csup\u003e\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e\u003c/sup\u003e, with 51 patients, reported \u003cem\u003eTPM3-NTRK1, LMNA-NTRK1, MIR548F1-NTRK1, SQSTM1-NTRK1, TPR-NTRK1, STRN-NTRK2, ETV6-NTRK3\u003c/em\u003e, and \u003cem\u003eEML4-NTRK3\u003c/em\u003e gene fusions (0.28% of patients with sarcoma). Further details are shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003e\u003cem\u003eNTRK1-3\u003c/em\u003e fusions with the number of studies and patients.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"3\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eNTRK\u003c/em\u003e fusions*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eNumber of studies*\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eNumber of patients*\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e29\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e83\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, LMNA-NTRK1, MIR548F1-NTRK1, SQSTM1-NTRK1, TPR-NTRK1, STRN-NTRK2, ETV6-NTRK3, EML4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e51\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e20\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3- NTRK1, KIRREL1- NTRK1, MEF2D-NTRK1, PEAB1- NTRK1, PHF20-NTRK1, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e19\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, LMNA-NTRK1, IRF2BP2-NTRK1, ETV6-NTRK3, RBPMS-NTRK3, MORF4L1-NTRK3, PPFIA2-NTRK3, MEF2A-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, TPR-NTRK1, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e17\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, TPR-NTRK1, TSNAX-NTRK1, LMNA-NTRK1, CCDC171-NTRK1, VAMP4-NTRK1, GON4L-NTRK1, RAB14-NTRK3, FANCI-NTRK3, MCTP2-NTRK3, RBPMS-NTRK3, ETV6-NTRK3, TFG-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, KANK1-NTRK2, ETV6-NTRK3, EIF2S2-NTRK3, STRN3-NTRK3, STRN-NTRK3, RPS17-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e15\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, PEAR-NTRK1, ETV6-NTRK3, TPM4-NTRK3, EEF1A1-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, TPR\u0026ndash;NTRK1, SPECC1L\u0026ndash;NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e13\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, CPSF6-NTRK1, TPM3-NTRK1, GAS2L1-NTRK1, IGR-NTRK1, SQSTM1-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3- NTRK1, SPECCL1-NTRK3, EML4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, EML4-NTRK3, ETV6-NTRK3, STRN-NTRK3, RBPMS-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e12\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e11\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPR-NTRK1, LMNA-NTRK1, ETV6\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPR-NTRK1, TPM3-NTRK1, MEF2D-NTRK1, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, EML4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e9\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSQSTM1-NTRK1, LMNA-NTRK1, TPR-NTRK1, TFG-NTRK3, ETV6\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e7\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPR-NTRK1, TPM3-NTRK1, SPECC1L\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3\u0026ndash;NTRK1, LMNA\u0026ndash;NTRK1, TPR\u0026ndash;NTRK1, ETV6\u0026ndash;NTRK3, SPECC1L\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, TRN-NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, IRF2BP2-NTRK1, MEF2A-NTRK3, ITFG1-NTRK3, ETV6-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, LMNA-NTRK1, SQSTM1-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, YWHAE‑NTRK3, PPFIBP‑NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPR-NTRK1, TPM3-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, ETV6-NTRK3, TFG-NTRK3, SPECC1L-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, ETV6-NTRK3, RBPMS - NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, MTMR2\u0026ndash;NTRK2, ETV6\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1, TPR-NTRK1, RBPMS-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM4-NTRK3, ETV6-NTRK3, TFG-NTRK3, EML4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, SPECC1L\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eEML4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTMP3-NTRK1, STRN3-NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM3-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSPECC1L\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, SQSTM1-NTRK3, SPECC1L\u0026ndash;NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eUFD1-NTRK2, VPS18-NTRK3, RALGPS2-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, STRN3-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eLMNA-NTRK1, TPM4-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, UPF2-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPR-NTRK1, KANK1-NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eETV6-NTRK3, TFG-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSQSTM1-NTRK1, TFG-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSTRN-NTRK3, STRN3-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM3-NTRK1, LPPR1-NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e2\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eKHDRBS1-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003ePHF20-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eDCTN1\u0026ndash;NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTPM4-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSNRNP70-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eFN1-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSPECC1L-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eNUMA1-NTRK1\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eHMBOX1-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eTMTC2-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSTRN-NTRK2\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003e\u003cem\u003eSQSTM1-NTRK3\u003c/em\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"3\"\u003e* NTRK fusions, number of studies, and number of patients are mutually exclusive, they are not repeated twice.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eTreatment outcomes with TRK inhibitors\u003c/h2\u003e \u003cp\u003eMost studies investigated the efficacy and safety of larotrectinib alone; 24 studies explored larotrectinib monotherapy with a cumulative follow-up of 622 months \u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e,\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e,\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e,\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e,\u003cspan citationid=\"CR127\" class=\"CitationRef\"\u003e127\u003c/span\u003e,\u003cspan citationid=\"CR128\" class=\"CitationRef\"\u003e128\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e,\u003cspan citationid=\"CR133\" class=\"CitationRef\"\u003e133\u003c/span\u003e,\u003cspan citationid=\"CR136\" class=\"CitationRef\"\u003e136\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR142\" class=\"CitationRef\"\u003e142\u003c/span\u003e,\u003cspan citationid=\"CR143\" class=\"CitationRef\"\u003e143\u003c/span\u003e,\u003cspan citationid=\"CR147\" class=\"CitationRef\"\u003e147\u003c/span\u003e,\u003cspan citationid=\"CR151\" class=\"CitationRef\"\u003e151\u003c/span\u003e\u003c/sup\u003e. A total of 1,106 patients with sarcoma were included in those studies, of which 142 had NTRK1-3 gene fusions and received larotrectinib therapy. In patients treated with larotrectinib, the response rate to therapy was 83.80% (119/142), with 2.82% (4/142) deaths, 8.45% (12/142) metastases, and 2.11% (3/142) recurrences. Entrectinib was explored in six studies \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e,\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e,\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e,\u003cspan citationid=\"CR140\" class=\"CitationRef\"\u003e140\u003c/span\u003e,\u003cspan citationid=\"CR150\" class=\"CitationRef\"\u003e150\u003c/span\u003e\u003c/sup\u003e where 33 patients were treated with a total follow-up period of 114 months. Entrectinib showed a response rate of 63.64% (21/33). Moreover, five studies \u003csup\u003e\u003cspan citationid=\"CR74\" class=\"CitationRef\"\u003e74\u003c/span\u003e,\u003cspan citationid=\"CR86\" class=\"CitationRef\"\u003e86\u003c/span\u003e,\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e,\u003cspan citationid=\"CR119\" class=\"CitationRef\"\u003e119\u003c/span\u003e,\u003cspan citationid=\"CR126\" class=\"CitationRef\"\u003e126\u003c/span\u003e\u003c/sup\u003e explored the effects of combined larotrectinib and entrectinib therapies, reporting a response rate of 41.67% (10/24), metastasis rate of 41.67% (10/24), recurrence rate of 25% (6/24), and a death rate of 20.83% (5/24). One study \u003csup\u003e\u003cspan citationid=\"CR138\" class=\"CitationRef\"\u003e138\u003c/span\u003e\u003c/sup\u003e included 22 patients taking triple therapy of larotrectinib, entrectinib, and selitrectinib, which were followed up on for an average of 70 months. The response rate was 31.82% (7/22), with 9.09% recurrence (2/22) and a mere 4.55% (1/22) reported metastasis and death \u003csup\u003e\u003cspan citationid=\"CR138\" class=\"CitationRef\"\u003e138\u003c/span\u003e\u003c/sup\u003e. Limited data are available for combining larotrectinib with selitrectinib or repotrectinib, with three studies \u003csup\u003e\u003cspan citationid=\"CR68\" class=\"CitationRef\"\u003e68\u003c/span\u003e,\u003cspan citationid=\"CR106\" class=\"CitationRef\"\u003e106\u003c/span\u003e,\u003cspan citationid=\"CR148\" class=\"CitationRef\"\u003e148\u003c/span\u003e\u003c/sup\u003e and one study \u003csup\u003e\u003cspan citationid=\"CR120\" class=\"CitationRef\"\u003e120\u003c/span\u003e\u003c/sup\u003e on these combinations, respectively. In these smaller cohorts, outcomes suggest moderate responses with some recurrences and metastases. Further details are depicted in Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eThe therapeutic outcomes from studies investigating the efficacy of various TRK inhibitors, including larotrectinib, entrectinib, and combinations with other inhibitors, such as selitrectinib and repotrectinib, in the context of \u003cem\u003eNTRK\u003c/em\u003e-positive sarcomas.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eTRK inhibitor\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eNo. of studies\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"2\" nameend=\"c4\" namest=\"c3\"\u003e \u003cp\u003eNo. of patients\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eFollow-up (months)\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colspan=\"4\" nameend=\"c9\" namest=\"c6\"\u003e \u003cp\u003eOutcome\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c3\"\u003e \u003cp\u003eTotal\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003eOn TRK inhibitors\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003eResponse to therapy\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003eDeath\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003eMetastasis\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003eRecurrence\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eLarotrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1106\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e622\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e119/142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4/142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e12/142\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e3/142\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e83.80%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e2.82%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e8.45%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e2.11%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eEntrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e6\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e521\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e114\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e21/33\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0/7*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0/7*\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1/7*\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e63.64%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e0.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e14.29%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eLarotrectinib, Entrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e94\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e159\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e10/24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e5/24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e10/24\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e6/24\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e41.67%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e20.83%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e41.67%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e25.0%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eLarotrectinib, Entrectinib, Selitrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e70\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e7/22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1/22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1/22\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e2/22\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e31.82%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e4.55%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e4.55%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e9.09%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eLarotrectinib, Repotrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eNA\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e1/1\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e1/1\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e0.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e0.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e100.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e100.0%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e\u003cb\u003eLarotrectinib, Selitrectinib\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c2\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e3\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c3\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003e25\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e1/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e3/5\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c6\"\u003e \u003cp\u003e60.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c7\"\u003e \u003cp\u003e20.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e60.0%\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e60.0%\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003e* Although 33 patients received Entrectinib, detailed data on death, metastasis, and recurrence were available for only 7 patients in our review.\u003c/td\u003e\u003c/tr\u003e \u003ctr\u003e\u003ctd colspan=\"9\"\u003eNA: not available\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this systematic review, we synthesized and analyzed available evidence on \u003cem\u003eNTRK1-3\u003c/em\u003e fusions in soft tissue tumors/sarcomas. Our findings indicate that \u003cem\u003eNTRK1-3\u003c/em\u003e fusions are present in a small subset of sarcomas, with most fusions being \u003cem\u003eNTRK1\u003c/em\u003e or \u003cem\u003eNTRK3\u003c/em\u003e. Tumors harboring \u003cem\u003eNTRK1-3\u003c/em\u003e fusions often exhibit distinct clinical and pathological characteristics, such as younger age, and distinctive morphologic features, such as densely packed spindle cells and myxoid stroma \u003csup\u003e\u003cspan citationid=\"CR153\" class=\"CitationRef\"\u003e153\u003c/span\u003e\u003c/sup\u003e. These tumors commonly affect specific anatomical sites, like the extremities in infantile fibrosarcoma and the lungs or abdomen in inflammatory myofibroblastic tumors \u003csup\u003e\u003cspan citationid=\"CR153\" class=\"CitationRef\"\u003e153\u003c/span\u003e\u003c/sup\u003e. \u003cem\u003eNTRK1-3\u003c/em\u003e fusions involve gene rearrangements leading to constitutive activation of the TRK signaling pathway, promoting tumorigenesis \u003csup\u003e\u003cspan citationid=\"CR104\" class=\"CitationRef\"\u003e104\u003c/span\u003e,\u003cspan citationid=\"CR153\" class=\"CitationRef\"\u003e153\u003c/span\u003e\u003c/sup\u003e. The clinical behavior of these cancers may substantially vary, with some showing favorable responses to TRK inhibitors, highlighting the importance of routine comprehensive genomic testing for personalized treatment \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eOur systematic review provides an updated and comprehensive synthesis of the literature on \u003cem\u003eNTRK1-3\u003c/em\u003e fusions in sarcomas, addressing gaps left by previous reviews. It builds upon prior work by incorporating studies published in recent years, which reflect advancements in diagnostic techniques and the identification of additional \u003cem\u003eNTRK\u003c/em\u003e fusion-positive cases. Unlike the review by Assi et al. \u003csup\u003e\u003cspan citationid=\"CR154\" class=\"CitationRef\"\u003e154\u003c/span\u003e\u003c/sup\u003e that was current to 2020, our review includes studies up to mid-2024. Moreover, several prior reviews focused on specific sarcoma subtypes or did not cover the entire spectrum of sarcomas, thereby limiting the generalizability of their conclusions \u003csup\u003e\u003cspan citationid=\"CR155\" class=\"CitationRef\"\u003e155\u003c/span\u003e,\u003cspan citationid=\"CR156\" class=\"CitationRef\"\u003e156\u003c/span\u003e\u003c/sup\u003e. Other reviews focused on one population demographic, like reporting \u003cem\u003eNTRK1-3\u003c/em\u003e fusions in the pediatric population only \u003csup\u003e\u003cspan citationid=\"CR102\" class=\"CitationRef\"\u003e102\u003c/span\u003e\u003c/sup\u003e. Our systematic review attempted to cover the entire spectrum of soft tissue sarcomas and incorporate the newest publications, providing a more complete and contemporary understanding of the prevalence and clinical implications of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions.\u003c/p\u003e \u003cp\u003eThis systematic review confirms that the \u003cem\u003eNTRK1-3\u003c/em\u003e fusions are rare in soft tissue sarcomas. Our descriptive analysis shows that \u003cem\u003eETV6-NTRK3\u003c/em\u003e fusion is the most prevalent, with documentation in 174 patients. Following this, a cohort of \u003cem\u003eNTRK1\u003c/em\u003e-related fusions, such as \u003cem\u003eTMP3-NTRK1\u003c/em\u003e and \u003cem\u003eLMNA-NTRK1\u003c/em\u003e, indicates a notable presence in \u003cem\u003eNTRK\u003c/em\u003e-positive sarcomas. Our review identified 1,019 female patients with gynecological sarcomas. The molecular characterization study by Gatalica et al. supports these findings, highlighting \u003cem\u003eETV6-NTRK3\u003c/em\u003e and \u003cem\u003eTMP3-NTRK1\u003c/em\u003e as the most prevalent fusions \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Furthermore, a systematic review and meta-analysis by Forsythe et al. revealed the prevalence of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions to be 90.56% in 91 patients with infantile fibrosarcomas and 0.34% in 93 patients with uterine sarcomas \u003csup\u003e\u003cspan citationid=\"CR155\" class=\"CitationRef\"\u003e155\u003c/span\u003e\u003c/sup\u003e. However, due to the rarity of these tumors, no large studies have been able to rigorously explore or confirm the association between \u003cem\u003eNTRK1-3\u003c/em\u003e fusions and specific sarcoma subtypes beyond the few known rare entities.\u003c/p\u003e \u003cp\u003eVarious diagnostic techniques are employed to detect \u003cem\u003eNTRK1-3\u003c/em\u003e fusions, each with advantages and limitations. FISH and RT-PCR are traditional methods that have been widely used for their sensitivity and specificity \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. However, genomic sequencing (DNA or RNA-based) has emerged as the gold standard and is the most commonly used diagnostic modality, offering comprehensive genomic profiling and the ability to detect a wide range of genomic alterations, including novel and rare fusions \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e. Despite its higher cost and technical complexity, genomic sequencing is increasingly preferred in clinical settings due to its robust diagnostic capabilities and was recommended by the ESMO guideline for routine testing in patients with advanced cancers, including sarcomas \u003csup\u003e\u003cspan citationid=\"CR157\" class=\"CitationRef\"\u003e157\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThe identification and targeting of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions have several critical clinical implications. For oncologists, incorporating routine genetic testing for \u003cem\u003eNTRK1-3\u003c/em\u003e fusions into diagnostic workflows can significantly enhance the precision of treatment plans. Patients diagnosed with \u003cem\u003eNTRK1-3\u003c/em\u003e fusion-positive sarcomas can be directed toward TRK inhibitors, which offer a more effective and less toxic alternative compared to traditional chemotherapy as shown in clinical trials \u003csup\u003e\u003cspan citationid=\"CR158\" class=\"CitationRef\"\u003e158\u003c/span\u003e,\u003cspan citationid=\"CR159\" class=\"CitationRef\"\u003e159\u003c/span\u003e\u003c/sup\u003e. Second, it provides important prognostic information, as \u003cem\u003eNTRK\u003c/em\u003e fusion-positive sarcomas have distinct clinical behaviors and outcomes as previously mentioned. Lastly, the detection of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions can guide the development of personalized treatment plans, improving overall patient management and outcomes.\u003c/p\u003e \u003cp\u003eTRK inhibitors, such as larotrectinib and entrectinib, have revolutionized the treatment landscape for patients with \u003cem\u003eNTRK1-3\u003c/em\u003e fusion-positive tumors. Clinical trials have demonstrated significant responses, with high overall response rates and durable responses in many patients \u003csup\u003e\u003cspan citationid=\"CR160\" class=\"CitationRef\"\u003e160\u003c/span\u003e\u003c/sup\u003e. Although with limited evidence due to the infrequency of \u003cem\u003eNTRK\u003c/em\u003e gene fusion mutation and the new emergence of TRK inhibitor drugs, we observed that larotrectinib was the most utilized TRK inhibitor, employed as monotherapy in 24 studies \u003csup\u003e\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e,\u003cspan citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e,\u003cspan citationid=\"CR59\" class=\"CitationRef\"\u003e59\u003c/span\u003e,\u003cspan citationid=\"CR67\" class=\"CitationRef\"\u003e67\u003c/span\u003e,\u003cspan citationid=\"CR70\" class=\"CitationRef\"\u003e70\u003c/span\u003e,\u003cspan citationid=\"CR72\" class=\"CitationRef\"\u003e72\u003c/span\u003e,\u003cspan citationid=\"CR75\" class=\"CitationRef\"\u003e75\u003c/span\u003e,\u003cspan citationid=\"CR78\" class=\"CitationRef\"\u003e78\u003c/span\u003e,\u003cspan citationid=\"CR80\" class=\"CitationRef\"\u003e80\u003c/span\u003e,\u003cspan citationid=\"CR88\" class=\"CitationRef\"\u003e88\u003c/span\u003e,\u003cspan citationid=\"CR97\" class=\"CitationRef\"\u003e97\u003c/span\u003e,\u003cspan citationid=\"CR101\" class=\"CitationRef\"\u003e101\u003c/span\u003e,\u003cspan citationid=\"CR117\" class=\"CitationRef\"\u003e117\u003c/span\u003e,\u003cspan citationid=\"CR121\" class=\"CitationRef\"\u003e121\u003c/span\u003e,\u003cspan citationid=\"CR127\" class=\"CitationRef\"\u003e127\u003c/span\u003e,\u003cspan citationid=\"CR128\" class=\"CitationRef\"\u003e128\u003c/span\u003e,\u003cspan citationid=\"CR130\" class=\"CitationRef\"\u003e130\u003c/span\u003e,\u003cspan citationid=\"CR133\" class=\"CitationRef\"\u003e133\u003c/span\u003e,\u003cspan citationid=\"CR136\" class=\"CitationRef\"\u003e136\u003c/span\u003e,\u003cspan citationid=\"CR139\" class=\"CitationRef\"\u003e139\u003c/span\u003e,\u003cspan citationid=\"CR142\" class=\"CitationRef\"\u003e142\u003c/span\u003e,\u003cspan citationid=\"CR143\" class=\"CitationRef\"\u003e143\u003c/span\u003e,\u003cspan citationid=\"CR147\" class=\"CitationRef\"\u003e147\u003c/span\u003e,\u003cspan citationid=\"CR151\" class=\"CitationRef\"\u003e151\u003c/span\u003e\u003c/sup\u003e, and demonstrated a response rate of 83.80% (119/142 patients). This high response rate reinforces the clinical value of identifying \u003cem\u003eNTRK\u003c/em\u003e fusions and initiating targeted therapy. Among the 142 cases, only four (2.82%) patients died, 12 (8.45%) developed metastasis and three (2.11%) exhibited local recurrence. Similarly, entrectinib was also predominantly used as monotherapy in six studies \u003csup\u003e\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e,\u003cspan citationid=\"CR79\" class=\"CitationRef\"\u003e79\u003c/span\u003e,\u003cspan citationid=\"CR82\" class=\"CitationRef\"\u003e82\u003c/span\u003e,\u003cspan citationid=\"CR99\" class=\"CitationRef\"\u003e99\u003c/span\u003e,\u003cspan citationid=\"CR140\" class=\"CitationRef\"\u003e140\u003c/span\u003e,\u003cspan citationid=\"CR150\" class=\"CitationRef\"\u003e150\u003c/span\u003e\u003c/sup\u003e with 33 patients, yielding a response rate of 63.64%. While our findings suggest that larotrectinib may offer a marginal advantage over entrectinib, these results should be interpreted with caution given the differences in sample sizes between the two treatment groups. Nevertheless, the overall findings of our review are consistent with those reported by Suh et al. \u003csup\u003e\u003cspan citationid=\"CR161\" class=\"CitationRef\"\u003e161\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eThus, with the evidence presented here, we recommend screening for \u003cem\u003eNTRK1-3\u003c/em\u003e fusion genes in patients with soft tissue sarcomas unresponsive to common modalities of management, including surgery, chemotherapy, and radiotherapy \u003csup\u003e\u003cspan citationid=\"CR162\" class=\"CitationRef\"\u003e162\u003c/span\u003e\u003c/sup\u003e. Based on literature review, patients with a high suspicion of \u003cem\u003eNTRK1-3\u003c/em\u003e fusion, genomic DNA- or RNA-based sequencing is recommended. RNA-based genomic sequencing provides the highest sensitivity and specificity in detecting \u003cem\u003eNTRK1-3\u003c/em\u003e fusions, with specificity reaching up to 100% \u003csup\u003e163\u003c/sup\u003e. In cases with a lower suspicion of \u003cem\u003eNTRK1-3\u003c/em\u003e fusion, such as in sarcomas other than congenital fibrosarcoma, the initial step should be to perform pan-TRK IHC. If the IHC results are positive, then RNA-based NGS should be used to confirm the presence of an \u003cem\u003eNTRK\u003c/em\u003e fusion \u003csup\u003e\u003cspan citationid=\"CR164\" class=\"CitationRef\"\u003e164\u003c/span\u003e\u003c/sup\u003e. Moreover, TRK inhibitors are highly effective in treating soft tissue sarcomas in adult and pediatric populations, with low rates of non-adherence, severe adverse effects, and mortality.\u003c/p\u003e \u003cp\u003eThis systematic review provides evidence-based recommendations for using TRK inhibitors in clinical settings, aiding clinicians in decision-making and providing precision medicine options for refractory cases. Some limitations of our studies include the variations in study design, patient populations, detection methods, and reporting standards, making it difficult to combine and compare results and draw firm conclusions. Additionally, there is limited availability of data regarding specific types of sarcomas and the presence of various \u003cem\u003eNTRK1-3\u003c/em\u003e fusion partners and types for each sarcoma subtype, which can complicate the synthesis and interpretation of prevalence data and constrain the review's comprehensiveness.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eThis systematic review confirms the rarity of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions in soft tissue sarcomas. Given the notable clinical efficacy of TRK inhibitors in sarcomas, genomic testing remains essential in all sarcoma cases to identify these potentially targetable alterations and should be incorporated into diagnostic workflows in the era of precision oncology.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eThe authors have no conflicts of interest to declare.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCRediT Authors contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSH \u0026ndash; Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing, Funding acquisition, Supervision, Project administration\u003c/p\u003e\n\u003cp\u003eZAN\u0026ndash; Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing, Supervision, Project administration\u003c/p\u003e\n\u003cp\u003eAMH\u0026ndash; Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing\u003c/p\u003e\n\u003cp\u003eAAR\u0026ndash; Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing\u003c/p\u003e\n\u003cp\u003eHER\u0026ndash; Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing\u003c/p\u003e\n\u003cp\u003eMAA- Conceptualization, Investigation, Validation, Visualization, Data Curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing\u003c/p\u003e\n\u003cp\u003eGRB\u0026ndash; Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing, Funding acquisition, Supervision\u003c/p\u003e\n\u003cp\u003eZG- Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Review \u0026amp; Editing\u003c/p\u003e\n\u003cp\u003eSV\u0026ndash; Conceptualization, Investigation, Formal analysis, Validation, Visualization, Data curation, Resources, Software, Methodology, Writing - Original Draft, Writing - Review \u0026amp; Editing, Funding acquisition, Supervision, Project administration, Guarantor of Review\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData availability\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study is a systematic review of published studies, and the data used in this work are from the included studies. The availability of the underlying individual patient data is subject to the primary publications\u0026rsquo; journal policies.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eLange AM, Lo HW: Inhibiting TRK Proteins in Clinical Cancer Therapy. Cancers (Basel) 10, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNakagawara A: Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 169:107\u0026ndash;14, 2001\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmatu A, Sartore-Bianchi A, Siena S: NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 1:e000023, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGatalica Z, Xiu J, Swensen J, et al: Molecular characterization of cancers with NTRK gene fusions. Mod Pathol 32:147\u0026ndash;153, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarchetti A, Ferro B, Pasciuto MP, et al: NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies. Pathologica 114:199\u0026ndash;216, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZito Marino F, Pagliuca F, Ronchi A, et al: NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine. Int J Mol Sci 21, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSchwartzberg L, Kim ES, Liu D, et al: Precision Oncology: Who, How, What, When, and When Not? Am Soc Clin Oncol Educ Book 37:160\u0026ndash;169, 2017\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVranic S, Basu GD, Hall DW, et al: Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Med Acad 51:217\u0026ndash;231, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVranic S, Gatalica Z: Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy. Biomol Biomed 24:673\u0026ndash;675, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCocco E, Scaltriti M, Drilon A: NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 15:731\u0026ndash;747, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMarchi\u0026ograve; C, Scaltriti M, Ladanyi M, et al: ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol 30:1417\u0026ndash;1427, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdministration USFaD: FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAdministration USFaD: FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBridgewater J, Jiao X, Parimi M, et al: Prognosis and oncogenomic profiling of patients with tropomyosin receptor kinase fusion cancer in the 100,000 genomes project. Cancer Treat Res Commun 33:100623, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDemetri GD, De Braud F, Drilon A, et al: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res 28:1302\u0026ndash;1312, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrownstein JM, DeLaney TF: Malignant Soft-Tissue Sarcomas. Hematol Oncol Clin North Am 34:161\u0026ndash;175, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHechtman JF: NTRK insights: best practices for pathologists. Mod Pathol 35:298\u0026ndash;305, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNguyen MA, Colebatch AJ, Van Beek D, et al: NTRK fusions in solid tumours: what every pathologist needs to know. Pathology 55:596\u0026ndash;609, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAhmed AI, Kaleem MZ, Elshoeibi AM, et al: MASTER scale for methodological quality assessment: Reliability assessment and update.\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKnezevich SR, McFadden DE, Tao W, et al: A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18:184\u0026ndash;7, 1998\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRubin BP, Chen CJ, Morgan TW, et al: Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol 153:1451\u0026ndash;8, 1998\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKnezevich SR, Garnett MJ, Pysher TJ, et al: ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58:5046\u0026ndash;8, 1998\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eArgani P, Fritsch M, Kadkol SS, et al: Detection of the ETV6-NTRK3 chimeric RNA of infantile fibrosarcoma/cellular congenital mesoblastic nephroma in paraffin-embedded tissue: application to challenging pediatric renal stromal tumors. Mod Pathol 13:29\u0026ndash;36, 2000\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBourgeois JM, Knezevich SR, Mathers JA, et al: Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 24:937\u0026ndash;46, 2000\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePunnett HH, Tomczak EZ, Pawel BR, et al: ETV6-NTRK3 gene fusion in metastasizing congenital fibrosarcoma. Med Pediatr Oncol 35:137\u0026ndash;9, 2000\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSheng WQ, Hisaoka M, Okamoto S, et al: Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. Am J Clin Pathol 115:348\u0026ndash;55, 2001\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHisaoka M, Sheng WQ, Tanaka A, et al: Gene expression of TrkC (NTRK3) in human soft tissue tumours. J Pathol 197:661\u0026ndash;7, 2002\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHenno S, Loeuillet L, Henry C, et al: Cellular mesoblastic nephroma: morphologic, cytogenetic and molecular links with congenital fibrosarcoma. Pathology-Research and Practice 199:35\u0026ndash;40, 2003\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMcCahon E, Sorensen PH, Davis JH, et al: Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol 40:288\u0026ndash;92, 2003\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOotsuka S, Asami S, Sasaki T, et al: Analyses of novel prognostic factors in neuroblastoma patients. Biol Pharm Bull 30:2294\u0026ndash;9, 2007\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMari\u0026ntilde;o-Enr\u0026iacute;quez A, Li P, Samuelson J, et al: Congenital fibrosarcoma with a novel complex 3-way translocation t(12;15;19) and unusual histologic features. Hum Pathol 39:1844\u0026ndash;8, 2008\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHimori K, Hatori M, Watanabe M, et al: Infantile fibrosarcoma of thigh\u0026ndash;a case report. Ups J Med Sci 110:85\u0026ndash;93, 2005\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGadd S, Beezhold P, Jennings L, et al: Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J Pathol 228:119\u0026ndash;30, 2012\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWalther C, Nilsson J, von Steyern FV, et al: Cytogenetic and single nucleotide polymorphism array findings in soft tissue tumors in infants. Cancer Genet 206:299\u0026ndash;303, 2013\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrenca M, Rossi S, Polano M, et al: Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST. J Pathol 238:543\u0026ndash;9, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaller F, Knopf J, Ackermann A, et al: Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. J Pathol 238:700\u0026ndash;10, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShi E, Chmielecki J, Tang CM, et al: FGFR1 and NTRK3 actionable alterations in \"Wild-Type\" gastrointestinal stromal tumors. J Transl Med 14:339, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNagasubramanian R, Wei J, Gordon P, et al: Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101. Pediatr Blood Cancer 63:1468\u0026ndash;70, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWong V, Pavlick D, Brennan T, et al: Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. J Natl Cancer Inst 108, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgaram NP, Zhang L, Sung YS, et al: Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors. Am J Surg Pathol 40:1407\u0026ndash;16, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHechtman JF, Benayed R, Hyman DM, et al: Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions. Am J Surg Pathol 41:1547\u0026ndash;1551, 2017\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eObayashi J, Koizumi H, Hoshikawa M, et al: A Case of Congenital Infantile Fibrosarcoma of the Bowel Presenting as a Neonatal Intussusception. Pathol Int 67:644\u0026ndash;648, 2017\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePavlick D, Schrock AB, Malicki D, et al: Identification of NTRK fusions in pediatric mesenchymal tumors. Pediatr Blood Cancer 64, 2017\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChmielecki J, Bailey M, He J, et al: Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. Cancer Res 77:509\u0026ndash;519, 2017\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHung YP, Fletcher CDM, Hornick JL: Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology 73:634\u0026ndash;644, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKao YC, Fletcher CDM, Alaggio R, et al: Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas: Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma. Am J Surg Pathol 42:28\u0026ndash;38, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlson N, Rouhi O, Zhang L, et al: A novel case of an aggressive superficial spindle cell sarcoma in an adult resembling fibrosarcomatous dermatofibrosarcoma protuberans and harboring an EML4-NTRK3 fusion. J Cutan Pathol 45:933\u0026ndash;939, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRudzinski ER, Lockwood CM, Stohr BA, et al: Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors. Am J Surg Pathol 42:927\u0026ndash;935, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKohsaka S, Saito T, Akaike K, et al: Pediatric soft tissue tumor of the upper arm with LMNA-NTRK1 fusion. Hum Pathol 72:167\u0026ndash;173, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTakahashi A, Kurosawa M, Uemura M, et al: Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report. J Int Med Res 46:3498\u0026ndash;3503, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuurmeijer AJH, Dickson BC, Swanson D, et al: A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosomes Cancer 57:611\u0026ndash;621, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLao IW, Sun M, Zhao M, et al: Lipofibromatosis-like neural tumour: a clinicopathological study of ten additional cases of an emerging novel entity. Pathology 50:519\u0026ndash;523, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou N, Sch\u0026auml;fer R, Li T, et al: A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report. BMC Cancer 18:842, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAntunes BP, Becker RG, Brunetto AT, et al: Expression of neurotrophins and their receptors in primary osteosarcoma. Rev Col Bras Cir 46:e2094, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBender J, Anderson B, Bloom DA, et al: Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib. Cold Spring Harb Mol Case Stud 5, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChiang S, Cotzia P, Hyman DM, et al: NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Am J Surg Pathol 42:791\u0026ndash;798, 2018\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCroce S, Hostein I, Longacre TA, et al: Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms. Modern Pathology 32:1008\u0026ndash;1022, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eD\u0026rsquo;Alpino Peixoto R, Medeiros BA, Cronemberger EH: Resected high-risk rectal GIST harboring NTRK1 fusion: a case report and review of the literature. Journal of Gastrointestinal Cancer 52:316\u0026ndash;319, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavis JL, Lockwood CM, Stohr B, et al: Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. The American journal of surgical pathology 43:435\u0026ndash;445, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWarren M, Anselmo D, Takeda M, et al: NTRK-rearranged mesenchymal tumour in a 3‐year‐old female: a diagnostic quandary. Histopathology 75, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYamazaki F, Nakatani F, Asano N, et al: Novel NTRK3 Fusions in Fibrosarcomas of Adults. Am J Surg Pathol 43:523\u0026ndash;530, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSolomon JP, Linkov I, Rosado A, et al: NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol 33:38\u0026ndash;46, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuurmeijer AJ, Dickson BC, Swanson D, et al: The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements. Genes, Chromosomes and Cancer 58:739\u0026ndash;746, 2019\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAmeline B, Saba KH, Kovac M, et al: NTRK fusions in osteosarcoma are rare and non-functional events. The Journal of Pathology: Clinical Research 6:107\u0026ndash;112, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBertolini R, Bode PK, Sawatzki M: Unusual colonic polyp in a young woman. Gastroenterology 160:e12-e13, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBoyle W, Williams A, Sundar S, et al: TMP3-NTRK1 rearranged uterine sarcoma: a case report. Case Reports in Women's Health 28:e00246, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCaldwell KJ, De La Cuesta E, Morin C, et al: A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib. Pediatric Blood \u0026amp; Cancer 67:e28330, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoh XN, Seng MS-F, Loh AHP, et al: Larotrectinib followed by selitrectinib in a novel DCTN1\u0026ndash;NTRK1 fusion undifferentiated pleomorphic sarcoma. Journal of Oncology Pharmacy Practice 27:485\u0026ndash;489, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKang J, Park JW, Won J-K, et al: Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Diagnostic pathology 15:1\u0026ndash;11, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOlsen MR, Denu RA, Lyon JB, et al: Undifferentiated and unresectable sarcoma with NTRK3-fusion in a pediatric patient treated with larotrectinib and proton beam radiotherapy. Journal of pediatric hematology/oncology 44:e770-e774, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePanse G, Reisenbichler E, Snuderl M, et al: LMNA-NTRK1 rearranged mesenchymal tumor (lipofibromatosis‐like neural tumor) mimicking pigmented dermatofibrosarcoma protuberans. Journal of cutaneous pathology 48:290\u0026ndash;294, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRabban JT, Devine WP, Sangoi AR, et al: NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology 77:100\u0026ndash;111, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSo YK, Chow C, To KF, et al: Myxoid spindle cell sarcoma with LMNA-NTRK fusion: expanding the morphologic spectrum of NTRK-rearranged tumors. International journal of surgical pathology 28:574\u0026ndash;578, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVargas AC, Ardakani NM, Wong DD, et al: Chromosomal imbalances detected in NTRK-rearranged sarcomas by the use of comparative genomic hybridisation. Histopathology 78:932\u0026ndash;942, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKhuong-Quang D-A, Brown LM, Wong M, et al: Recurrent SPECC1L\u0026ndash;NTRK fusions in pediatric sarcoma and brain tumors. Molecular Case Studies 6:a005710, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRekhi B, Shetty O, Bapat P, et al: A Case of Inv (1)(q23q31) TPR-NTRK1 Fusion-Positive Spindle Cell Neoplasm in an Infant\u0026mdash;Uncovered by Next-Generation Sequencing: Diagnostic Challenge, Review, and Therapeutic Implications. International Journal of Surgical Pathology 29:102\u0026ndash;108, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang W-x, Xu C-w, Lei L, et al: Large-scale study of NTRK fusions in Chinese solid tumors and using next generation sequencing: A multicenter study. Cancer Research 80:38\u0026ndash;38, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAtiq MA, Davis JL, Hornick JL, et al: Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST). Modern Pathology 34:95\u0026ndash;103, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrčić I, Godschachner TM, Bergovec M, et al: Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Modern Pathology 34:396\u0026ndash;407, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen T, Wang Y, Goetz L, et al: Novel fusion sarcomas including targetable NTRK and ALK. Annals of Diagnostic Pathology 54:151800, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen W, Wang H, Jiang D, et al: Unclassified mesenchymal sarcoma with NTRK1-KHDRBS1 gene fusion: a case report of long-term tumor-free survival with crizotinib treatment. World Journal of Surgical Oncology 19:1\u0026ndash;6, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGoulding E, Morreau P, De Silva M, et al: Case report: NTRK1-rearranged cervical sarcoma with fibrosarcoma like morphology presenting in a 13-year-old managed with a neo-adjuvant TRK-inhibitor and surgical excision. Gynecologic Oncology Reports 37:100845, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHodgson A, Pun C, Djordjevic B, et al: NTRK-rearranged cervical sarcoma: expanding the clinicopathologic spectrum. International Journal of Gynecological Pathology 40:73\u0026ndash;77, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePunjabi LS, Sittampalam K: Expanding the spectrum of adult NTRK3-rearranged spindle cell neoplasms: a recurrent NTRK3-SQSTM1 fusion spindle cell tumor with deceptively bland morphology. American Journal of Clinical Pathology 157:485\u0026ndash;493, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLam SW, Briaire-de Bruijn IH, van Wezel T, et al: NTRK fusions are extremely rare in bone tumours. Histopathology 79:880\u0026ndash;885, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLanman T, Hayden Gephart M, Bui N, et al: Isolated leptomeningeal progression in a patient with NTRK fusion\u0026thinsp;+\u0026thinsp;uterine sarcoma: a case report. Case Reports in Oncology 14:1841\u0026ndash;1846, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu YJ, Wang W, Yeh J, et al: Calcified chondroid mesenchymal neoplasms with FN1-receptor tyrosine kinase gene fusions including FGFR2, FGFR1, MERTK, NTRK1, and TEK: a molecular and clinicopathologic analysis. Modern Pathology 34:1373\u0026ndash;1383, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePercy C, Schubert T, Galant C, et al: Larotrectinib in a NTRK-rearranged soft tissue sarcoma in the neoadjuvant setting: A case report. Clinical Case Reports 9:1694, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu L, Xie X, Shi X, et al: Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma. Oncology Letters 21:1\u0026ndash;12, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeng Y, Chen H, Zhao X, et al: The capability of NTRK fusion detection by next-generation sequencing/FISH/IHC in 25976 solid tumor patients. Cancer Research 81:2285\u0026ndash;2285, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBai C, Zhang L, Wang Y, et al: A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma. J Cancer Res Clin Oncol 148:2933\u0026ndash;2937, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCzaja R, Layng KV, Barrett A, et al: An NTRK-1-associated soft tissue tumor showing distinctive nodules with peripheral accentuation of cellularity. J Cutan Pathol 50:343\u0026ndash;348, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDang X, Xiang T, Zhao C, et al: EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review. Front Med (Lausanne) 9:832376, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHibar DP, Demetri GD, Peters S, et al: Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. PLoS One 17:e0270571, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJiang H: A novel ETV6-NTRK3 gene fusion in primary renal fibrosarcoma. Eur Rev Med Pharmacol Sci 26:4705\u0026ndash;4708, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOverfield CJ, Edgar MA, Wessell DE, et al: NTRK-rearranged spindle cell neoplasm of the lower extremity: radiologic-pathologic correlation. Skeletal Radiol 51:1707\u0026ndash;1713, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRecine F, De Vita A, Fausti V, et al: Case Report: Adult NTRK-Rearranged Spindle Cell Neoplasm: Early Tumor Shrinkage in a Case With Bone and Visceral Metastases Treated With Targeted Therapy. Front Oncol 11:740676, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSilvertown JD, Lisle C, Semenuk L, et al: Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients. Mol Diagn Ther 27:87\u0026ndash;103, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobayashi H, Makise N, Shinozaki-Ushiku A, et al: Dramatic response to entrectinib in a patient with malignant peripheral nerve sheath tumor harboring novel SNRNP70-NTRK3 fusion gene. Genes Chromosomes Cancer 62:47\u0026ndash;51, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKyriazoglou A, Dimitriadis E, Mahaira L, et al: Myxoid spindle cell sarcoma with ETV6-NTRK3 fusion. Cancer Genet 268\u0026ndash;269:93\u0026ndash;96, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNilforoushan N, Wethington SL, Nonogaki H, et al: NTRK-Fusion Sarcoma of the Uterine Cervix: Report of 2 Cases With Comparative Clinicopathologic Features. Int J Gynecol Pathol 41:642\u0026ndash;648, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNozzoli F, Lazar AJ, Castiglione F, et al: NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities. Pathol Oncol Res 28:1610237, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRahim S, Alkhaldi SS, Alasousi K, et al: Intestinal LMNA::NTRK1-fused spindle cell neoplasm with S100 and CD34 coexpression: a new case. BMJ Case Rep 15, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSiozopoulou V, Marcq E, De Winne K, et al: NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects. Pathol Oncol Res 28:1610423, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuh K, Carlson JJ, Xia F, et al: The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma. J Manag Care Spec Pharm 28:622\u0026ndash;630, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eThorwarth A, Haase K, R\u0026ouml;efzaad C, et al: Genomic Evolution and Personalized Therapy of an Infantile Fibrosarcoma Harboring an NTRK Oncogenic Fusion. JCO Precis Oncol 6:e2100283, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTsai JW, Lee JC, Hsieh TH, et al: Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements. Mod Pathol 35:911\u0026ndash;921, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVan Bockstal MR, Beniuga G, Craciun L, et al: The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study. Pathobiology 89:393\u0026ndash;406, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang Z, Wang J: Primary NTRK-rearranged spindle cell neoplasm of bone harboring an HMBOX1::NTRK3 gene fusion. Genes Chromosomes Cancer 62:477\u0026ndash;482, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYoung V, Wong D, Yan M, et al: NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern. Human Pathology Reports 28:300618, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoyers JT, Brazel D, Kumar P, et al: Abstract 2184: Landscape of genomic alterations of ultra-rare sarcomas (URS) from 1,079 patients in the AACR GENIE real world database: Clinical implications. Cancer Research 82:2184\u0026ndash;2184, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGong H, Gao K, Mao P, et al: A rare case of spindle cell neoplasm with NTRK-fusion in central nervous system. Pathol Int 73:52\u0026ndash;54, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAgostara AG, Patelli G, Bencardino K, et al: 72P Molecular characterization of advanced primary cardiac sarcomas. ESMO Open 8, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBornstein-Quevedo L, Bautista-Wong C, Mojica-Gonz\u0026aacute;lez Z, et al: Identification of NTRK fusion genes. Experience in Mexico. Gaceta Mexicana de Oncologia 22, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCammareri C, Beltzung F, Michal M, et al: PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications. Virchows Arch 483:145\u0026ndash;156, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChalla B, Jones D, Kim AC, et al: NTRK-rearranged mesenchymal tumour in oesophagus with DOG1 immunohistochemical expression: is it a gastrointestinal stromal tumour? Pathology 56:602\u0026ndash;604, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCorral S\u0026aacute;nchez MD, Jim\u0026eacute;nez Carrascoso R, Rubio Aparicio P, et al: Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series. Clin Transl Oncol 25:3307\u0026ndash;3311, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCreus-Bachiller E, Fern\u0026aacute;ndez-Rodr\u0026iacute;guez J, Magall\u0026oacute;n-Lorenz M, et al: Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities. Mol Oncol 18:895\u0026ndash;917, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDufresne A, Pissaloux D, Ngo C, et al: Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. ESMO Open 8:101202, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFurtado LV, Kacar M, Mostafavi R, et al: Progressive metastatic infantile fibrosarcoma with multiple acquired mutations. Cold Spring Harb Mol Case Stud 9, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePalmerini E, Frega G, Gambarotti M, et al: NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report. Front Oncol 13:1252359, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYin L, Shi C, He X, et al: NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China. Pathology 55:362\u0026ndash;374, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKobayashi H, Teramura Y, Yamashita K, et al: Imaging findings of NTRK\u0026ndash;rearranged spindle cell neoplasms: A case series. Mol Clin Oncol 18:14, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKojima N, Mori T, Motoi T, et al: Frequent CD30 Expression in an Emerging Group of Mesenchymal Tumors With NTRK, BRAF, RAF1, or RET Fusions. Mod Pathol 36:100083, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKrskov\u0026aacute; L, Balko J, Strnadov\u0026aacute; M, et al: 60P Spindle cell sarcomas with tyrosine kinase rearrangement. ESMO Open 8, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKubota Y, Kawano M, Iwasaki T, et al: Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. Medicine (Baltimore) 102:e36232, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKummar S, Shen L, Hong DS, et al: Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer 129:3772\u0026ndash;3782, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLin R, Mallick AB, Wang ZX, et al: Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy. Diagn Pathol 18:116, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRomanko AA, Mulkidjan RS, Tiurin VI, et al: Cost-Efficient Detection of NTRK1/2/3 Gene Fusions: Single-Center Analysis of 8075 Tumor Samples. Int J Mol Sci 24, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSahni S, Rastogi S, Yadav R, et al: Limb salvage of an infant with infantile fibrosarcoma using TRK inhibitor larotrectinib. Ecancermedicalscience 17:1575, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuurmeijer AJH, Xu B, Torrence D, et al: Kinase fusion positive intra-osseous spindle cell tumors: A series of eight cases with review of the literature. Genes Chromosomes Cancer 63:e23205, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu B, Suurmeijer AJH, Agaram NP, et al: Head and Neck Mesenchymal Tumors with Kinase Fusions: A Report of 15 Cases With Emphasis on Wide Anatomic Distribution and Diverse Histologic Appearance. Am J Surg Pathol 47:248\u0026ndash;258, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eXu Y, Shi X, Wang W, et al: Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China. NPJ Precis Oncol 7:75, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDong R, Li L, Gong L, et al: Abstract 2152: Targetable oncogenic fusions and other alterations in bone and soft-tissue tumors assessed by RNA and DNA-based next-generation sequencing in real-world experience. Cancer Research 83:2152\u0026ndash;2152, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMoura MS, Costa J, Velasco V, et al: Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls. Histopathology 84:451\u0026ndash;462, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHasegawa N, Hayashi T, Niizuma H, et al: Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Clin Orthop Relat Res 482:549\u0026ndash;563, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHernandez S, Conde E, Molero A, et al: Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach. Arch Pathol Lab Med 148:318\u0026ndash;326, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKlub\u0026iacute;čkov\u0026aacute; N, Dermawan JK, Mosaieby E, et al: Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations. J Pathol 263:61\u0026ndash;73, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eOrbach D, Carton M, Khadir SK, et al: Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study). ESMO Open 9:103006, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSzalai L, Vereczkey I, Szemes M, et al: NTRK-rearranged spindle cell sarcoma of the uterine cervix with a novel NUMA1::NTRK1 fusion. Virchows Arch 484:527\u0026ndash;531, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNakada E, Fujiwara T, Kunisada T, et al: Abstract 6456: The utility of clinical sequencing in the diagnosis and treatment of soft tissue sarcomas; Real world data based on nation-wide database. Cancer Research 84:6456\u0026ndash;6456, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang J, Song M, Lu S, et al: Clinical and molecular characteristics and targeted therapy of pediatric non-infantile fibrosarcoma NTRK rearrangement\u0026ndash;related tumors, American Society of Clinical Oncology, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVince CSC, Brassesco MS, Man\u0026ccedil;ano BM, et al: Beyond Clinical Trials: Understanding Neurotrophic Tropomyosin Receptor Kinase Inhibitor Challenges and Efficacy in Real-World Pediatric Oncology. JCO Precision Oncology 8:e2300713, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang W, Schmitz AA, Kallionp\u0026auml;\u0026auml; RE, et al: Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland. Acta Oncologica (Stockholm, Sweden) 63:542\u0026ndash;551, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCao Q, Huang Z, Liang H, et al: Case report: Adult NTRK-rearranged spindle cell neoplasms with TPM3-NTRK1 fusion in the pelvic. Front Oncol 14:1308916, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ede Castro JVA, Dos Santos PJS, Mantoan H, et al: Uterine Sarcoma With EML4::NTRK3 Fusion: A Spectrum of Mesenchymal Neoplasms Harboring Actionable Gene Fusions. Int J Gynecol Pathol 43:56\u0026ndash;60, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGao X, Xu S, Zhu P, et al: Primary NTRK -rearranged Spindle Cell Neoplasm of the Gastrointestinal Tract: A Clinicopathological and Molecular Analysis of 8 Cases. Am J Surg Pathol 48:623\u0026ndash;631, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGrant L, Boyle W, Williams S, et al: Uterine Neurotrophic Tyrosine Receptor Kinase Rearranged Spindle Cell Neoplasms: Three Cases of an Emerging Entity. Int J Gynecol Pathol 43:326\u0026ndash;334, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNakata E, Osone T, Ogawa T, et al: Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan. Cancer Med 13:e7351, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChen Y, Steiner S, Hagedorn C, et al: Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA:: NTRK1-rearranged soft‐tissue sarcoma cell model. The Journal of Pathology 263:257\u0026ndash;269, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWillis C, Au T, Hejazi A, et al: Clinical characteristics and treatment patterns of patients with NTRK fusion\u0026ndash;positive solid tumors: A multisite cohort study at US academic cancer centers. Journal of managed care \u0026amp; specialty pharmacy 30:672\u0026ndash;683, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMotta M, Barresi S, Pizzi S, et al: RAF1 gene fusions are recurrent driver events in infantile fibrosarcoma-like mesenchymal tumors. The Journal of Pathology 263:166\u0026ndash;177, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSiozopoulou V, Smits E, De Winne K, et al: NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics (Basel) 11, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAssi T, Rassy E, Nassereddine H, et al: TRK inhibition in soft tissue sarcomas: A comprehensive review. Semin Oncol 47:73\u0026ndash;84, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eForsythe A, Zhang W, Phillip Strauss U, et al: A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther Adv Med Oncol 12:1758835920975613, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDavis JL, Al-Ibraheemi A, Rudzinski ER, et al: Mesenchymal neoplasms with NTRK and other kinase gene alterations. Histopathology 80:4\u0026ndash;18, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMosele MF, Westphalen CB, Stenzinger A, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group. Annals of Oncology 35:588\u0026ndash;606, 2024\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSimmons C, Deyell RJ, MacNeill AJ, et al: Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma. Int J Cancer 149:1691\u0026ndash;1704, 2021\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDemetri GD, Antonescu CR, Bjerkehagen B, et al: Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol 31:1506\u0026ndash;1517, 2020\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLassen U, Bokemeyer C, Garcia-Foncillas J, et al: Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis. JCO Precis Oncol 7:e2200651, 2023\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSuh K, Carlson JJ, Xia F, et al: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers. J Comp Eff Res 11:1011\u0026ndash;1019, 2022\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBagaria SP, Ashman JB, Daugherty LC, et al: Compliance with National Comprehensive Cancer Network guidelines in the use of radiation therapy for extremity and superficial trunk soft tissue sarcoma in the United States. J Surg Oncol 109:633\u0026ndash;8, 2014\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeadling C, Wald AI, Warrick A, et al: A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. J Mol Diagn 18:165\u0026ndash;75, 2016\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePenault-Llorca F, Rudzinski ER, Sepulveda AR: Testing algorithm for identification of patients with TRK fusion cancer. J Clin Pathol 72:460\u0026ndash;467, 2019\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Soft tissue tumors, Sarcomas, NTRK1-3 fusions, TRK inhibitors, Systematic review","lastPublishedDoi":"10.21203/rs.3.rs-6512957/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-6512957/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e \u003cb\u003ePurpose\u003c/b\u003e \u003c/p\u003e \u003cp\u003eGene fusions involving Neurotrophic Receptor Tyrosine Kinase (\u003cem\u003eNTRK\u003c/em\u003e) genes lead to Tropomyosin Receptor Kinase (TRK) overexpression, an oncogenic mechanism rarely prevalent in soft tissue tumors. Detecting \u003cem\u003eNTRK1-3\u003c/em\u003e fusions through advanced molecular techniques has revolutionized cancer care through personalized medicine, such as TRK inhibitors (e.g., larotrectinib, entrectinib). In this systematic review, we examined the prevalence and types of \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions in soft tissue sarcomas.\u003c/p\u003e \u003cp\u003e \u003cb\u003eDesign\u003c/b\u003e \u003c/p\u003e \u003cp\u003eUsing terms related to \u003cem\u003eNTRK1-3\u003c/em\u003e and sarcomas, we conducted a comprehensive search of databases (PubMed/MEDLINE, SCOPUS, Web of Science). We screened titles and abstracts, followed by a full-text assessment. We extracted data on study characteristics, molecular characteristics, and clinical outcomes. Data synthesis involved narrative and thematic analysis and study quality assessment using the MASTER scale.\u003c/p\u003e \u003cp\u003e \u003cb\u003eResults\u003c/b\u003e \u003c/p\u003e \u003cp\u003eWe included 136 studies (n\u0026thinsp;=\u0026thinsp;18,077 patients). The most common tumor categories were unclassified soft tissue sarcomas (2,004 patients, 11.09%), gynecological sarcomas (1,019 patients, 5.64%), and liposarcomas (609 patients, 3.37%). Most tumors were gynecological in origin (1,019 patients, 5.64%), followed by the limbs (262 patients, 1.45%). Genomic sequencing was the predominant diagnostic method used in 110 studies. Overall, 551 patients with sarcoma tested positive for \u003cem\u003eNTRK1-3\u003c/em\u003e gene fusions, primarily involving \u003cem\u003eNTRK1\u003c/em\u003e and \u003cem\u003eNTRK3\u003c/em\u003e (~\u0026thinsp;93%), with \u003cem\u003eETV6-NTRK3\u003c/em\u003e fusion being the most frequently reported fusion (174/551). Larotrectinib was used in 142 patients, demonstrating an 83.80% response rate, with low mortality (2.82%) and recurrence (2.11%) rates. Entrectinib had a lower response rate of 63.64% (21/33).\u003c/p\u003e \u003cp\u003e \u003cb\u003eConclusions\u003c/b\u003e \u003c/p\u003e \u003cp\u003eThis systematic review highlights the rarity of \u003cem\u003eNTRK1-3\u003c/em\u003e fusions in sarcomas. TRK inhibitors show high efficacy in sarcomas, emphasizing the necessity of genomic testing in all cases.\u003c/p\u003e","manuscriptTitle":"NTRK1-3 Fusions in Sarcomas: Prevalence, Significance, and Clinical Implications – A Systematic Review","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-05-23 15:03:37","doi":"10.21203/rs.3.rs-6512957/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"89bfcdc3-3a19-45c1-8dd8-12dc0c46b768","owner":[],"postedDate":"May 23rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":48812827,"name":"Biological sciences/Cancer"},{"id":48812828,"name":"Health sciences/Biomarkers"},{"id":48812829,"name":"Health sciences/Molecular medicine"},{"id":48812830,"name":"Health sciences/Oncology"}],"tags":[],"updatedAt":"2025-05-23T15:03:37+00:00","versionOfRecord":[],"versionCreatedAt":"2025-05-23 15:03:37","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-6512957","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-6512957","identity":"rs-6512957","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}